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Abstract 
 
 
The influence of the hormonal milieu on functional prostaglandin and oxytocin 
receptors and their downstream signal pathways in isolated human myometrium 
 
Deborah Peninnah Fischer 
 
Although prostaglandins (PG) and oxytocin are crucial mediators of uterine 
contractility, their receptor-mediated effects during the menstrual cycle, pregnancy 
and labour are not fully understood. The aim of this thesis was to elucidate the 
functional expression of EP, FP, TP and oxytocin receptors in isolated human 
myometrium relative to myocyte mRNA and signal transduction pathways. 
 
Myometrial samples were obtained from consenting non-pregnant and pregnant 
donors. Functional techniques were used to determine isometric muscle contractions. 
Primary uterine myocytes and fibroblasts were cultured at term to identify stimulated 
changes in calcium (Ca2+), cyclic adenosine monophosphate (cAMP) and mRNA.  
 
Myometrial strips exhibited spontaneous contractions, which were most active mid-
cycle under oestrogenic conditions. At this time intrinsic contractility and 
responsiveness to uterotonins decreased towards the fundus. PGE2 produced bell-
shaped responses with predominant utero-relaxant effects mediated via the EP2 
subtype. Although activity was partially restored by PGE2 through EP3/1 receptors, 
tissue excitation was more pronounced at FP, TP and oxytocin receptors. Despite high 
FP mRNA expression, the lower segment uterus was particularly responsive to 
U46619 and oxytocin at term pregnancy. Even so, Ca2+ mobilisation by oxytocin was 
greater via principal release from intracellular stores. Incubations with atosiban, 
progesterone and a rho-kinase inhibitor reduced oxytocin-stimulated Ca2+ transients. 
EP2 also attenuated oxytocic effects but this appeared to be mediated through cAMP 
rather than Ca2+ signalling pathways. With advancing labour, intrinsic myogenic 
activity declined in parallel with oxytocin desensitisation. However, TP-induced 
contractions were continued in the lower parturient uterus. 
 
These findings demonstrate that PG and oxytocin receptor expression are regulated in 
a hormone-dependent temporal and spatial manner. EP2-mediated cAMP formation 
appears to promote uterine quiescence, whilst TP receptors may control muscle tonus 
during parturition. These receptors and their messenger systems represent effective 
tocolytic targets for uterine hypercontractile disorders, such as dysmenorrhoea and 
preterm labour. 
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Chapter 1: Introduction 
 
 
 
1.1 The human uterus 
The uterus is a dynamic organ. During the reproductive years, it responds to the 
hormonal milieu (Europe-Finner et al., 1994; Lopez Bernal, 2001; Blanks et al., 2007) 
and to physical stimuli, such as the arrival of a blastocyst (Lim et al., 2002; Critchley 
& Saunders, 2009). Maternal physiological adaptations to the menstrual cycle, 
pregnancy and parturition can be dramatic. Even so, some events may be 
accompanied by common gynaecological disorders, including excessive blood loss 
(menorrhagia), menstrual cramps (dysmenorrhoea) and premature labour.  
The uterus, a hollow fibromuscular organ, is supported deep within the pelvic cavity 
by broad, round and uterosacral ligaments. At puberty the uterus is pyriform in shape 
with two anatomical regions, the body or corpus and the cervix. The isthmus, a slight 
constriction, marks the junction of the cervix and the body. In a non-pregnant adult, 
the uterine body narrows from the fundus caudally to the cervix, which projects 
through the anterior wall of the vagina (Figure 1.1).  
The uterine wall is composed of three layers: the outer serosa, the thick muscular 
layer (myometrium) and the inner mucosal membrane (endometrium), tapering the 
uterine cavity. In the non-gravid state, myometrial tissue can be further structured into 
external (stratum supravasculare), mid (stratum vasculare) and inner (stratum 
subvasculare) layers. Even so, the boundaries between each stratum are not well 
defined. 
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Figure 1.1: Anterior view of the uterus, uterine tubes and associated ligaments. Cut 
sections of the uterus and vagina illustrate their internal anatomy (Seeley et al., 2006). 
 
 
 
1.2 The menstrual cycle 
The menstrual cycle is controlled by episodic changes in ovarian hormone secretion, 
which prepare the uterus to receive a fertilised ovum. In non-pregnant healthy women 
of reproductive age, the complete cycle is approximately 28 days in length. By 
convention, menses marks the first 4-5 days of the cycle, during which endometrial 
tissue is sloughed together with blood from ruptured arteries. After menstruation, 
circulatory oestrogen gradually rises due to its secretion by ovarian granulosa and 
theca cells within the developing dominant follicle. The binding of oestrogen to its 
abundant uterine receptors causes the endometrial cells and, to a lesser extent, the 
myometrial cells to proliferate (Yin et al., 2007). Moreover, oestrogen induces the 
synthesis of specific receptors for progesterone (refer to Page 8). This primes the 
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uterus for progesterone binding after ovulation, signified by the transformation of the 
follicular cavity into the corpus luteum (Figure 1.2).  
The subsequent luteal phase is dominated by progesterone secretion from the corpus 
luteum, concentrations of which peak at 7.48 ± 3.86 ng/ml between days 18 to 24 of 
the cycle (Erden et al., 2005). During this phase, as well as antagonising oestrogen, 
progesterone suppresses myometrial activity and thickens the endometrial lining. 
Spiral arteries also fully develop in preparation for pregnancy. However, without 
successful fertilisation and implantation of the ovum, the corpus luteum regresses and 
progesterone and oestrogen synthesis declines. With the withdrawal of steroid 
support, uterine spiral arteries constrict causing ischaemia and oxidative damage to 
the endometrium. The shedding of the endometrial tissue then prepares the uterus for 
the next menstrual cycle. 
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Figure 1.2: During a typical menstrual cycle, luteinising hormone (LH) stimulates the 
production of androgens by theca cells in the ovary, providing a substrate for 
oestrogen synthesis by ovarian granulosa cells. Follicle-stimulating hormone (FSH) 
facilitates follicle maturation and oestrogen-dependent proliferation of endometrial 
and myometrial cells. A mid-cycle surge in LH triggers ovulation, followed by a drop 
in FSH and LH release. At the site of the ruptured follicle a corpus luteum develops. 
This secretes progesterone and causes endometrial cells to differentiate and stabilise. 
If pregnancy is not established, menstruation results from endometrial shedding 
secondary to the rapid decline in oestrogen and progesterone synthesis from the 
demise of the corpus luteum (adapted from www.sciencedaily.com).  
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1.3 Myometrial structure 
Although the myometrium is predominantly composed of smooth muscle cells, it also 
contains a heterogeneous arrangement of fibroblasts, blood vessels, lymphatic vessels 
and immune cells embedded in a matrix of connective tissue. In humans, the 
myometrial fibres tend to be oriented in a longitudinal direction close to the serosa 
and gradually form a circular muscle layer next to the endometrium (Weiss et al., 
2006). However, the interconnection between bundles and numerous interspersed 
oblique fibres reduce any clear distinction between layers. 
Human myometrial cells are long (300-600µm), narrow (5-10µm) and generally 
spindle-shaped (Finn & Porter, 1975). The complex cytoskeletal structure enables 
contractile forces to be generated within each cell and then transmitted through the 
myometrium via gap junctions, directly linking adjacent cells. Interaction with 
connective tissue collagen fibres facilitates the electrical coupling and transforms the 
uterus from its intrinsic relaxed state into an effective contractile syncytium. Although 
suppressed during pregnancy, the synchronous uterine contractions are phasic in 
nature and driven by action potentials propagated by pacemaker cells (Marshall, 
1962). This myogenic activity imparts directional force essential for progressive 
cervical dilation and delivery of the foetus at parturition.  
The structural basis of contractions involves actin and myosin filaments, which form 
cross-bridges to generate force. Myosin is a hexamer composed of two identical heavy 
chains and four light chains. As well as possessing actin binding-sites, myosin 
hydrolyses ATP to provide the energy required for contraction. As with other types of 
smooth muscle, the interaction between actin and myosin is regulated by the enzyme 
myosin light chain kinase (MLCK) (Word et al., 1994). Action potentials depolarise 
the cell membrane causing calcium (Ca2+) influx through voltage-operated channels 
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(Somlyo et al., 1994). A crucial rise in intracellular-free Ca2+ promotes the binding of 
Ca2+ to calmodulin, which activates MLCK phosphorylating myosin light chain 
(MLC20). As a result, myogenic activity is stimulated and amplitude, duration and 
frequency of contractions are enhanced. By contrast a rapid reduction in Ca2+ 
availability due to extrusion through the plasma membrane and Ca2+ uptake into the 
sarcoplasmic reticulum leads to muscle relaxation (Word et al., 1994). This 
mechanism helps to maintain the uterus in an auto-inhibited, quiescent state during 
pregnancy.  
 
1.4 Pregnancy 
After conception, the uterus becomes conducive to blastocyst attachment and 
implantation to establish pregnancy. Embryonic trophoblast cells and maternal 
endometrial tissue develop to form the placenta, a specialised vascular region required 
for nutrient and waste product exchange between the mother and conceptus. Although 
blood supplies remain separate, the remodelling of arteries within these structures 
assists the progressive rise in uterine blood flow throughout gestation. Moreover, to 
protect the conceptus, the velocity of blood is slowed by the convoluted and dilated 
nature of terminal arteries supplying the endometrial decidua. This also acts to 
mediate steroid hormone transfer, important for embryo implantation and the timing 
and onset of parturition. 
 
1.5 The role of ovarian steroids in the uterus 
Changes in the hormonal milieu, especially ovarian steroid secretions, directly target 
the myometrium, endometrium and uterine vasculature. Whilst progesterone is crucial 
in preparing the endometrium during the luteal phase, a rise in oestrogen is required 
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for blastocyst metabolism and attachment (Lim et al., 2002). As a result, the release of 
both ovarian hormones coordinates uterine events in a spatiotemporal manner. 
With the onset of pregnancy, steroidogenesis is enhanced initially by conceptus signal 
cascades on the functional corpus luteum and then superseded by the foeto-placental 
unit. Interferon-τ is considered to be the recognition signal that has roles in 
embryogenesis and foetal development (Asselin et al., 1997). Circulatory 
progesterone and oestrogen concentrations continue to increase throughout pregnancy 
(Table 1.1); this promotes uterine quiescence to accommodate the development and 
growth of the foetus. To reduce the capacity for myogenic activation, progesterone in 
the presence of oestrogen suppresses gap junction dynamics within the uterus 
(Garfield et al., 1980). As gap junctions are transmembrane channels between 
myometrial cells, the absence of direct cytoplasmic linkage during pregnancy limits 
electric and metabolic communication (Garfield, 1984; Riemer et al., 1998). This 
prevents synchronised contractions of the uterus. Nevertheless, in humans, labour is 
preceded by increased myometrial gap junction formation, identified by the elevated 
expression of connexin isoforms (Cx) 43, 26, 40 and 45, which constitute the channels 
between cells (Kilarski et al., 2000; Di et al., 2001). Although cellular mechanisms 
have not been fully elucidated, the rise in Cx43 transcripts, mRNA and protein 
expression correlate to oestrogen treatments ( Kilarski et al., 2000; Di et al., 2001) 
and oestrogen-mediated gene regulation (Grummer et al., 2004). Therefore, in 
contrast to progesterone, heightened oestrogen may be integral for priming the uterus 
for parturition.  
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Table 1.1 Plasma progesterone and oestrogen concentrations in women during the 
luteal phase of the cycle and late pregnancy (Johnson et al., 1995). 
 
Steroid Progesterone Oestriol Oestrone 17β Oestradiol 
Luteal phase (ng/ml) 11 - 0.2 0.2 
Pregnancy (ng/ml) 125-200 113 53 15 
 
Whilst plasma progesterone increases throughout gestation, oestriol synthesis is 
promoted at term by foetal cortisol secretion, which elevates the oestrogen: 
progesterone ratio. In contrast to other species, progesterone withdrawal is not 
detectable in humans at parturition. This implies that the hormonal control of 
parturition may involve a regulated change in myometrial receptors or their signalling 
pathways.  
Two main isoforms of the human progesterone receptor (PR) exist encoded by a 
single gene. Despite being independently regulated, PR-A is a truncated form of PR-
B, lacking the first 164 N-terminal amino acids. Due to receptor co-expression in 
myocytes, the relative proportions of each PR subtype have been proposed to regulate 
uterine activity during pregnancy. PR-A dominantly represses the transcriptional 
activity mediated by PR-B (Giangrande & McDonnell, 1999; Pieber et al., 2001), and 
a substantial increase in the myometrial PR-A: PR-B ratio has been identified at term 
labour in humans (Smith et al., 2002) and non-human primates (Haluska et al., 2002). 
In addition to reducing the active suppression of genes required for parturition, the 
increased expression of PR-A has been associated with enhanced myometrial 
responsiveness to oestrogen via the oestrogen receptor (ER)-α (Mesiano, 2001). This 
suggests that the interaction between PR and ER in human myometrium may 
contribute to coordinating the preparatory phase of labour.  
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1.6 Mechanisms of human parturition 
The onset of parturition is under tight endocrine control. Although functional 
progesterone withdrawal is pivotal in the human parturition cascade (Astle et al., 
2003), other maternal and foetal mechanisms are required to prepare the uterus for 
labour. In women, this process is only partially understood. 
Relative myometrial quiescence during pregnancy is maintained through the 
autocrine-paracrine actions of putative inhibitors, such as progesterone, prostacyclin, 
relaxin, parathyroid hormone-related peptide, nitric oxide and corticotrophin-releasing 
hormone. These compounds may both impede or stimulate uterine contractility via 
different signalling pathways (Challis et al., 2000). In late pregnancy, a shift in 
genomic mechanisms is proposed to diminish the production of inhibitory agents and 
concomitantly upregulate contractile-associated proteins (CAPs), including gap-
junctions, agonist receptors and proteins encoding ion channels (Norwitz et al., 1999; 
Challis et al., 2000). Stimulation can then produce synchronised contractions of the 
uterus; this is predominantly orchestrated by prostanoids acting as uterotonins (Figure 
1.3). 
Concurrent to the establishment of regular uterine contractions, the effacement and 
dilation of the uterine cervix facilitates the passage of the foetus during labour. 
Cervical changes involve connective tissue remodelling, mediated by a decline in 
matrix metalloproteinase inhibitors (Becher et al., 2004). Distension of the uterus and 
maturation of the foetal pituitary-adrenal axis appear to have only a supportive rather 
than essential role in labour (Lopez Bernal et al., 1993; Alfaidy et al., 2001;). 
However, alterations in both Ca2+ metabolism and prostaglandin synthesis are 
implicated as crucial parallel mechanisms, which coordinate the timing of parturition 
(Weiss, 2000).  
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Figure 1.3: Hormones involved in the regulation of pregnancy and parturition. 
Labour-onset is preceded by an increase in the myometrial progesterone receptor 
(PR)-A: PR-B ratio, together with elevated oestrogen receptor (ER)-α expression. 
Oestrogen activation increases the genes encoding for contractile-associated proteins 
(CAPs), including oxytocin (OT) and prostaglandin (PG) receptors, cyclooxygenase 
(COX)-2, rho-associated coiled coil-forming protein kinase (ROCK) and connexin-
43. These enhance myometrial responsiveness to uterotonins and promote labour 
contractions.  
 
 
 
1.7 Prostanoids 
Prostanoids are classified as prostaglandins (PGs) and thromboxane (TXA), 
consisting of a cyclopentane and cyclohexane ring respectively. Naturally existing 
PGs are further subdivided into prostaglandin (PG) D, E, F and I, according to slight 
modifications of the ring structure. Due to their chemical and metabolic instability, 
prostanoids act as local mediators and maintain homeostasis in a variety of tissues and 
cells (Tsuboi et al., 2002). Although integral to inflammatory, ovulatory and luteolytic 
processes, changes in prostanoids are also essential in the initiation and maintenance 
of labour, reflected by changes in their biosynthesis (Giannoulias et al., 2002; Jabbour 
& Sales, 2004). 
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1.7.1 Prostanoid biosynthesis 
As part of the eicosanoid family, the PGs are regulated through a common 
biosynthetic pathway (Figure 1.4). In humans the primary precursor of PGs is 
arachidonic acid, a C20 esterified fatty acid stored in membrane phospholipids. To 
liberate free arachidonic acid for PG production, cytosolic phospholipase A2 (PLA2) 
translocates from the cytosol to the cell membrane upon activation by Ca2+. 
Alternatively, phospholipase C (PLC) and diacylglycerol lipase indirectly catalyse the 
process. Free arachidonate is subsequently converted to form the unstable 
intermediate endoperoxide PGH2. This requires oxidation by the cyclooxygenase 
enzyme (COX), of which three isoforms exist (Chandrasekharan et al., 2002). Despite 
catalytic and structural similarities, COX-1 is expressed in most cells whereas 
hormones, growth factors and cytokines are necessary to readily induce COX-2 and -3 
(Morita, 2002). Following the biosynthesis of PGH2, the endoperoxides are rapidly 
converted to the series-2 bioactive PGs by specific prostaglandin and thromboxane 
synthases. These terminal enzymes are named according to the prostanoid produced, 
such that PGD2 PGE2, PGF2α, PGI2 and TXA2 are synthesised by their respective 
synthases denoted PGDS, PGES, PGFS, PGIS and TXS (Narumiya et al., 1999). 
Transporters mediate the rapid efflux of the newly synthesised PGs, facilitating local 
PG receptor binding. 
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1.7.2 Prostanoid receptors 
PGs transmit their signals via rhodopsin-type seven transmembrane receptors that 
couple to different guanine nucleotide-binding (G) proteins and downstream effector 
systems. Each receptor type, classified as DP, EP, FP, IP and TP, is based on 
respective sensitivities to the five primary prostanoids PGD2 PGE2, PGF2α, PGI2 and 
TXA2 (Coleman et al., 1994). Separate genes encode a further four EP subtypes (EP1-
4), differing in structure, signalling pathways and pharmacological action. A ninth 
subtype has recently been identified in mast cells of PGD2 as a potent agonist at the 
chemoattractant receptor-homologous molecule expressed on T helper 2 cells 
(CRTH2) (Hirai et al., 2001). Through use of alternative splice variants, two isoforms 
of EP1 have been cloned in the rat, whilst two TP and nine variants of the EP3 receptor 
have been identified in humans (Negishi et al., 1993; Pierce & Regan, 1998), in 
conjunction with two ovine FP isoforms (Pierce et al., 1997). In each receptor type 
similar binding properties are maintained due to splice variant modifications 9-12 
amino acids into the carboxyl-terminal domain. As a result, prostanoid receptor 
isoforms mainly differ in terms of localisation, G-protein coupling and agonist-
induced desensitisation (Negishi et al., 1993). Molecular cloning techniques have 
improved the analysis of prostanoid subtype ligand binding properties and signal 
transducing pathways (Table 1.2; Figure 1.4).  
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PGE2-9-ketoreductase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: The biosynthetic pathway of the series-2 prostanoids (PGs) and their 
metabolites derived from arachidonic acid (adapted from Bos et al., 2004). 
Arachidonic acid is metabolised by cyclooxygenase (COX)-1 or COX-2 to the 
unstable endoperoxide PGH2. Thromboxane (TxA2), PGD2, PGE2, PGI2 and PGF2α 
are generated from this common precursor by individual PG synthase enzymes 
(TxAS, PGDS, PGES, PGIS and PGFS) before eliciting biological effects at their 
cognate cell surface receptors.  
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Prostanoid receptors can be broadly divided into relaxant (DP, EP2, EP4, IP) and 
contractile (EP1, EP3, FP, TP) groups according to their actions on smooth muscle 
cells. Except for EP1, specific G protein species have been identified for each 
prostanoid receptor (Kiriyama et al., 1997), classified according to their α-subunit 
(Table 1.2).  
 
Table 1.2: Signal transduction pathways of prostanoid and oxytocin receptors. The 
Gαq and Gαi proteins increase and potentiate uterine contractility, whilst Gαs 
proteins cause muscle relaxation. Corresponding secondary messengers mediate 
effects via inositol trisphosphate (IP3) and changes in cyclic adenosine 
monophosphate (cAMP) (Narumiya et al., 1999; Tsuboi et al., 2002; Hata & Breyer, 
2004). 
 
Type Subtype Isoforms G Protein Second messenger 
DP  DP Gαs cAMP 
  CRTH2 (DP2) Gαi cAMP,   Ca2+   IP3 
EP    EP1 EP1, EP1-variant (rat)  Unknown Ca2+,  low  IP3 
 EP2  Gαs cAMP 
    EP3 EP3-1a, 1b, II, III, IV, V, VI, e, f  Gαi, Gαs, Gαq cAMP, IP3 
 EP4  Gαs cAMP 
FP     FP-A & FP-B (ovine)          Gαq IP3 
IP   Gαs, Gαq, Gαi  IP3,   cAMP 
OT   Gαi, Gαq          Ca2+,    IP3 
TP  TPα Gαs, Gαq, Gα12,13, Gαh IP3,    cAMP 
  TPβ Gαi, Gαq, Gα12,13 IP3,    cAMP 
 
 
 
 
Among the different receptors DP, EP2, EP4 and IP have a profound inhibitory effect 
on contractility by stimulating the Gαs protein coupled to adenylyl cyclase (AC). In 
contrast, TP, FP and EP1 receptors enhance strong contractile effects through Gαq and 
Gαi proteins. Gαq activates PLC, catalysing the production of diacylglycerol and 
inositol 1,4,5-trisphosphate (IP3), whilst Gαi inhibits cyclic adenosine monophosphate 
(cAMP). The resultant Ca2+ mobilisation is essential for the actions of uterotonins, 
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especially towards term pregnancy (Shlykov & Sanborn, 2004). Although associated 
with a general decline in cAMP, EP3 may conversely increase AC activity depending 
on the splice variant and cell type (Narumiya et al., 1999). Nevertheless, it is likely 
that cross-communication of downstream signalling pathways potentiate all 
prostanoid effects in the myometrium. 
 
1.7.3 Prostanoids in the myometrium 
PGs have long been implicated in regulating uterine contractility via myometrial 
receptors. In the non-pregnant and term pregnant state, functional studies on the 
human myometrium have characterised the expression of heterogeneous DP, EP, FP, 
IP and TP receptors (Senior et al., 1992; Senior et al., 1993). Differences in the 
response to PGs, both regional and hormone-related, indicate either altered receptor 
populations or the production of uterine contractile-associated proteins (Myatt & Lye, 
2004). In addition, the expression of prostanoid receptors varies with tissue 
distribution. The TP receptor, for instance, is predominantly localised in platelets and 
blood vessels, EP1 in fibroblasts, FP in renal cells and EP2 and EP4 in smooth muscle 
cells (Narumiya et al., 1999; Bos et al., 2004). In the myometrium these reflect 
uterine physiology and activity, especially towards the onset of parturition. 
 
1.7.4 Prostaglandin receptors in pregnancy and parturition 
PG synthesis and receptor expression are intimately involved in the parturition 
process. This involves the switch between relaxant to contractile receptor populations. 
Unlike DP, which is least abundant in human myometrium, the main arachidonic acid 
metabolite in uteri from non-pregnant and term pregnant donors is prostacyclin (PGI2) 
(Christensen et al., 1983). As well as an increase at menstruation, PGI2 synthesis is 
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augmented during pregnancy to reduce myogenic activity and regulate uterine and 
placental blood flow. Pregnancy maintenance is also related to an increase in 
relaxatory EP receptor responses, primarily EP2 (Senior et al., 1993; Brodt-Eppley & 
Myatt, 1999), in conjunction with elevated coupling of Gαs-proteins to AC in 
response to PGE2 (Europe-Finner et al., 1994; Europe-Finner et al., 1997).  The 
concomitant rise in uterine cAMP formation activates cAMP-dependent protein 
kinase A (PKA) to phosphorylate MLCK. This promotes myometrial relaxation by 
reducing the affinity for the Ca2+-calmodulin complex and inhibiting voltage-gated 
Ca2+ channels (Word et al., 1994). The reduction in cAMP at labour indicates a loss 
of this inhibitory pathway (Europe-Finner et al., 1994; Lopez Bernal et al., 1995). 
The onset of labour is associated with elevated PG synthesis within the uterus. This 
increase, particularly in PGE2 and PGF2α production by the foetal membranes and 
decidua, coincides with augmented COX-2 expression (Erkinheimo et al., 2000). 
Others have reported no change in COX-2 mRNA at parturition but differences in 
contractile receptor responsiveness (Sparey et al., 1999; Giannoulias et al., 2002). 
Although downregulated during pregnancy (Matsumoto et al., 1997), the expression 
of human myometrial EP3 and FP receptors increase dramatically at parturition 
(Brodt-Eppley & Myatt, 1999). A concurrent loss of EP2 receptors (Astle et al., 2005) 
and withdrawal of PGIS in myometrium at term pregnancy may also contribute to the 
labour process (Giannoulias et al., 2002).  
PGE2 is important in myometrial contractility as, clinically, PGE1 and PGE2 
analogues are used for the induction of labour and for cervical ripening. Even so, 
other uterotonic agents such as PGF2α and oxytocin contribute to successful 
parturition, their functional roles determined by gene knockout mice. As PGF2α is a 
luteolytic agent, impaired parturition in FP-deficient mice was attributed to the 
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absence of a decline in progesterone and a lack of oxytocin receptor expression 
(Sugimoto et al., 1999). Aberrant COX-1 genes are related to parturition failure, 
whereas COX-2 defects cause infertility with abnormalities in ovulation, fertilisation, 
implantation and decidualisation (Lim et al., 1997). In addition, gene ablation of EP2 
receptors inhibited ovulation in mouse models (Tilley et al., 1999), whereas the 
failure to close the ductus arteriosus at birth in EP4-deficient mice caused neonatal 
deaths (Nguyen et al., 1997). As oxytocin also stimulates ovarian PGF2α release in a 
positive feedback manner (Chibbar et al., 1993), it is likely that a balance of factors 
and signalling pathways ultimately regulate uterine activity. These complex 
interrelated receptor cascades are not well defined in humans and need further 
elucidation. 
 
1.7.5 TP receptors in parturition 
The TP receptor gene has been localised in the human myometrium, foetal 
membranes and placenta (Swanson et al., 1992), corresponding to functional roles in 
uterine contractility and vascular tone. The TP splice variants have been identified in 
human myocytes from both non-pregnant and pregnant donors (Moore et al., 2002; 
Moran et al., 2002) although little is known about TP receptors in relation to labour-
onset. 
The two receptor isoforms, TPα and TPβ, differ exclusively in their carboxyl-terminal 
domains (Raychowdhury et al., 1994). While both mediate identical ligand binding, 
each isoform exhibits critical differences in signalling and patterns of expression, 
indicative of distinct pathophysiological roles (Miggin & Kinsella, 1998; Moore et al., 
2002). The TPα receptor activates AC, increasing cAMP production through Gαs 
(Hirata et al., 1996). By contrast, in addition to inhibiting AC through Gαi-protein 
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coupling, TPβ stimulates intracellular Ca2+ via the IP3 pathway. Due to the synergism 
of signal cascades, this mechanism enhances myogenic contractility. 
Both TP receptors activate RhoA, a small GTPase, stimulating the two target proteins, 
rho-associated coiled coil-forming protein kinase (ROCK)I and its isoform ROCKII 
(Amano et al., 2000). By direct phosphorylation of MLC20 and inactivation of myosin 
phosphatase, the uterus becomes sensitised to Ca2+ (Figure 1.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Thromboxane stimulates phospholipase C (PLCβ) production of inositol 
trisphosphate (IP3) and diacylglycerol (DAG). IP3 releases Ca2+ from the sarcoplasmic 
reticulum intracellular stores. Upon binding with calmodulin (Cal), cytosolic-free 
Ca2+ activates myosin light chain kinase (MLCK), which catalyses MLC20 
phosphorylation and induces uterine contractility. Activation of the rho-associated 
coiled coil-forming protein kinase (ROCK) pathway inhibits MLC20 phosphatase 
(MLCP), denoted by X, preventing MLC20 dephosphorylation; this sensitises the 
uterus to Ca2+ and potentiates contractility. 
 
 
 
The increased myometrial contractility in non-pregnant donors was irrespective of the 
phase of the menstrual cycle (Senior et al., 1992; Senchyna et al., 1999), suggesting 
that small changes in steroid hormones or related transcription factors do not 
influence TP affinity and density. In contrast, ROCKI isoforms have been reported to 
both upregulate (Moore et al., 2000; Moore & Lopez Bernal, 2003) and remain 
unaltered during human pregnancy (Friel et al., 2005). However, an apparent increase 
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in RhoA mRNA at parturition implies a role for ROCKI in the preparatory phase and 
activation of pregnancy (Lartey et al., 2007). Moreover, aberrant ROCKI expression 
has been associated to uterine contractile dysfunctions, such as preterm labour or 
prolonged full term labour (Moore & Lopez Bernal, 2003; Lartey et al., 2007). 
Therefore greater understanding and control of these proteins may improve tocolytics 
for labour-associated disorders.  
 
1.8 Oxytocin biosynthesis 
Oxytocin is one of the most potent uterotonic agents used for augmenting uterine 
contractions during labour (Fuchs et al., 1985; Wathes et al., 1999; Nilsson et al., 
2003). As a nonapeptide hormone, oxytocin is primarily synthesised in the 
paraventricular and supraoptic nuclei of the hypothalamus with storage and release 
from the posterior pituitary. Local production from the gravid uterus and chorio-
decidua is also well documented (Chibbar et al., 1993), suggesting that oxytocin may 
act by both endocrine and paracrine mechanisms to promote parturition.  
 
1.8.1 Oxytocin receptors in pregnancy and parturition  
Although systemic oxytocin concentrations do not correlate with the progression of 
labour (Dawood et al., 1978) an increase in pulse frequency and the number of 
myometrial oxytocin receptors have been reported (Fuchs et al., 1984; Kimura et al., 
1996; Riemer & Heymann, 1998). Oxytocin has been shown to bind to its cognate 
myometrial Gαq and Gαi receptors for enhanced phasic and tonic uterine activity 
(Phaneuf et al., 1993; Riemer & Heymann, 1998; Wathes et al., 1999). During 
pregnancy, myometrial oxytocin mRNA transcripts increase 100-fold at 32 weeks and 
300-fold at parturition relative to the receptors expressed in the non-gravid uterus 
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(Kimura et al., 1996). This would likely sensitise the uterus to oxytocin immediately 
prior to labour-onset (Keelan et al., 1997). Even so, in the absence of maternal and 
foetal oxytocin, the delivery of a litter ends successfully at the same gestational age as 
wild-type mice (Young et al., 1996; Nishimori et al., 1996). Similarly in knockout 
mice deficient for both oxytocin and COX-1, labour contractions are timely but 
prolonged and neonatal deaths occur from maternal failure to establish lactation 
(Gross et al., 1998). This indicates possible compensatory or redundant mechanisms 
for oxytocin in the parturition process. Nevertheless, as only a few oxytocin receptors 
exist in the peripheral system (Kiss & Mikkelsen, 2005) and oxytocin stimulates 
preterm and term human uteri (Fuchs et al., 1984; Wathes et al., 1999; Nilsson et al., 
2003), the oxytocin receptor is considered a suitable target in the management of 
preterm labour.  
 
1.9 Preterm labour 
Preterm birth, defined as parturition before 37 weeks (259 days) of gestation, is a 
major obstetric problem related to perinatal mortality and morbidity. In Western 
countries, although only 6-10 percent of deliveries are premature, the associated 
complications result in more than two-thirds of perinatal deaths (Lumley, 2003). This 
is most severe with both early gestational age and low birth-weight infants. Over the 
past 20-30 years, advances in neonatal medicine and perinatal care have reduced 
mortality rates (Tucker et al., 2004). However, this has been counterbalanced by 
increased short-term morbidity and long-term physical and mental disability in infant 
survivors of very preterm birth. The immature development of foetal organs in third 
trimester of pregnancy is linked to a high prevalence of respiratory distress syndrome. 
Moreover, preterm delivery contributes to 50% of childhood neurological disabilities, 
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including subnormal cognitive function, cerebral palsy, blindness and deafness (Hack 
et al., 2000). As a result, the cost in terms of neonatal intensive care, long-term 
treatment and emotional trauma suffered by the parents are considerable. Therefore 
many risk factors have been identified in women to anticipate preterm delivery for 
improving neonatal outcome. 
Despite the multiple aetiologies of preterm birth, poor socio-economic status is 
principally associated with an increased risk of spontaneous preterm delivery. 
Contributing factors include increased frequency of cigarette smoking, nutritional 
deprivation, greater use of recreational drugs such as cocaine, psychological stress and 
involvement in heavy physical work. Nevertheless, these lifestyle risk factors have not 
been shown to exert independent adverse effects on pregnancy outcome (Slattery et 
al., 2002). 
 
Table 1.3 The factors known to be associated with preterm delivery (Steer, 2005). 
 
Factors associated with preterm delivery 
Spontaneous (70-80%) Iatrogenic (20-30%) 
Spontaneous rupture of the membranes Hypertension/ pre-eclampsia 
Infection Diabetes 
Multiple pregnancy Intrauterine growth restriction 
Cervical dysfunction/ uterine malformation  
Placental haemorrhage  
Malnutrition, stress  
 
 
 
 
Previous low neonatal birth weight or preterm delivery increases the prospect of 
subsequent premature births by 2.5-fold, implying the recurrence of active causal 
factors in subsequent pregnancies (Mercer et al., 1999). A high incidence of preterm 
labours has also been associated with low maternal body mass index, height below 
1.46m and very young or older maternal age groups (Steer, 2005). Large racial and 
ethnic disparities have been reported in the USA (Regan et al., 2005) but are not as 
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notable in other developed countries (Steer, 2005). Moreover, regardless of race, 
approximately half of all twin pregnancies that reach 20 weeks of gestation end 
prematurely (Gardner et al., 1995), linked to a high incidence of pre-eclampsia, 
placental abruption and uterine over-distension. Even so, some cases of preterm birth 
are iatrogenic because of maternal illness or developing foetal compromise (Table 
1.3). 
Systemic, intrauterine or genital tract-infections, arising at a preterm period of 
gestation, have been directly linked to the onset of labour (Keelan et al., 2003). In 
response to bacterial endotoxins, leukocytes infiltrate the uterus and cytokines and 
other inflammatory mediators are produced. The resulting augmentation of PG 
synthesis and activation of metalloproteinases are postulated to be principal 
mechanisms of infection-driven preterm labour. Although antibiotic treatments can 
reduce maternal infection, a meta-analysis of neonatal outcome showed an associated 
increase in functional impairments and cerebral palsy (Kenyon et al., 2008).  
 
1.10 Current treatments for preterm labour 
At present no effective diagnostic indicators exist for preterm labour. The only 
absolute proof is contractions of the uterus, accompanied by the progressive dilation 
of the cervix. However, by this time, tocolytic drugs and antibiotics are relatively 
ineffective, suppressing contractions temporarily in high-risk patients but rarely 
preventing preterm births (Caritis, 2005). Placebo-controlled studies suggest that 
current treatments only prolong pregnancy for 24-48 hours. This provides time to 
arrange transfer of the mother and the neonate to specialist care units and to 
administer glucocorticoids, which enhance foetal maturity and neonatal survival. Even 
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so, tocolytics are associated with a number of adverse maternal and foetal effects 
(Table 1.4).  
Table 1.4 Tocolytic therapies used clinically for preterm labour and their associated 
adverse effects (Plested & Lopez Bernal, 2001; Goldenberg, 2002; Meis et al., 2005; 
Papatsonis et al., 2009). 
 
Drug Mechanism Major side effects & comments 
Nifedipine Ca2+ blocker 
Maternal hypotension, altered uteroplacental blood flow, 
foetal tachychardia. Recommended by Papatsonis et al., 
2009. 
Ritodrine, 
Terbutaline 
β2-adrenergic 
agonists 
Cardiac arrhythmias, pulmonary oedema, myocardial 
ischaemia. Limited efficacy due to adverse effects and 
rapid desensitisation. 
Atosiban 
Oxytocin 
antagonist 
Maternal nausea, hyperglycaemia and headaches; no 
reported foetal side effects. 
Indometacin 
COX 
inhibitor 
Maternal gastrointestinal disturbance, ductus arteriosus 
constriction, lack of amniotic fluid. Not used >32 wks 
gestation. 
Magnesium 
sulphate 
Ca2+ 
antagonist 
Respiratory arrest, cardiac arrest, maternal nausea and 
headaches. Often used in pre-eclampsia. 
17-α-hydroxy-
progesterone 
caproate 
Progesterone 
agonist 
Fatigue, depression and headaches. Reduced incidence of 
preterm labour only in high-risk patients with a history of 
previous spontaneous premature deliveries.  
 
 
 
Current tocolytics include Ca2+ channel blockers, β2-mimetics, magnesium sulphate, 
COX inhibitors, progesterone analogues and oxytocin receptor antagonists. Recent 
trends have favoured agents with lower maternal side-effect profiles. These include 
Ca2+ channel blockers and oxytocin receptor antagonists, which are better tolerated 
than β2 agonists (Coomarasamy et al., 2002; Kashanian et al., 2005). To improve 
treatments all aspects of delayed labour, minimised side effects to mother and foetus 
and long-term health implications have to be evaluated. Agents with potential 
beneficial pharmacological properties include FP receptor antagonists, oxytocin 
antagonists and more novel inhibitory receptor agonists, such as those that target the 
EP3 receptor.  
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1.11 Aims 
The overall aim of this thesis is to investigate the functional expression of EP, FP, TP 
and oxytocin receptors in isolated human myometrium during the menstrual cycle, 
term pregnancy and parturition. At present, the relationship between PGs and 
oxytocin is not well elucidated. Whilst it is recognised that PG and oxytocin receptors 
modulate uterine contractions, cellular effects are dependent on the type of receptor 
engaged, coupled to divergent signalling pathways. Their responses have been 
difficult to define pharmacologically due to the moderate selectivity of some synthetic 
analogues (Coleman et al., 1994; Wilson et al., 2004). Section I of this thesis will 
address the effects of PGs and oxytocin using a range of standard and novel receptor 
agonists and antagonists. Assessment of their roles in smooth muscle contractility will 
be investigated using functional immersion and superfusion assays and tissues from 
different hormonal stages.  
PG and oxytocin receptors are subject to hormonal and gestational-dependent 
regulation. Although precise endocrine changes remain elusive, progesterone is 
associated with uterine quiescence whilst oestrogen promotes PG and oxytocin-
induced contractions (Thornton et al., 1999). This is regulated in a temporal and 
topographical manner (Giannopoulos et al., 1985; Adelantado et al., 1988; Brodt-
Eppley et al., 1999; Smith et al., 2001). To study total uterine function in the non-
pregnant state, spontaneous activity and PG and oxytocin receptor function will be 
investigated according to anatomical location and the stage of menstrual cycle of the 
donor. During pregnancy and parturition, in accordance with ethical constraints, 
myometrial specimens will only be recovered from the lower uterine segment. In this 
lower region, myogenicity and agonist-mediated contractions will be measured to 
identify the changes in PG and oxytocic effects at term and preterm pregnancy and 
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labour. As previous functional studies using human tissues obtained during labour are 
limited, the results of this thesis should particularly enhance knowledge of the 
parturient uterus. 
In conjunction with in vitro studies, a primary cell culture model will be developed to 
examine the separate functions of uterine smooth muscle cells and fibroblasts at term 
pregnancy (Section II). By establishing a method for the high throughput screening of 
compounds, PG and oxytocin-induced activation of Ca2+ (Wray, 1993) and cAMP 
signals (Europe-Finner et al., 1997; Price et al., 2000) will be studied relative to 
receptor mRNA. In conjunction with the results from Section I, cellular and molecular 
studies should clarify the contribution of receptors or messenger targets that culminate 
in opposing actions on myometrial tone.  
Using these methods, it may be possible to develop better therapeutic strategies to 
prevent or control myometrial disorders caused by uterine hypercontractility. 
 
 
 
 
   
  
  
 
 
 
Section I: 
Functional studies 
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Chapter 2: Materials and Methods 
 
 
 
2.1 Surgical specimens 
Human uterine smooth muscle was excised and donated for research from: 
- Longitudinal, full-thickness sections of the anterior uterus from non-pregnant 
donors, taken at hysterectomy. 
- Transverse, anterior, lower uterine segments from pregnant, non-labouring and 
labouring donors, taken at Caesarean section. 
 
2.2 Approval and ethical consent 
Ethical approval for all studies was obtained from the Local Regional Ethics 
Committees: Bradford Hospital NHS Trust and the University of Bradford Ethics 
Committee. All women who donated tissue gave informed written consent before 
surgical procedures were performed. Uterine specimens from non-pregnant donors 
were obtained from the Yorkshire Clinic and the Nucleus Theatres at the Bradford 
Royal Infirmary and samples from pregnant donors were collected from the Maternity 
unit at the Bradford Royal Infirmary. Patient consent forms and information sheets are 
included in the Appendix (Figures A1, A2, A3 and A4). 
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2.3 Uterine smooth muscle 
Longitudinal uterine specimens, taken at hysterectomy, were pale with visible 
distinctions between dense muscle, serosa and cervical tissue (Figure 2.1). In contrast, 
transverse muscle from pregnant donors was highly vascular, especially in samples 
taken after labour-onset. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 2.1: Uterine biopsies taken from a) non-pregnant and b) term pregnant, non-
labouring donors. 
 
2.3.1 Non-pregnant donors 
Human myometrial samples were obtained from pre-menopausal women undergoing 
hysterectomy for benign disorders, such as menorrhagia and dysmenorrhoea (Figure 
2.2). At the time of surgery, none of the donors were using oral contraceptives or had 
received any hormone therapy. The stage of menstrual cycle was recounted to the 
nearest week and recorded on patient information forms. Donor ages ranged from 29 
to 52 years (median 42 years) and 80 percent of uteri were removed during the 
follicular stage of the menstrual cycle. Specimens were excised from the anterior wall 
of the corpus uteri and a ligature was tied at the fundus to indicate orientation. 
 
a) 
b) 
Myometrium 
Serosa 
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Figure 2.2: Reasons recorded on patient information forms for hysterectomy for the 
treatment of benign disorders. 
 
2.3.2 Pregnant donors not in labour 
Segments of the upper margin of lower uterine muscle were obtained from preterm 
(33-36+6 weeks) and term (37-41 weeks) pregnant women, aged between 19 to 44 
years (median 30 years), undergoing elective, non-emergency Caesarean section. 
During this routine operation and due to ethical restrictions, myometrium was only 
removed from the superior edge of the transverse incision site, whilst fundal tissue 
was not available for biopsy. Subjects with maternal metabolic diseases, multiple 
foetuses or after labour-onset were grouped and analysed separately.  
 
2.3.3 Pregnant donors in labour 
At emergency Caesarean section, after delivery of the foetus and placenta, transverse 
myometrial biopsies were excised from the upper edge of lower uterine segments 
from labouring donors. Labour was defined as the presence of regular uterine 
contractions with early, mid and late labour in patients identified at 0-2.5cm, 3-8.5cm 
and ≥9cm cervical dilation respectively. Donors were between 18 and 37 years of age 
(median 29 years) at preterm (32-36+2 weeks) and term (37-42 weeks) gestations. The 
menorrhagia 
pelvic pain 
dys rrhoea 
previous endometrial ablation 
35% menorrhagia 
& dysmenorrhoea 
 
 
2% fibroids & 
dysmenorrhoea 
 
7% fibroids & 
menorrhagia 
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indications for Caesarean delivery included foetal distress, failed progression of 
labour, breech presentation, previous Caesarean sections, placental abruption, 
maternal pregnancy-induced hypertension, epilepsy and asthma.  
 
Table 2.1: Patient characteristics for term pregnant, not in labour (n=129), early-mid 
(n=35) and late (n=17) labouring donors. 
 
  Term pregnancy Early-mid labour Late-labour 
Donor details n   % n   % n   % 
White British 89   69.0 17   48.6.7 6   35.3 
Pakistani/ Indian 10   7.8 11   31.4 7   41.2 
Other ethnic groups 12   9.3 2   5.7 1   5.9 
Details not recorded 18   14.0 5   14.3 3   17.6 
Previous abortions/ miscarriages 33   25.6 12   35.3 2   14.3 
Previous labours 61   60.4 14   41.2 3   21.4 
Previous Caesarean sections 88   68.8 13   61.9 4   28.6 
Cigarette smokersa 32   24.8 8   23.5 2   11.8 
Medical conditionsb 18   14.0 11   32.4 7   41.2 
Current medication 15   11.6 10   29.4 7   41.2 
 
a Patients smoked 3 to 20 cigarettes per day throughout pregnancy 
b Medical conditions included: gestational diabetes, pregnancy-induced hypertension, asthma, 
epilepsy, sickle cell anaemia, Streptococcus B infections and Crohn’s disease. 
 
2.4 Compounds 
Agonists and antagonists used in functional studies were prepared as a 10mM stock 
solution according to the manufacturers’ advice (Table 2.2). Serial dilutions were 
made with 0.9% w/v normal saline and kept on ice throughout experiments. 
 
2.4.1 Solutions 
Prior to immersion and superfusion assays, Krebs’-Heinseleit physiological salt 
(Krebs’) solution (pH 7.4) was freshly prepared at the following composition (mM): 
NaCl 118.9; KCl 4.7; KH2PO4 1.2; MgSO4 1.2; CaCl2 2.5, NaHCO3 25.0, glucose 
10.0 and oxygenated with 95% O2 and 5% CO2. 
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Table 2.2: Agonists and antagonists used to identify functional receptors in human myometrium. Time-matched vehicles, matched for solvent, 
caused no effect on myogenicity of tissue strips. The key indicates line colour on concentration-effect curves. 
 
Compound Key Receptor target Action Chemical name 
Stock 
Vehicle Source 
AGN201734 
Elworthy et al. (2004) 
 EP4 agonist 
7-2-[(E)-3-hydroxy-4-(3-trifluoromethyl-phenyl)-phenyl)-
but-1-enyl]-5-oxo-pyrrolidin-1-yl)-heptanoic acid) ethanol Allergan Inc., USA 
AGN211329 
Belley et al. (2005) 
 EP3 antagonist 
3-(-2-(3-[2-2, 6-dichloro-benzloxy)-3-methyl-phenyl]-allyl]-
phenyl)-acrylic acid ethanol Allergan Inc., USA 
AGN211330 
Belley et al. (2005) 
 EP2 agonist 1-(benzyloxy-2-vinylbenzene)-2-bromocinnamic acid ethanol Allergan Inc., USA 
AH13205 
Coleman et al. (1994) 
 EP2 agonist 
trans-2-(4-(1-Hydroxyhexyl)phenyl-5-oxocyclopentane- 
heptanoic acid DMSO Sigma-Aldrich, UK 
AH-6809 
Coleman et al. (1994) 
 EP1, EP2, EP3 
& DP1 
antagonist 6-Isopropoxy-9-xanthone-2-carboxylic acid DMSO Cayman chemicals, USA 
Atosiban 
Nilsson et al., (2003) 
 OTR antagonist 1-(3-mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithine-oxytocin 
0.1% BSA 
in dH2O 
Sigma-Aldrich, UK 
Butaprost 
Gardiner (1986) 
 EP2 agonist 
9-oxo-11α, 16S-dihydroxy-17-cyclobutyl-prost-13E-en-1-oic 
acid, methyl ester 
ethanol Cayman Chemicals, USA 
Caspase-3 Inhibitor 
Moore et al., (2002) 
 Caspase-3 (6, 
7, 8 & 10) inhibitor 
(3S)-3-[[(2S)-2-[(2S)-2-acetamido-3-methylbutanoyl]amino 
propanoyl]amino]-4-oxobutanoic acid DMSO Calbiochem, USA 
CP533,536 
Li et al., (2003); 
Paralkar et al. (2003) 
 
EP2 agonist 
3-[(4-tert-butyl-benzyl)-pyridine-3-sulfonyl-amino)-methyl)-
phenoxy]-acetic acid sodium salt ethanol 
Allergan Inc., USA 
a Pfizer compound 
GR32191B 
Lumley et al. (1989) 
 TP antagonist 7-[5-[[(1, 1’-biphenyl)-4-yl] methoxy]-3-hydroxy-2-(1-piperidinyl) cyclopentyl]-4-heptanoic acid ethanol 
GlaxoSmith-Kline, 
UK 
GW627368x 
Wilson et al. (2006) 
 EP4 antagonist 
(N-(2-[4[(4,9-diethoxy-1-oxo-1,3-dihydro-2H-
benzo[f]isoindol-2-yl)phenyl]-acetyl]benzene-sulphonamide DMSO 
GlaxoSmith-Kline, 
UK 
Indometacin 
Durn et al. (2010) 
 COX inhibitor 1[p-chlorobenzoyl]5-methoxy-2-methlindole-3-acetic acid ethanol Sigma-Aldrich, UK 
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L-902688 
Billot et al. (2003) 
 EP4 agonist 
5-(3-Hydroxy-4-phenyl-but-1-enyl)-1- [6-(1H-tetrazol-5-
yl)-hexyl]-pyrrolidin-2-one. ethanol Allergan Inc., USA 
Lanthanum chloride 
Fu et al. (2000) 
 Ca2+ channels inhibitor trichlorolanthanum ethanol Sigma-Aldrich, UK 
Nifedipine 
Phillippe & Basa (1997) 
 L-type Ca2+ 
channels inhibitor 
dimethyl2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-
3,5-dicarboxylate ethanol Sigma-Aldrich, UK 
ONO-D1-004 
Oka et al. (2003) 
 EP1 agonist 
4-[2-[(1,2,3)-3-hydroxy-2-[3-hydroxy-5-methylnon-1-enyl]-
5-oxocyclopentyl]acetyl]cyclohexane-1-carboxylic acid ethanol Allergan Inc., USA 
Oxytocin 
Noe et al. (1999) 
 
OTR agonist 
(1-(2-amino-2-oxoethylamino)-4-methyl-1-oxopentan-2-yl)-
1-(19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-
oxopropyl)-13-sec-butyl-16-(4-hydroxybenzyl)-pentaoxo-
1,2-dithia-pentaazacycloicosane 
dH2O Sigma-Aldrich, UK 
Prostaglandin E2 
Coleman et al. (1994) 
 EP1-4 agonist 9-oxo-11α, 15S-dihydroxy-prosta-5Z,13E-dien-1-oic acid ethanol Cayman Chemicals, USA 
Prostaglandin F2α 
Coleman et al. (1994) 
 FP agonist 9α, 11α, 15S-trihydroxy-prosta-5Z, 13E-dien-1-oic acid, tris 
(hydroxymethyl) aminomethane salt 
ethanol Cayman Chemicals, USA 
Rho-kinase inhibitor 
Ikenoya et al. (2002) 
 ROCK inhibitor (S)-(+)-2-Methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]homopiperazine, 2HCl dH2O Calbiochem, USA 
SQ29,548 
Ogletree et al. (1985) 
 
TP antagonist 
[1S-[1α,2α(Z),3α,4α]]-7-[3-[[2-
[(phenylamino)carbonyl]hydrazino]methyl]-7-
oxabicyclo[2.2.1]hept-2-yl]-5-heptanoic acid 
ethanol Cayman Chemicals, USA 
Sulprostone 
Schaaf et al, 1981 
 EP3/1 agonist 
N-(methylsulfonyl)-9-oxo-11α,15R-dihydroxy-16-phenoxy-
17,18,19,20-tetranor-prosta-5Z,13E-dien-1-amide 
ethanol Cayman Chemicals, USA 
Thapsigargin 
Fomin et al. (1999) 
 
Ca2+-ATPase inhibitor 
6-(acetyloxy)-4-(butyryloxy)-3-dihydroxy-3,6,9-trimethyl-8-
([(2Z)-2-methylbut-2-enoyl]oxy)-2-oxo-2,3,4,5,6,7,8,9-
decahydroazuleno[4,5]furan-7-yl octanoate 
ethanol Sigma-Aldrich, UK 
U46619 
Coleman et al. (1994) 
 TP agonist 9,11-dideoxy-9α,11α-methanoepoxy-prosta-5Z, 13E-dien-1-
oic acid 
ethanol Cayman Chemicals, USA 
 
Alterative code names for the EP3 antagonist AGN211329:  L-826266 (Belley et al., 2005), the caspase-3 inhibitor: Z-D(OMe)E(Ome)VD(OMe)-
FMK (Moore et al., 2002) and the rho-kinase inhibitor: H1152 (Shum et al., 2003). 
  Chapter Two: Materials & Methods 
  Page 32
   
2.5 Tissue collection and preparation 
Immediately following surgical removal of uterine specimens, the biopsies were 
places in Krebs’ solution for transport to the laboratory. The uterine samples were 
then trimmed of endometrial, serosal, fat and fibrous tissue and dissected to produce 
strips (10 x 2 x 3mm) of predominantly longitudinal muscle. Myometrial strips were 
then set-up for functional studies using immersion and superfusion techniques. 
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2.6 Immersion 
Vilhelm Magnus (1871-1929) first introduced the idea of suspending an isolated 
portion of smooth muscle in a chamber containing a nutrient fluid and measuring 
changes in tissue tone. Traditional organ baths used by Sir Henry Dale (1875-1968) 
were modified for this study. The dissected strips of myometrium were mounted 
longitudinally in individual 8ml water-jacketed muscle baths (York Glassware 
Services, York, UK), containing aerated (95% O2, 5% CO2) Krebs’ solution at 37°C 
(Figure 2.3). Immersed tissue strips were maintained at a constant temperature and pH 
(Table 2.3) with the volume of Krebs’ solution adjusted via a tap and overflow 
system.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Immersion equipment used to examine functional receptors in the isolated 
human uterus and a myometrium sample anchored to a tissue holder. 
Uterine muscle 
Muscle bath at 
37°C 
Tissue holder 
Isometric tension 
transducer 
Heating coils at 
37°C 
Krebs’ supply 
Overflow outlet 
Filter supplying 
95%O2, 5% CO2 
Krebs’ inlet tap 
Krebs’ solution 
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Table 2.3: Changes in the pH of Krebs’ solution over time whilst equilibrating human 
myometrial strips (n=3). Results are expressed as means ± S.E. 
 
Equilibration Time: 0hrs 3hrs 6hrs 
pH of Krebs’ solution: 7.42 ± 0.03 7.41 ± 0.03 7.39 ± 0.07 
 
 
 
Changes in tension were measured after attaching myometrial strips to isometric force 
transducers (Grass Instruments Inc., Rhode Island, USA), connected to a personal 
computer (Dell Inc) via bridge amplifiers (AD Instruments, Hastings, UK). Traces 
were recorded digitally on a PowerLab data acquisition system running Microsoft 
Chart v5.4 software (sampling frequency 2Hz; AD Instruments, Hastings, UK). 
 
Muscle baths were refilled with Krebs’ solution and an initial, optimum resting 
tension of 2g was applied to each strip (Morrison et al., 1993; Slattery et al., 2001). 
Isolated tissues from non-pregnant and term pregnant donors were equilibrated for a 
minimum of 60 and 90 minutes respectively or until regular phasic contractions had 
developed (Figure 2.4). This myogenic activity was recorded over a subsequent 30-
minute period before addition of the study drug and remained stable for at least 5 
hours (Popescu et al., 2006; Figure 2.4), demonstrating the viability of tissue strips 
within immersion baths. In myometrium from labouring donors, experiments were 
initiated after 2.5 hours of equilibration, regardless of the presence or absence of 
contractile activity.  
 
       
   
   
  Chapter Two: Materials & Methods 
              Page 35
   
0-30 30-60 60-90 90-120 120-150
0
250
500
750
1000
1250
1500
**
*** ***
Equilibration (mins)
A
r
e
a
 
u
n
d
e
r
 
t
h
e
 
c
u
r
v
e
 
(
g
.
s
)
0-30 30-60 60-90 90-120
0
250
500
750
1000
1250
1500
Equilibration (mins)
A
r
e
a
 
u
n
d
e
r
 
t
h
e
 
c
u
r
v
e
 
(
g
.
s
)
 
 
 
 
 
. 
 
 
 
 
 
 
 
                                                                                                        
Figure 2.4: Equilibration for regular contractions to develop in myometrium taken at a) hysterectomy (fundus) (n=10) and b) elective Caesarean 
section from term pregnant, non-labouring women (n=10). Contractile activity was measured as the integrated area under the curve (g.s), 
expressed as means ± S.E. Univariate ANOVA with Bonferroni’s post-hoc test showed an increase in myogenic activity compared to the activity 
established between 0-30 minutes of tissue set-up **p<0.01; ***p<0.001.  
Traces are representative of stable contractions developed by immersed vehicle control strips after equilibrating for a) 60 and b) 90 minutes. 
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b) 
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Although 89 percent of tissues were set-up within a 2-hour post-operative period, the 
samples that could not be processed immediately were stored in oxygenated Krebs’ 
solution at room temperature for up to 18 hours. As well as no obvious signs of 
bacterial contamination, ambient temperatures avoided the reduction in spontaneous 
activity observed with tissues stored at 4ºC (personal communication, Hutchinson, 
2005). Similar myogenic responses to prostanoid compounds between fresh and 
stored tissues have been previously demonstrated (Hillock & Crankshaw, 1999; Popat 
& Crankshaw, 2001) and maintenance of tissue viability was validated in this study 
(Figure 2.5). As a result, data from fresh and stored tissues were pooled and 
collectively analysed.  
  
 
 
 
  
 
  
 
 
Figure 2.5: Spontaneous activity of isolated myometrium from a) non-pregnant (n=4) 
and b) pregnant (n=4) donors set-up for immersion within 2 or 18 hours of surgery. 
All hysterectomy samples were fundus-end and excised during the follicular stage of 
the menstrual cycle. Regular myogenicity was measured over 30 minutes as the 
integrated area under the curve (g.s) and expressed as means ± S.E. 
 
a) b) 
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2.6.1 Administration of drugs 
Following tissue equilibration, vehicle and drugs were added to immersion baths at a 
maximum volume of 8µl to prevent fluctuations in temperature and pH. Tissue strips 
were randomly assigned treatments and cumulative concentration-effect curves were 
constructed at 30-minute intervals, using log unit concentration increases. The 
concentration range of agonists [10-12M to 10-5M] was adjusted to encompass full 
concentration-effect curves and spanned at least 5 log units. Responses were 
expressed as a percentage of hypotonic shock (details in Section 2.6.3). 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Concentration-response curves for PGE2 in myometrium from term 
pregnant donors added in a cumulative (n=12) and a non-cumulative (n=5) manner to 
immersion baths. Traces show the changes in regular spontaneous activity with 
additions of PGE2 a) at 10-6M, b) at 10-5M and c) added sequentially to myometrial 
strips. 
 
By pooling successive agonists, a wide range of compounds could be assayed per 
donor tissue and individual drug effects were directly comparable to the same 
myometrial strip. Moreover, similar responses to PGE2 in cumulative and non-
PGE2 10-6M
PGE2 10-5M
PGE2 10-6M 10-5M 
Hypotonic shock
Hypotonic shock
Hypotonic shock
30 minutes 
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cumulative treatments indicated that myometrial receptors did not desensitise during 
experiments (Figure 2.6).  
In some cases, at least one tissue strip from the same biopsy was challenged for 30 
minutes with an antagonist before the addition of time-matched agonist 
concentrations. This served to validate the selectivity of agonists on receptors. Some 
agonist-treated tissue strips were washed with fresh Krebs’ solution and equilibrated 
for 30 minutes to re-establish contractile activity (Figure 2.7). However, this was 
avoided when testing antagonists due to difficulties in complete removal of lipophillic 
compounds (Nilsson et al., 2003). 
 
 
 
 
 
Figure 2.7: Representative traces of myometrial strips from a) non-pregnant and b) 
term pregnant, non-labouring donors after refilling immersion baths with fresh Krebs’ 
solution. Washing tissue caused a brief period of quiescence before the return of 
myogenic activity. 
 
 
2.6.2 Measurement of tissue activity 
Myometrial activity was quantified as the integrated area under the contraction curve, 
which accounted for changes in contractile frequency, duration and amplitude. To set 
the lower base tension for area calculation, integral above mean settings were applied 
using Chart v5.4. Data were measured over 30-minute epochs (Thornton et al., 1999) 
as this time-period of activity most clearly distinguished drug-induced effects from 
spontaneous contractions (Figure 2.8).  
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Figure 2.8: Spontaneous activity and the concentration-effect of U46619 in 
myometrial strips from term pregnant, non-labouring donors (n=6) measured at 5, 10, 
20 and 30-minute intervals after agonist additions to muscle baths. Results are 
expressed as means ± S.E. and analysed using repeated measures ANOVA with 
Bonferroni’s post-hoc test; *p<0.05; **p<0.01; ***p<0.001 for the reduction in 
measured activity over a) 5, b) 10 and c) 20 minutes compared to 30-minute responses 
to U46619. 
 
 
 
 
 
 
 
Figure 2.9: A representative trace showing the concentration-dependent increase in 
contractile activity to U46619 in an isolated myometrium taken at term pregnancy, not 
in labour. The trace was measured over a) 5, b) 10, c) 20 and d) 30 minutes after 
U46619 additions to the immersion bath.  
30 minutes a 
c 
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d 
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2.6.3 Normalising responses 
 
 
 
 
 
 
 
Figure 2.10: Traces showing unique 30-minute profiles of spontaneous activity from 
parallel myometrial strips taken from the same piece of isolated uterine tissue donated 
at term pregnancy. 
 
Traces of spontaneous activity were unique for each muscle strip and functionally 
idiosyncratic (Figure 2.10). This was attributed to the intrinsic variability between 
donor hormonal states and the differences in receptor dominance, cell types and 
filament composition of myometrial strips (Crankshaw, 2001; Popat & Crankshaw, 
2001). To reduce intra- and inter-assay variations, the data were therefore normalised.  
Previous functional studies have quantified agonist-induced responses (T) as a ratio of 
the background activity (B) (Senior et al., 1991; Duckworth et al., 2002). However, 
this would not have represented isolated myometrium taken at late labour, which 
frequently lacked background contractility. Instead, measured responses were 
expressed as a percentage of a reference contraction, induced by displacing the Krebs’ 
solution with distilled water (Popat & Crankshaw, 2001). This hypotonic shock was 
performed after the final drug incubation to avoid disrupting receptor and tissue 
activity. In addition, compounds interacting with G-protein coupled receptors would 
not alter the reference contraction, mediated via Ca2+-activated potassium and 
chloride channels.  
Preliminary experiments were conducted on isolated myometrium to ensure that the 
reference contraction was reliable and reproducible. Compared to sustained 
contractions by potassium chloride (KCl), maximal tissue responses to distilled water 
30 minutes 
10g 10g 6g 
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were higher in amplitude and declined more steadily with time (Figures 2.11 & 2.12). 
As a result, hypotonic shock was used to normalise response data in this study. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11: Reference contractions induced by the displacement of Krebs’ solution in 
immersion baths with a) distilled water (hypotonic shock) and b) potassium chloride 
(KCl, 60mM) in myometrial strips from term pregnant, non-labouring donors 
displaying regular spontaneous activity. Traces show that the contraction by KCl was 
sustained but lower in amplitude than that produced by hypotonic shock. 
 
 
 
 
 
Figure 2.12: A comparison between the reference contractions induced by distilled 
water (hypotonic shock) and potassium chloride (KCl, 60mM) in myometrial strips 
from term pregnant donors (n=5). Activity was measured as a) the integrated area 
under the contraction curve over 30 minutes and b) the amplitude of contractions.  
Results are expressed as means ± S.E. 
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2.7 Superfusion 
The superfusion technique was performed in parallel to the immersion procedure to 
measure myometrial responses to bolus doses of compounds. Although first described 
by Finkleman (1930), the method was modified to allow direct administration of test 
substances into the superfusate (Gaddum et al., 1939). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13: Superfusion apparatus for functional studies using isolated human 
myometrium. 
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Each uterine segment was secured to a metal tissue holder, and mounted 
longitudinally within a glass superfusion chamber (York Glassware Services, York, 
UK), heated to 37°C (Figure 2.13). After aerating with 95% O2: 5% CO2, the Krebs’ 
solution was driven through heating coils within the superfusion chamber by a 
Watson & Marlow MHRE peristaltic pump at a rate of 2ml min-1 (Senior et al., 1991). 
A short section of re-sealable silicon tubing (Watson-Marlow Bredel Pumps Ltd., 
Cornwall, UK) was used to direct the constant flow of Krebs’ solution out of the 
chamber and over the suspended myometrial strip.  
Isometric tissue contractions were recorded using force transducers (Grass 
Instruments Inc., Rhode Island, USA) at a passive tension of 2g (Senior et al., 1991; 
Duckworth et al., 2002). The signals were amplified, digitally converted and stored in 
a personal computer (Dell Inc.) by PowerLab data acquisition software running 
Microsoft Chart v5.4 (sampling frequency 2Hz; AD Instruments, Hastings, UK). 
Tissue strips from non-pregnant and pregnant donors were equilibrated for at least 60 
and 90 minutes respectively or until regular phasic contractions were achieved. This 
mechanical activity was measured and analysed over the following 30 minutes. 
Compared to the immersion set-up, the development of tissue strip contractions were 
attenuated in amplitude rather than frequency (Figure 2.14), suggesting that fluid 
tension facilitated the contractile force of immersed myometrium. As the spontaneous 
activity of isolated tissues from labouring donors was more sporadic, experiments 
were initiated after 2.5 hours of equilibration. 
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Figure 2.14: Spontaneous activity measured as area under the curve (AUC), frequency 
(number) and amplitude (g) of contractions over 30-minute intervals before the 
addition of test drugs in myometrium taken at a) hysterectomy and b) term elective 
Caesarean section using immersion and superfusion techniques. Results were 
expressed as means ± S.E and analysed using one-way ANOVA with Bonferroni’s 
post-hoc test; *p<0.05; ***p<0.001 compared to contractions established in immersed 
tissue strips. 
Traces show the intrinsic activity developed by isolated myometrium equilibrated in 
immersion and superfusion apparatus.  
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2.7.1 Administration of drugs 
Agonists were injected directly into the Krebs’ superfusate through re-sealable silicon 
tubing using a 100µl glass micropipette (Hamilton Co., Nevada, USA). For a 
consistent flow rate and accurate dosing, the maximum volume of agonist 
administered was 10µl. After tissue equilibration, vehicle and dose-response curves 
were constructed sequentially and doses, ranging from 10-14mol to 10-7mol, were 
adjusted according to drug potency. Tissues were treated at 30-minute intervals or 
until the resumption of baseline activity. This corresponded to immersion 
measurements and was sufficient to wash drugs from the tissues for uniform 
responses to repeated sub-maximal doses (Griffiths et al., 2006).  
In parallel studies, 30 minutes prior to agonist dosing, antagonists were added to 
superfusate reservoirs for constant perfusion over the tissue. Muscle strips from the 
same biopsy were also assigned as time-matched vehicle controls with intrinsic 
activity sustained for the duration of each experiment (Figure 2.15). Only one dose-
response curve was completed per tissue strip, after which the Krebs’ solution in the 
reservoir was replaced with distilled water and perfused for 30 minutes. This induced 
a large hypotonic contraction unique to each myometrial strip (Popat & Crankshaw, 
2001).  
 
2.7.2 Measurement of tissue activity  
Equivalent to immersion recordings, excitatory myometrial responses were measured 
immediately after dosing as the integrated area under the contraction curve over a 30-
minute period. This was expressed as a percentage of the activity integral induced by 
30 minutes of hypotonic shock. 
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Figure 2.15: Traces showing the activity of myometrial strips from a) non-pregnant 
and b) term pregnant, non-labouring donors equilibrated in the superfusion apparatus. 
Vehicle controls demonstrated that there was no temporal effect on frequency and 
amplitude of contractions. 
 
 
 
The hypotonic shock varied between non-pregnant and pregnant donor groups, with 
more transitory contractions reflecting smooth muscle remodelling and changes in 
proteins encoding ion channels during pregnancy (Challis et al., 2000). Even so, when 
measured as the area under the curve, responses to hypotonic shock were consistent 
regardless of the stage of menstrual cycle or gestational state (Table 2.4). This was 
applicable for both immersion and superfusion experiments validating further this 
method of data normalisation. 
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Table 2.4:  The mean force of contractions induced by hypotonic shock (distilled 
water) in myometrial strips taken at menses (n=6), follicular (n=13) and luteal (n=5) 
stages of the menstrual cycle and at term pregnancy, not in labour (n=20), early-mid 
(n=13) and late (n=11) labour equilibrated in immersion and superfusion apparatus. 
Results were measured for 30 minutes as the integrated area under the curve (g.s) and 
expressed as arithmetic means ± S.E. The hypotonic shock was not significantly 
different, regardless of assay technique. 
 
 Immersion Superfusion 
Stage of Menstrual Cycle Hypotonic shock (g.s) Hypotonic shock (g.s)
Menses 2093 ± 170 2282 ± 277 
Follicular 2294 ± 123 2071 ± 125 
Luteal 1996 ± 121 2234 ± 154 
Stage of Gestation Hypotonic shock (g.s) Hypotonic shock (g.s)
Term pregnancy 2161 ± 388 2260 ± 133 
Early-mid labour 2115 ± 367 2290 ± 467 
Late labour 1777 ± 185 1809 ± 266 
 
 
 
 
For inhibitory studies using superfusion, tissue myogenicity was not always re-
established within the 30-minute intervals. As a result, the inhibitory response to 
agonists was expressed as the extended time between spontaneous contractions. 
Agonists were administered immediately following the repolarisation phase of a 
contraction to avoid superimposing responses on background activity. This time 
period was measured from the point of agonist injection to the recurrence of a 
spontaneous contraction, measuring at least 80 percent of the previous contraction 
peak height (Senior et al., 1991). Any initial excitatory responses were excluded from 
this measurement and background activity was corrected by subtracting the time 
interval between preceding regular contractions (Figure 2.16).  
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Figure 2.16: A sample trace showing measurement of the inhibitory period induced by 
PGE2 added as bolus doses to myometrium from term pregnant, non-labouring 
donors. The response was measured as the time in minutes between agonist 
administration and the re-establishment of a defined spontaneous contraction minus 
the standard time between contractions before agonist dose administration.  
 
 
 
2.8 Choice of technique 
The contractile activity and receptor function of myometrial strips were comparable in 
immersion and superfusion studies, indicating the merits of using either technique. 
Due to the highly regulated tissue environments, each system provided data that were 
reliable and reproducible. 
When added to immersion baths in a cumulative manner, the contact time of 
compounds could be determined and prolonged drug incubations mimicked in vivo 
conditions. Whilst limited compounds were conserved in muscle baths, the chemically 
unstable compounds were better identified using superfusion (Gaddum et al., 1939). 
As bolus doses were immediately washed, the constant perfusion of the Krebs’ 
superfusate reduced any potential interactions of endogenous tissue metabolites. 
Therefore, both techniques were useful in characterising the receptors involved in 
myometrial activity of the isolated human uterus. 
 
PGE2 10-8mol 10-7mol 
Background Inhibitory period 
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2g 
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2.9 Statistical analysis 
Data were first tested for normality using a Kolmogorov-Smirnov test. To examine 
the relationship between agonist concentrations and treatment, contractile activity of 
myometrial strips was compared using a student’s t-test or one-way/ two-way analysis 
of variance (ANOVA) in a mixed model. Post-hoc comparisons were performed using 
Bonferroni’s adjustment. Estimates of the maximal effect (Em) and inhibitory (pIC50) 
or excitatory (pEC50) curve mid-points were calculated for agonists and antagonists at 
different stages of the menstrual cycle, term pregnancy and parturition using non-
linear regression (GraphPad Prism 4.0, San Diego, CA, USA). When Em was not 
reached, constraints for the lower asymptote were set at greater than zero to avoid 
curves that tended to infinity. For competitive antagonists, pA2 values were also 
estimated as a measure of affinity using the Schild’s equation. Results were expressed 
as arithmetic means ± S.E. and significance was attributed at p<0.05.  
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Chapter 3: Non-pregnant 
 
Functional prostanoid receptors in isolated non-gravid myometrium 
 
 
3.1 Introduction 
The uterus undergoes dramatic changes during the menstrual cycle, facilitating sperm 
transport, ovum fertilisation and implantation of the developing blastocyst. In the 
absence of pregnancy, the corpus luteum involutes and the resultant withdrawal of 
progesterone causes cyclic degradation and shedding of the superficial endometrial 
layer (menstruation).  This involves a process of tissue injury and spiral arteriole 
vasoconstriction predominantly mediated by elevated PGF2α, PGE2, COX enzymes, 
oxytocin and endothelin-1 (Marsh et al., 1995; Smith et al., 2007). Further increases 
in circulatory prostanoids and oxytocin have been associated with common 
gynaecological disorders, including menorrhagia (excessive menstrual blood loss) and 
dysmenorrhoea (painful periods) (Adelantado et al., 1988; Noe et al., 1999; Dawood 
& Khan-Dawood, 2007; Smith et al., 2007). Despite the accompanied 
hypercontractility of the uterus (Leyendecker et al., 2004; Altunyurt et al., 2005; 
Kataoka et al., 2005; Dawood & Khan-Dawood 2007), myometrial responsiveness to 
PGs and oxytocin receptor agonists remain unclear. 
To identify functional uterine PG and oxytocin receptor populations, in vitro studies 
were performed using myometrial biopsies taken at hysterectomy from pre-
menopausal women (aged 29 to 52 years). Phasic myometrial activity and receptor-
mediated effects were assessed according to the stage of menstrual cycle and excision 
site under physiological conditions. These results also provided a baseline comparison 
for gestational tissues taken before and after labour-onset. 
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Chapter 3.2: Results 
 
 
 
3.3 Samples from non-pregnant donors 
Although harvested at total hysterectomy, 83 percent of the provided uterine 
specimens were incomplete longitudinal sections taken from the fundus and adjoined 
upper corpus muscle. This corresponded to the fewer assays using lower segment 
tissues from non-pregnant donors. The orientation of uterine muscle was denoted by a 
ligature aligned with the upper serosal edge and experimental tissues were excised 
from the mid-uterine wall >5mm from either the endometrial or serosal surfaces. 
Regardless of regional location and stage of menstrual cycle, samples were 
equilibrated for 89 minutes (range: 77 to 153 minutes) to facilitate the development of 
regular phasic activity. In spite of intra- and inter-donor variations, myogenic 
contractile profiles were distinct in frequency and amplitude; this was particularly 
manifest during the different stages of the menstrual cycle.  
 
3.4 Myogenic activity at different stages of the menstrual cycle 
All myometrial strips obtained from non-pregnant donors at hysterectomy developed 
spontaneous activity. The undulating activity was most frequent, but sporadic during 
the menstrual phase of the cycle (Figure 3.1). However, the overall myogenicity was 
only at 37.2 ± 1.38 percent hypotonic shock due to the low amplitude of contractions 
(Table 3.1). In tissues taken mid-cycle from the fundus, the amplitude of contractions 
was 3.1 and 1.5 fold greater than myometrium from menstrual (p<0.001) and luteal 
phases, when contractions were slow and phasic. The rank order of myogenic activity 
was follicular > luteal > menstrual stages. Moreover, variation was exhibited 
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topographically during the follicular phase with activity 20 percent greater in lower 
compared with fundus-end tissues (p<0.001). This was due to the differences in 
amplitude rather than frequency of contractions. 
 
3.5 Indications for hysterectomy 
Hysterectomies were performed for benign gynaecological disorders, including 
menorrhagia, dysmenorrhoea and fibroids. All donors were premenopausal and use of 
oral contraceptives or hormone therapies had been discontinued for 6-8 weeks prior to 
surgery. Thereby, the only medications noted on patient forms for 3 individual donors 
were aspirin and Ventolin. Despite the different indications for hysterectomy, phasic 
contractile activity was not influenced by donor symptoms or underlying disease 
states (Table 3.2).  
 
3.6 Longitudinal and transverse myometrial sections. 
Although myometrial strips were dissected longitudinally for functional studies, the 
spontaneous contractions generated by transversely cut sections gained comparable 
intensity following equilibration in organ baths (Table 3.3). This was observed in both 
fundus and lower segment samples. 
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Figure 3.1: Spontaneous contractions of immersed myometrial strips taken at 
hysterectomy. Myometrium was excised from fundus (n=20) and lower (n=4) 
segment uterine muscle at the different stages of the menstrual cycle. After 
equilibration, myogenic activity was measured as 30 minutes area under the curve and 
expressed as a percentage of 30 minutes hypotonic shock. Data are arithmetic means 
± S.E. and statistics were performed using univariate ANOVA with Bonferroni’s post-
hoc adjustment; **p<0.01; ***p<0.001 reduction in contractility compared with 
tissues taken during the follicular stage from afundus and blower segment tissues. 
 
Traces display typical spontaneous activity of immersed 1) upper and 2) lower 
segment isolated myometrium obtained from non-pregnant donors during i) menses, 
ii) follicular and iii) luteal stages of the menstrual cycle. Each trace represents a 30-
minute time period. 
1ii) 
1i) 
1iii) 
2ii) 
4g 
5g 
2g 
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Table 3.1: Spontaneous activity measured as amplitude (g) and frequency of 
contractions over 30-minute intervals before the addition of study compounds in 
myometrium taken at hysterectomy (n=3-5). Myogenic profiles were evaluated 
according to menstrual cycle stage and uterine location using the immersion 
technique. Results are expressed as means ± S.E. and analysed using one-way 
ANOVA with Bonferroni’s post-hoc adjustment; *p<0.05; **p<0.01; ***p<0.001 for 
myogenic contractions compared to fundus end tissues taken at amenses, bfollicular 
and cluteal phases of the cycle. 
 
 Location Fundus Lower 
Stage of cycle Menses Follicular Luteal Follicular 
Amplitude (g) 1.3 ± 0.2 3.9 ± 2.6***a 2.6 ± 0.4*a 4.4 ± 0.6*b; ***ac 
Frequency (No) 9.9 ± 0.6 7.8 ± 1.3*a 6.7 ± 0.5**a 8.4 ± 1.7 
 
 
 
 
 
Table 3.2: Spontaneous activity of myometrial strips equilibrated in immersion baths 
and categorised according to the main indications noted on patient information forms. 
Uterine samples were harvested from non-pregnant donors with each group in the 
follicular stage of the menstrual cycle (n=3-5). Data were measured as 30 minutes 
area under the curve, expressed as a percentage of 30 minutes hypotonic shock (HS) 
and results are arithmetic means ± S.E. 
 
Indications Menorrhagia Dysmenorrhoea Menorrhagia & dysmenorrhoea 
Menorrhagia & 
fibroids 
Activity (%HS) 47.0 ± 2.3 46.8 ± 1.9 51.5 ± 2.9 50.9 ± 2.2 
 
 
 
 
 
Table 3.3: Spontaneous activity of immersed myometrial strips dissected 
longitudinally or transversely across fundus and lower segment uterine muscle (n=3). 
Myometrial samples were obtained at hysterectomy in the non-pregnant state. 
Following equilibration, regular myogenic activity was measured as 30 minutes 
integrated area under the curve and expressed as a percentage of 30 minutes hypotonic 
shock. Results are arithmetic means ± S.E. 
 
Location Fundus Lower segment 
Dissected fibres Longitudinal Transverse Longitudinal Transverse 
Activity (%HS) 36.0 ± 0.8 37.3 ± 1.8 53.7 ± 3.0 54.1 ± 1.8 
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3.7 Characterisation of EP receptors using PGE2 and EP analogues 
PGE2 is well characterised in its targeting of EP1-4 receptors (Coleman et al., 1994). 
To broadly identify myometrial responsiveness, PGE2 was assayed in the absence and 
presence of indometacin and across the different phases of the menstrual cycle.  
 
3.7.1 Indometacin on myometrial responses to PGE2 
Indometacin, a non-selective COX inhibitor, has been shown to block myometrial PG 
biosynthesis at 10-6M (Durn et al., 2010). In immersion studies, PGE2 alone 
diminished contractions in a concentration-dependent manner (10-10M to10-6M), with 
relative stimulation at 10-5M (Figure 3.3). Pre-incubation with indometacin (10-6M) 
did not significantly alter myogenic contractions or responses to PGE2 (F (1, 35) = 
0.55; ns). Therefore, to mimic physiological responses, indometacin was omitted from 
the Krebs’ solution in all further immersion and superfusion experiments. 
 
3.7.2 Myometrial EP receptors during the menstrual cycle 
Responses to PGE2 were similar in fundus-end myometrium taken at hysterectomy 
from non-pregnant donors at different stages of the menstrual cycle (F (2, 77) = 1.56; 
ns; Figure 3.4). PGE2 attenuated myogenic activity (10-10M to 10-6M) to an analogous 
extent at each phase of the menstrual cycle. At the highest concentration of 10-5M, 13 
percent stimulation relative to contractions at 10-6M was achieved. However, this 
varied between donors and appeared to be most pronounced, but not significantly so, 
in myometrium collected during the menstrual and luteal stages. With predominant 
collection of follicular stage tissues and comparable responses to PGE2, myometrial 
tissues were grouped irrespective of phase in functional studies. 
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Figure 3.3: Concentration-effect curves for PGE2 alone and in the presence of 
indometacin (10-6M) on isolated fundus-end myometrium from non-pregnant donors 
(n=4). Contractility was measured as 30 minutes area under the curve and expressed 
as a percentage of 30 minutes hypotonic shock. Results are arithmetic means ± S.E. 
Indometacin, the non-selective COX inhibitor, did not influence tissue myogenicity or 
responsiveness to PGE2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Concentration-effect curves and representative traces showing the 
response to PGE2 in isolated fundus-end myometrium taken at a) menses (n=4), b) 
follicular (n=8) and c) luteal (n=4) phases of the menstrual cycle. PGE2 was added in 
a cumulative manner to organ baths at 30-minute intervals and results are expressed as 
arithmetic means ± S.E. 
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3.7.3 Inhibitory effects of EP2 agonists on myogenic activity 
In immersed fundal myometrial strips from non-pregnant donors, the EP2 mimetics 
butaprost and CP533,536 evoked concentration-dependent inhibition of myogenic 
activity (10-10M to 10-5M) via a reduction in the frequency and amplitude of 
contractions (F (2, 90) = 35.54; p<0.001; Figure 3.5). Similar potency values were 
shown by respective pEC50 values at 6.87 ± 0.47M and 6.99 ± 0.43M and a 3.2-fold 
and 4.0-fold decline in myogenicity (Table 3.4).  
 
3.7.4 EP4 agonist effects on myogenic activity 
Compared to the sustained myogenicity with time-matched controls, the EP4 agonist 
AGN201734 (10-10M to 10-6M) attenuated contractions in a concentration-dependent 
manner (F (1, 82) = 37.15; p<0.001; Figure 3.5). The gradual reduction in activity 
from 46.2 ± 2.78 to 21.7 ± 4.13 percent of hypotonic shock plateaued at 10-6M with 
9.2 percent relative excitation at 10-5M. Despite similar biphasic curves and potency 
values, the efficacy of AGN201734 was lower than PGE2 (Table 3.4). 
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Figure 3.5: Concentration-effect curves and typical traces for the EP2 agonists a) 
butaprost, b) CP533,536 and the EP4 mimetic d) AGN201734 compared to c) vehicle 
in human fundal myometrium obtained from non-pregnant women (n=6-7). Agonists 
(10-10M to 10-5M) were added in a cumulative manner at 30-minute intervals to 
immersed myometrial strips. Results are expressed as arithmetic means ± S.E. and 
significant differences were determined using two-way ANOVA with Bonferroni’s 
post-hoc test; **p<0.01; ***p<0.001 compared to vehicle controls. 
 
 
 
Table 3.4: Mean pIC50 values (M) and percentage reduction in myogenicity for PGE2, 
butaprost, CP533,536 and AGN201734 concentration-effect curves in immersed 
myometrium from non-pregnant, pre-menopausal donors (n=6-9). 
 
Agonists: PGE2 Butaprost CP533,536 AGN201734 
pIC50 7.7 ± 0.2 6.9 ± 0.5 7.0 ± 0.4 7.7 ± 0.3 
% decrease 68.4 68.7 75.3 56.7 
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Figure 3.5: Vehicle, utero-relaxant effects and representative traces of a) PGE2,          
b) butaprost and c) AGN201734 in human fundus-end myometrial tissue from non-
pregnant women in the follicular stage of the cycle (n=3-5). Tissue strips were 
suspended in superfusion baths and bolus doses of agonists (10-11mol to 3x10-7mol) 
and vehicle were administered directly into the superfusate after a contraction of 
similar amplitude to the myogenic activity. Results are expressed as means ± S.E. 
with statistical analysis performed using two-way ANOVA with Bonferroni’s post-
hoc adjustment; *p<0.05; ***p<0.001 for EP agonists compared with vehicle 
controls. 
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Using the superfusion technique, bolus doses of the EP mimetics evoked immediate 
responses in fundus-end myometrial strips from non-pregnant donors (Figure 3.5). 
Whilst myogenic contractions were sustained with time-matched vehicles, PGE2 and 
AGN201734 exhibited biphasic responses (10-7mol to 3x10-7mol), consisting of an 
initial contraction followed by a period of inhibition (F (2, 84) = 54.37; p<0.001). 
Despite the higher potency of PGE2 (pEC50: 8.41 ± 0.23M), delays in contractility 
were analogous for PGE2 and AGN201734 at 3x10-7mol (F (1, 36) = 2.30; ns). This 
was observed as a significant reduction in the frequency of contractions before normal 
spontaneous activity was restored. 
Unlike PGE2 and AGN201734, exposure to butaprost produced a dose-related 
suppression of tissue activity without exerting tissue excitation (F (1, 48) = 145.2; 
p<0.001). The complete cessation of contractions reached 52.3 ± 5.38 minutes, which 
was 1.5 and 1.7-fold longer than challenge with PGE2 and AGN201734 respectively. 
Due to the restricted bolus volume, maximal responses were not achieved for 
AGN201734 or butaprost. 
 
3.7.5 EP agonists in the presence and absence of GW627368x 
To more fully characterise functional receptors, responses to EP agonists were 
examined alone and in the presence of the EP4 antagonist GW627368x (10-6M; 
Wilson et al., 2006). As shown by time-matched vehicle controls, GW627368x had 
no effect on the myogenic activity of fundus-end uteri from non-pregnant donors (F 
(1, 48) = 0.77; ns; Figure 3.6). Likewise, the concentration-related inhibitory effects 
of butaprost (F (1, 48 = 0.41; ns) and PGE2 (F (1, 36 = 1.32; ns) were unchanged, 
regardless of pre-incubation with GW627368x. Even so, GW627368x displaced the 
AGN201734 curve rightwards (F (1, 48) = 4.13; p<0.05). This was shown by a 
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change in pEC50 values (p<0.001; Table 3.5) and also by the estimate of pA2 (see 
below), rather than the percentage reduction in spontaneous activity. 
 
 
 
Table 3.5: Mean pEC50 values (M) and the percentage reduction in myogenicity for 
concentration-effect curves to EP agonists (10-10M to 10-5M) using immersed 
myometrial strips in the presence (treated) and absence (control) of the EP4 antagonist 
GW627368x (10-6M). Human myometrium was harvested from non-pregnant donors 
at hysterectomy (n=4-6). Data are shown as arithmetic means ± S.E. and statistical 
analysis was performed using Student’s t-tests; ***p<0.001 for AGN201734 pEC50 
values of control compared with treated groups. 
 
Control Treated 
EP agonists 
pEC50 % decrease pEC50 % decrease 
PGE2 8.4 ± 0.2 69.7 8.6 ± 0.2 70.2 
butaprost 7.5 ± 0.5 71.4 7.2 ± 0.4 68.5 
AGN201734 7.5 ± 0.2 51.9 5.3 ± 0.3*** 41.1 
 
 
 
To estimate the pA2 value for GW627368x, the Schild’s equation was applied where 
KB was the dissociation constant of the antagonist: 
 (EC50 antagonist/ EC50 agonist) -1 = [antagonist]/ KB pA2 = -log (KB) 
∴ (4.6x10-6M/ 1.3x10-7M) –1 = [10-6M]/ KB pA2 = -log (3x10-8M) = 7.53 
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Figure 3.6: a) Vehicle and concentration-effect curves for b) PGE2, c) butaprost and d) 
AGN201734 in isolated fundus-end myometrium donated by non-pregnant women at 
hysterectomy (n=4-6). Myometrial strips were incubated alone or in the presence of 
the EP4 antagonist GW627368x (10-6M), with agonists (10-10M to 10-5M) added in a 
cumulative manner at 30-minute intervals to immersion baths. Results are expressed 
as means ± S.E.  
Traces show typical myometrial responses to i) AGN201734 alone and ii) pre-
incubated with GW627368x (10-6M) in immersed fundus-end samples harvested mid-
cycle. 
 
 
 
a) b) 
c) d) 
 5g 4g 
i) AGN201734 ii) GW + AGN201734 30 minutes 30 minutes 
10-7M Hypotonic shock10-6M 10-5M 10-7M Hypotonic shock10-6M 10-5M
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3.7.6 Excitatory EP agonists on myogenic activity 
Using the immersion technique in fundus-end uterine samples, time-matched vehicle 
controls maintained myogenicity (Figure 3.7). Although the EP1 agonist ONO-D1-
004 had no effect on phasic contractions (F (1, 48) = 1.32; ns), excitation was evoked 
in response to the EP3/1 agonist sulprostone (F (1, 72) = 8.79; p<0.001). As a result, 
myogenic activity was elevated from 48.3 ± 2.39 to 60.1 ± 2.17 of the hypotonic 
shock value; this was sustained by sulprostone (10-6M to 10-5M), without adjusting 
the muscle tonus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Concentration-effect curves and representative traces for a) vehicle, b) the 
EP3/1 agonist sulprostone and c) the EP1 mimetic ONO-D1-004 in fundus-end uterine 
samples obtained from non-pregnant donors (n=4-7). Time-matched vehicles and 
spasmogens were added in a cumulative manner (10-10M to 10-5M) to individual organ 
baths at 30-minute intervals. Results are arithmetic means ± S.E. with significance 
determined using multivariate ANOVA with Bonferroni’s post-hoc test; *p<0.05; 
**p<0.01 for responses to sulprostone compared with vehicle controls. 
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shock 10
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c)  
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3.7.7 Topographical effect of EP receptor agonists 
After obtaining full-thickness longitudinal sections of the uterus at total hysterectomy, 
upper and lower segment myometrial strips were dissected from the cephalic and 
caudal extremities. To determine regional responsiveness to uterotonins, contractile 
parameters were established using immersed tissues from donors in the follicular 
stage of the menstrual cycle. Despite the 1.2-fold higher spontaneous activity 
exhibited by lower segment tissues compared with the fundus (p<0.001; Figure 3.1), 
the concentration-dependent trends of EP agonists were similar (Figures 3.8 & 3.9; 
Table 3.6). With PGE2, butaprost and AGN201734, the monophasic in vitro utero-
relaxant effects were more pronounced towards the cervix (p<0.001). Although 
differences were manifest between 10-10M to 10-7M (p<0.001), myogenic responses 
subsided to 15.7 ± 2.41 hypotonic shock at 10-5M. This was equivalent to the abolition 
of activity at 10-5M in fundus-end tissues.  
By contrast, the EP3/1 mimetic sulprostone evoked concentration-dependent excitation 
in myometrial strips, with peak contractility at 10-6M (F (1, 42) = 50.62; p<0.001). 
Compared with time-matched vehicle controls, contractions were augmented by 23.7 
and 25.1 percent in upper and lower tissue strips respectively. This demonstrated 
parallel responses to sulprostone, regardless of uterine topographical location (Table 
3.6). 
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Figure 3.8: Concentration-effect curves for a) PGE2, b) butaprost, c) AGN201734 and 
d) sulprostone in fundal and lower human myometrium taken at the follicular stage of 
the menstrual cycle (n=4-6). After equilibration in immersion baths, responses to EP 
mimetics were measured as 30 minutes integrated area under the curve and expressed 
as a percentage of 30 minutes hypotonic shock. Results are arithmetic means ± S.E.  
 
 
 
 
Table 3.6: Mean pEC50 values (M) ± S.E. for PGE2, butaprost, AGN201734 and 
sulprostone concentration-effect curves in immersed upper and lower segment 
myometrium from non-pregnant, pre-menopausal donors (n=4-6). 
 
Agonists Region  PGE2 Butaprost AGN201734 Sulprostone 
pEC50 Fundus 7.9 ± 0.1 7.3 ± 0.5 7.5 ± 0.2 6.9 ± 0.5 
pEC50 Lower 7.6 ± 0.2 6.6 ± 0.6 7.2 ± 0.1 7.2 ± 0.4 
 
a) b) 
c) d) 
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Figure 3.9: Typical traces showing the concentration-effect of a) PGE2, b) butaprost, c) AGN201734 and d) sulprostone (10-10M to 10-5M) in 
immersed lower segment myometrium from non-pregnant donors. Agonists were added to organ baths at the time-points indicated by the arrows.
30 minutes
3g 
a) 
10-10M 10-9M 10-7M 10-6M 10-8M Hypotonic shock 10-5M 
10-10M 10-9M 10-7M 10-6M 10-8M 10-5M Hypotonic shock 
10-10M 10-9M 10-7M 10-6M 10-8M 10-5M Hypotonic shock 
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d) 
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3.8 Topographical responsiveness to PGF2a and U46619 
The spasmogens PGF2α and U46619 increased the amplitude and frequency of 
contractions in myometrial tissues from non-pregnant donors whilst maintaining a 
constant baseline tension (Figures 3.10 & 3.12). At the fundus-end, PGF2α elicited a 
monophasic excitatory response (pEC50: 6.9 ± 0.80M), parallelled by the effect of 
U46619 in immersed tissue strips (pEC50: 6.8 ± 0.27M). Activity was increased to 
59.3 ± 2.43 and 65.2 ± 5.86 percent hypotonic shock respectively (Figure 3.11). 
Likewise in superfused tissues, bolus doses of PGF2α (F (1, 30) = 16.73; p<0.001) and 
U46619 (F (1, 30) = 13.44; p<0.001) augmented myometrial contractions by 2.6 and 
2.4-fold compared with time-matched controls. This demonstrated their similar 
efficacy and potency values in upper myometrial strips. 
In lower segment immersed tissues, PGF2α stimulated activity to 83.1 ± 10.4 percent 
hypotonic shock at 10-6M, after which the response was attenuated (F (1, 30) = 71.27; 
p<0.001; Figure 3.10). A similar concentration-related excitatory effect was observed 
with U46619; although contractions reached 104.5 ± 10.2 percent of the hypotonic 
shock value at 10-5M (F (1, 40) = 30.93; p<0.001). Therefore, a topographical gradient 
to both PGF2α and U46619 was observed, with responsiveness enhanced in lower 
segment uteri compared with fundus-end tissues. 
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Figure 3.10: Concentration-effect curves and representative traces for a) PGF2α and  
b) U46619 in 1) fundus and 2) lower segment human myometrium from non-pregnant 
donors in the follicular stage of the cycle (n=4-6). Myogenic activity was recorded per 
30-minute agonist incubation in the immersion apparatus and expressed as a 
percentage of 30 minutes hypotonic shock. Results are arithmetic means ± S.E. with 
significance determined using a multivariate ANOVA and Bonferroni’s post-hoc test; 
*p<0.05; ***p<0.001 for fundus compared with lower segment tissue responses. 
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Figure 3.11: Vehicle and excitatory dose-responses for PGF2α and U46619 in fundus-
end myometrium harvested from non-pregnant donors in the follicular stage of the 
menstrual cycle (n=4). Using the superfusion technique, myometrial responsiveness to 
bolus doses of agonists were measured over a 30-minute period (area under the curve) 
and expressed as a percentage of 30 minutes hypotonic shock. Data are arithmetic 
means ± S.E. and statistical analysis was performed using two-way ANOVA with 
Bonferroni’s post-hoc adjustment; ***p<0.001 for responsiveness to uterotonins at  
10-7mol compared with time-matched vehicle controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Representative traces showing the responses of upper segment uterine 
tissues taken mid-cycle to bolus doses of a) PGF2α and b) U46619 (10-9mol to         
10-7mol) in superfusion baths.  
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 Chapter 3.9: Discussion 
 
 
The results show that myometrial strips exhibited spontaneous activity relative to the 
stage of menstrual cycle and site of excision under in vitro conditions. Contraction 
amplitude was most pronounced during the follicular phase and was attenuated during 
menses. In contrast to the outer myometrial layers, sequential contractions are known 
to develop from the stratum subvasculare of the myometrium (Kunz et al., 1996; Noe 
et al., 1999; van Gestel et al., 2003). As the expression of oestrogen and its cognate 
receptors peak mid-cycle in this sub-endometrial layer (Noe et al., 1999), this 
suggests that the oestrogenic milieu is crucial in mediating uterine peristalsis. 
The acute rise in oestrogen during the periovulatory period of the follicular phase 
coincides with an increased expression of ERα, implying positive feedback within the 
uterus (Lecce et al., 2001). In addition to increasing cellular division and growth, 
oestrogen exerts uterotrophic effects, which enhance myometrial contractility and 
excitability via the upregulated expression of gap junctions (Garfield et al., 1980; 
Kilarski et al., 2000). In accord with previous functional studies (Hutchinson, 2005), 
contractions in this study were highest in myometrium taken at the follicular stage. 
Myogenic activity declined and was more sporadic in tissues taken during menses 
corresponding to a reduction in circulatory oestrogens and decreased uterine 
expression of ERα and PR-A (Ijland et al., 1998). This infers that the myogenic 
activity established in vitro maintained the receptor profile and hormonal influences 
of the donor at the time of hysterectomy. 
Whilst the underlying control of uterine activity is not well understood, it is 
recognised that paracrine ovarian steroids modulate myometrial transcriptional 
activity via specific growth factors, enzymes, hormones and receptors. The genomic 
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and non-genomic effects of oestrogen increase the expression of uterine progesterone 
receptor (PR) isoforms PR-A and PR-B (Lecce et al., 2001). PR-B mediates the 
proliferation of endometrial and, to a lesser extent, myometrial cells in the luteal 
phase, whilst the expression of PR-A suppresses progesterone effects in the follicular 
phase of the menstrual cycle (Ijland et al., 1998). The reported decrease in excitability 
of the uterine musculature in the luteal phase by magnetic resonance imaging (Bulletti 
et al., 1998) was reflected in the reduced spontaneous activity of isolated myometrial 
strips taken from non-pregnant donors at this stage. This quiescence was therefore 
likely to be facilitated by progesterone diminishing contractile associated proteins 
(CAPs) gene expression in the uterus (Garfield et al, 1980) as well as the paucity of 
oestrogen action. 
Myogenic activity was 10 percent greater in isolated lower segment tissues compared 
to the fundus; this seemed to reflect the physiological state of the uterus. The apparent 
functional regionalisation of the uterus may be attributed to the highest local 
expression of progesterone receptors in the fundus (Lye et al., 1998; Challis et al., 
2000, 2002). Moreover, the close apposition of the venous drainage of the ovary and 
ovarian bursa would enable sex steroids to reach the fundus prior to the lower 
segment of the uterus. This may facilitate spatial-hormonal effects, altering receptor-
binding properties and myometrial contractions. As a result, autocrine and paracrine 
influences are likely to affect regional variation within the uterus. 
In women of reproductive age, the structural and functional polarity of the non-gravid 
uterus has been discerned using magnetic resonance imaging, video-
vaginosonography and immunohistochemistry. Whilst the internal layer or junctional 
zone consists of mainly circular running fibres, the myofilaments in the thick mid 
layer are oriented obliquely to the axis of the muscle fibre (Weiss et al., 2006). As 
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well as sustaining forceful and prolonged contractions (Wray et al., 2001), this fibre 
arrangement may explain the uniform myogenic contractions in this study regardless 
of longitudinal or transverse incisions. Uterine smooth muscle composition also 
decreases caudally from the fundus towards cervix, with connective tissue 
composition at 38 and 68 percent of the dry-defatted tissues for the uterine body and 
cervix respectively (Leppert & Yu, 1991). Moreover, myocyte density is greater at the 
myometrial-endometrial surface compared to the middle stratum vasculare (Weiss et 
al., 2006), perhaps accounting for the intra-donor variation in spontaneous 
contractility. 
During the follicular phase, synchronised contractions of the uterus are primarily 
directed towards the fundus and fallopian tubes, facilitating the rapid transport of 
potential sperm (Kunz et al., 1996). Without conception, uterine activity decreases 
and is manifest as short and asymmetric bi-directional waves (Ijland et al., 1998; 
Bulletti et al., 2002). This may facilitate blastocyst implantation and the local supply 
of nutrients and oxygen during the luteal phase of the menstrual cycle. In addition, the 
caudal contractile direction at menses would assist uterine emptying. Even so, primary 
and secondary dysmenorrhoea (Leyendecker et al., 2004; Altunyurt et al., 2005; 
Kataoka et al., 2005; Dawood & Khan-Dawood 2007) and endometriosis (Bulletti et 
al., 2002) are associated with hyperactivity of the uterus, whilst chronic uterine 
infections attenuate contractile force (Hirsbrunner et al., 2006; Laird et al., 2003). 
Due to benign gynaecological conditions, it is recognised that the myometrial 
specimens taken for this study may have displayed compromised characteristic 
functions. Even so, over a third of the women at hysterectomy have normal uteri 
removed (Clarke, 1995) and myogenic activity could not be distinguished between 
samples, regardless of patient disorder. This demonstrates that menstrual cycle 
  Chapter Three: Non-pregnant 
  Page 73
  
dysfunctions, which contribute to major morbidity in reproductive health, require 
further elucidation at a cellular level. 
The Spanish pathologist and Nobel laureate Santigo Ramon y Cajal discovered cells 
thought to have a pacemaker role in propagating smooth muscle contractility. These 
interstitial cells of Cajal have abundant thin cytoplasmic processes, numerous 
mitochondria, intermediate filaments and caveolae, which are localised between 
muscle bundles and layers to provide a pathway for the transmission of depolarisation 
(Ciontea et al., 2005; Popescu et al., 2006). Their regional distribution and 
inappropriate electric impulses has been implicated in reduced fecundity in adolescent 
females (Dixon et al., 2009). This appeared to be manifest as unstable baseline 
contractions in specimens inhibited by PG agonists or obtained at menses. As 
interstitial cells of Cajal express oestrogen and progesterone receptors (Cretoiu et al., 
2006), their activation may vary temporally and spatially across the menstrual cycle. 
The over-expression of oestrogen and progesterone receptors in symptomatic uterine 
leiomyomata (fibroids), which are benign neoplasms of the smooth muscle cell, may 
also be responsible for abnormal contractile status (Severino et al., 1996; Kunz et al., 
2000). Moreover, with endometriosis, the heightened retrograde activity facilitating 
the dissemination and implantation of endometrial tissue outside the uterine cavity is 
oestrogen-dependent and decreases the propensity for a typical menstrual cycle 
(Bulletti et al., 2002). Therefore, ovarian hormones contribute to the subtle and 
transient changes in uterine activity according to pathology (Kataoka et al., 2005). 
Even so, increases in PG synthesis that promote the inflammation, fibrosis and 
adhesion formation are symptoms of these conditions. Consequently, to elucidate 
uterine physiology and pathophysiology, contractile responses to exogenous PGs were 
examined. 
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PGE2 and PGF2α were the first abundant vasoactive substances to be detected in 
menstrual fluid and the endometrium (Pickles, 1967). These bioactive autacoids and 
their endoperoxide precursors diffuse through the walls of the effluent veins of the 
endometrium to reach the myometrium (Baird et al., 1996). For PGE2 biosynthesis, 
membrane-derived arachidonic acid is liberated by phospholipases and metabolized to 
the labile intermediate PGH2 by COX enzymes. Of the three co-existing isoforms in 
myometrial cells, COX-1 is constitutively expressed, whereas COX-2 and COX-3 are 
inducible by inflammatory, mitogenic and physical stimuli (Murakami et al., 1999). 
Downstream of the COX pathway, the conversion of PGH2 to PGE2 is catalysed by 
cytosolic and membrane-bound PGE synthase (cPGES and mPGES). Although the 
mechanisms are obscure, perturbed PGE2 pathways have been particularly associated 
with reproductive disorders. 
Whilst fibroids attenuate PG output (personal communication, Durn, 2009), the 
overproduction of PGE2 and EP mRNA expression has been correlated to 
menorrhagia (Hofmann et al., 1983; Adelantado et al., 1988; Smith et al., 2007) and 
the hyperalgesic effects of dysmenorrhoea (Sales & Jabbour, 2003). In addition, 
COX-1 and COX-2 expression are elevated in women with menorrhagia (Smith et al., 
2007). To prevent uterine PG generation, non-steroidal anti-inflammatory drugs 
(NSAIDs) have been employed as tocolytic agents that block COX signalling 
cascades. Indometacin, a well characterised NSAID, is widely reported to inhibit 
endogenous PG biosynthesis in vitro (Crankshaw, 2001; Jabbour & Sales, 2004) and 
to remove intrinsic tonus for a stable resting tension (Dong et al., 1986). To determine 
the role of endogenous prostanoids in uterine contractility, myogenic responsiveness 
to PGE2 was assessed relative to the effect of indometacin. 
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Despite the presence of mPGES, COX-1 and COX-2 mRNA in human myometrium 
(Slater et al., 1999; Giannoulias et al., 2002; Sooranna et al., 2006), nonselective 
blockade of COX enzymes with indometacin [1µM] in this study did not influence 
spontaneous contractility or myometrial responses to PGE2. However, at higher 
concentrations, the reported complete abolition of myogenic activity (Sawdy et al., 
2003; Cao et al., 2004) implicates indometacin effects that are unrelated to PG 
production. This was substantiated by its direct attenuation of PGF2α-induced Ca2+ 
release (Landen et al., 2001; Smith & Langenbach, 2001; Sawdy et al., 2003) and 
inhibition of gap junction formation (Garfield et al., 1980). Due to its ambiguous 
mechanisms, the addition of indometacin was omitted from all other functional 
studies. 
PGE2 exhibits diverse effects on smooth muscle contractility via EP1-4 receptor 
subtypes (Coleman et al., 1994), which are likely expressed on uterine myocytes as 
well as the interstitial cells of Cajal. By acting through divergent intracellular 
signalling pathways, a functional complement of heterogeneous uterine EP receptors 
has been identified. In isolated human non-gravid myometrium, time-matched 
vehicles sustained myogenicity throughout the duration of experiments. However, 
challenge with PGE2 produced different types of response curves (Popat & 
Crankshaw, 2001), predominantly consisting of initial contractions before profound 
inhibition of myogenic activity (Senior et al., 1991; Hillock & Crankshaw, 1999; 
Popat & Crankshaw, 2001). In contrast, the observed biphasic response to PGE2 in 
this study was characterised by concentration-dependent inhibition followed by partial 
restoration of contractility. This trend was uniform across the different phases of the 
menstrual cycle.  
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In premenopausal women, circulatory PGE2 increases in conjunction with uterine 
activity at the follicular phase of the cycle (Maslow et al., 2004) and also at 
menstruation (Rees et al., 1984; Adelantado et al., 1998). This corresponds to the 
spatial and temporal expression of PGE synthase, EP4 receptors and COX-2 in human 
epithelial cells (Milne et al., 2001). In ruminant endometrium and myometrium, 
whilst EP4 receptors were undetectable, EP2 mRNA and protein peaked mid-cycle 
(Arosh et al., 2003). EP2 receptor expression correlated well with upregulated 
antiapoptotic genes and vascular endothelial growth factor (VEGF) (Jones et al., 
1998). Due to the associated epithelial cell proliferation, angiogenesis and 
microvascular tube formation, roles of PGE2 in decidualisation, menses, blastocyst 
implantation and embryonic development have been proposed (Lim & Dey, 1997; 
Arosh et al., 2003; Critchley & Saunders, 2009). Little is known of the cyclic 
expression pattern of EP subtypes in human non-gravid tissues. Even so, endothelial 
EP2 and EP4 receptors were expressed throughout the menstrual cycle without 
modulation (Milne et al., 2001) together with the ligand binding affinity of PGE 
(Giannopoulos et al., 1985). If transposed to the human myometrium, this would 
account for the observed consistent functional responsiveness to PGE2. To elucidate 
further uterine EP receptor targets, the effect of PGE2 was compared with selective EP 
analogues. However, due to limited myometrial specimens, tissues recovered from 
different stages of the menstrual cycle were combined. 
Even though PGE2 binds to its receptor subtypes with a rank order of affinity of EP3III 
>EP4 >EP2 >EP1 (Kiriyama et al., 1997; Abramovitz et al., 2000), its actions are also 
dependent on receptor density and signal transduction gain. With the abundant 
expression of EP2 or EP4 subtypes in uterine muscle (Katsuyama et al., 1995), the 
observed inhibitory effects on myogenic activity indicate that either of these EP 
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subtypes were engaged. In addition, treatment with PGE2 evoked a concentration-
dependent increase in cAMP (Arosh et al., 2003); this has been shown to directly 
impair mitogen-activated protein (MAP) kinase activity and Ca2+ signalling for utero-
quiescence (Sanborn et al., 1998).  
To identify the functional significance of EP2 receptors, test compounds included 
butaprost (Gardiner, 1986) and CP533,536 (Li et al., 2003; Paralkar et al., 2003). As a 
methyl ester, butaprost was shown to have a 40-fold lower affinity for EP2 compared 
to the non-commercially available free acid form of the molecule (Abramovitz et al., 
2000). Even so, both butaprost and the pyridyl sulphonamide CP533,536 are well 
documented for high selectivity at the EP2 receptor. Respective Ki values for EP2 were 
110nM and 50nM with negligible binding affinity at other EP or PG receptor subtypes 
(Kiriyama et al., 1997; Li et al., 2003; Paralkar et al., 2003). Accordingly, butaprost 
and CP533,536 were equipotent in this study at attenuating myogenic activity in a 
monophasic concentration-dependent manner. In immersion studies using human and 
guinea pig isolated myometrium, similar utero-relaxant effects were observed for 
butaprost (Hillock & Crankshaw, 1999; Popat & Crankshaw, 2001) and for 
CP533,536 (Lebel et al., 2004; Terry et al., 2007), re-enforcing the presence of 
operative EP2 receptors in non-gravid uterine tissue.  
Functional EP4-mediated responses were distinguished using AGN201734 (Elworthy 
et al., 2004). As a lactam, this synthetic agonist is reported to confer greater than 
1000-fold selectivity for EP4 (Elworthy et al., 2004). Nevertheless, in immersion 
studies, AGN201734 produced biphasic curves with an initial reduction in myogenic 
activity followed by relative excitation. Although its efficacy was lower, the potency 
of AGN201734 was 6-fold higher than butaprost and CP533,536. Contractile 
responses, followed by a period of inhibition, were conversely elicited in superfused 
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myometrial strips. These profiles mimicked the in vitro effects of PGE2 and indicated 
that EP4 receptors contributed to utero-relaxation in fundus end myometrial segments 
with some off-target mechanisms displayed, perhaps at EP1 and EP3 receptors.  
When compared to other EPs, the EP4 receptor is a less compact structure with a long 
intracellular third loop and C-terminus (Regan et al., 1994). Of these receptors, the 
amino acid sequence of the relaxant EP2 and EP4 subtypes exhibit only 38 percent 
homology (Toh et al., 1995). As a result, their signalling pathways are not identical. 
The mechanisms of EP2-induced cAMP accumulation mainly involve phosphorylation 
of glycogen kinase-3 (GSK-3) by protein kinase A (PKA), whereas EP4 receptors also 
activate phosphatidylinositol kinase (Fujino et al., 2005; Fujino & Regan, 2006). This 
downstream activation of IP3 and Ca2+ by EP4 may account for the evoked contractile 
responses to AGN201734. Moreover, murine EP4 receptors contain 38 serine and 
threonine residues. In response to PGE2, these putative phosphorylation sites were 
shown to produce rapid desensitisation (Nishigaki et al., 1996) and internalisation 
(Desai et al., 2000) of EP4 but not EP2 receptors. Deactivation of the EP4 subtype may 
also have contributed to restored myogenic activity with incubations and bolus doses 
of AGN201734. Even so, in order to clarify the identity of EP receptor subtypes, an 
EP4 receptor antagonist was used. 
Although EP4 was purported to be devoid of action (Hillock & Crankshaw, 1999), the 
tested EP4 antagonist AH23848 has since been shown to have moderate selectivity at 
EP4 over EP1-3 and IP receptors (Abramovitz et al., 2000; Jones & Chan, 2001). 
Instead, GW627368x was assayed due its more potent EP4 selectivity in human 
(Wilson et al., 2006), piglet (Wilson et al., 2003) and rabbit (Jones & Chan, 2005) 
preparations. Despite additional TP receptor binding, GW627368x displayed at least 
100-fold greater affinity for EP4 over the other PG receptors (Wilson et al., 2006). 
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This was observed with GW627368x-mediated antagonism of the EP4 receptor 
agonist AGN201734. The rightward displacement of the AGN201734 log 
concentration-effect curve with an estimated pA2 value of 7.5 indicated competitive 
inhibition at EP4 receptors. However, GW627368x did not alter responses to PGE2, 
butaprost or spontaneous contractions in fundus segment tissues strips. Moreover, in 
the presence of the antagonist, PGE2 produced maximal inhibition of the tissue and 
was the most potent agonist tested (pEC50: 8.4 ± 0.2M). This implies that, despite the 
presence of EP4 receptors, the EP2 subtype is predominantly involved in PGE2-
induced utero-relaxation. 
To evaluate the contribution of excitatory EP receptors, concentration-effect curves 
for sulprostone (Schaaf et al., 1981) and ONO-D1-004 (Oka et al., 2003) were 
constructed. Despite high affinities for EP1 and FP receptors, sulprostone is most 
potent at EP3 (Coleman et al., 1994; Kiriyama et al., 1997; Abramovitz et al., 2000). 
By contrast, ONO-D1-004 displays 70-fold higher selectivity at EP1 than at the other 
EP receptors (Oka et al., 2003). In accord with previous functional studies, 
sulprostone evoked significant myometrial contractility (Senior et al., 1991; Popat & 
Crankshaw, 2001). However, ONO-D1-004 produced negligible uterotonic effects. 
This may be attributed to the lower binding affinity of ONO-D1-004 compared to 
sulprostone with respective Ki values of 150nM and 0.6nM at EP1 (Oka et al., 2003) 
and EP3 receptors (Kiriyama et al., 1997). Even so, activation of the EP3 subtype is 
consistent with the greater EP3 mRNA expression relative to EP1 receptors (Astle et 
al., 2005; Sugimoto & Narumiya, 2007). On the basis of contraction, these results 
indicate that EP3 receptors are predominant in non-gravid human myometrium and 
may contribute to the excitatory component of PGE2 responses. Nevertheless, the 
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profound utero-relaxation exerted by PGE2 implicates that inhibitory EP-coupled 
pathways exceed EP1 and EP3-mediated effects within this tissue.  
The polarity of functional EP receptors was compared in upper and lower segment 
human myometrium harvested at the follicular phase of the menstrual cycle. Marked 
relaxatory responses to PGE2, butaprost and AGN201734 were displayed in lower 
segment tissues relative to the fundus. The differences in spontaneous activity may 
have potentiated this regional effect, whereas excitatory responses to the highest 
concentration of these agonists were absence from lower segment uteri. Along the 
length of the uterus, however, functional EP3 and EP1 receptors were manifest with an 
identical contractile profile stimulated by sulprostone.  
In longitudinal sections, uterine smooth muscle density depreciates from the fundus-
corpus area to the lower segment in parallel with a decrease in PGE-binding affinity 
(Hofmann et al., 1983; Giannopoulos et al., 1985). This gradient conversely reflects 
blood flow into the lower uterus before distribution to the fundus. During the peri-
ovulatory phase, the intrinsic intensity of lower uterine peristalsis and EP1 and EP3-
mediated effects may aid retrograde contractions. As the concentration of PGE2 in 
seminal plasma is considerable (Templeton et al., 1978; Muller et al., 2006), this 
could facilitate the transport of sperm towards the distal end of the fallopian tubes. 
Although the topographical distribution of EP receptors in the non-gravid uterus is not 
well defined, only genetic EP2 knockout mice exhibit ovulation, fertilisation and peri-
implantation defects (Tilley et al., 1999). Therefore, EP2 receptors are a vital 
prerequisite for the successful establishment of pregnancy. 
Anatomical responsiveness to PGF2α and U46619, a stable thromboxane mimetic 
(Coleman et al., 1994), were also investigated in follicular stage non-gravid human 
myometrium. These spasmogens enhanced myogenic contractions in a concentration-
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dependent manner. As in previous immersion (Word et al., 1992; Hutchinson, 2005; 
Janicek et al., 2007) and superfusion (Rees et al., 1984; Senior et al., 1992) studies, 
the contraction profiles displayed an initial tonic increase in force magnitude followed 
by a marked rise in frequency. Responses to both PGF2α and U46619 were of similar 
potency, with greater FP and TP-mediated activity in lower compared to upper 
segment myometrium. For PGF2α, this was contrary to the reported functional uterine 
FP topography in the rat (Oropeza et al., 2002), mouse (Griffiths et al., 2006) and 
porcine myometrium (Cao et al., 2005). In human tissues, the gradient of uterine 
PGF2α binding sites also decreased from the fundus to the lower uterine body 
(Hofmann et al., 1983; Giannopoulos et al., 1985). However, polarised regional FP-
mediated effects appear to be reduced under oestrogen-primed conditions (Word et 
al., 1992; Griffiths et al., 2006). This might explain the observed PGF2α sensitivity 
superimposed on the higher intrinsic contractions of cervical region tissues in this 
study. 
Both PGE2 and PGF2α are principal metabolites of the human endometrium. As well 
as a peak in PGF2α output (Downie et al., 1974), maximal FP receptor expression and 
signalling have been identified in endothelial and perivascular cells during the 
follicular phase of the menstrual cycle (Milne & Jabbour, 2003). This promotes 
endometrial thickening in case of ovum fertilisation (Milne & Jabbour, 2003) and 
luteal regression under non-pregnant conditions (Sugino et al., 2004). Moderate 
activity in the upper uterine region may also facilitate blastocyst implantation. 
However, PGF2α consistently stimulates myometrial contractions with the greatest 
uterotonic contractions at menses (Rees et al., 1984; Myatt & Lye, 2004; Hutchinson, 
2005). This is speculated to facilitate the expulsion of endometrial debris from the 
uterine lumen. Activation of FP receptors by PGF2α results in tyrosine 
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phosphorylation, phosphatidylinositol hydrolysis and subsequent intracellular Ca2+ 
flux. Even so, at high concentrations, PGF2α can also bind with EP1, EP3 and TP 
receptors (Coleman et al., 1994; Narumiya et al., 1999; Breyer et al., 2001). Whilst 
functional EP receptor interactions have not yet been confirmed, responses to PGF2α 
remain unaltered in the presence of selective TP antagonists (Hutchinson, 2005; 
Griffiths et al., 2006). This indicates that the excitation evoked by PGF2α is not due to 
off-target TP activity.  
U46619 is a potent and stable thromboxane A2 mimetic (Coleman et al., 1994) with 
full contractile activity in non-gravid uterine smooth muscle preparations (Senior et 
al., 1992; Senchyna & Crankshaw, 1999; Hutchinson, 2005). At putative TP receptors 
(Kiriyama et al., 1997; Abramovitz et al., 2000), TP receptor antagonists reduced 
U46619-induced excitation in isolated myometrial strips (Hutchinson, 2005; Griffiths 
et al., 2006). This confirms the operational expression of TP receptors in the human 
uterus.  
Responsiveness to U46619 increased from the fundus towards the cervix in this study. 
In contrast, TP receptor activation was reported to be homogeneous in non-gravid 
human myometrium regardless of tissue excision site (Senchyna & Crankshaw, 1999). 
As differences in spontaneous contractility were not mentioned, anatomical variations 
may reflect the mechanical properties of the uterus. Even so, it is likely that the 
hormonal milieu could also account for these regional effects. Progesterone is 
associated with a decrease in TP receptor mRNA (Minshall et al., 2001) and TP 
binding affinity (Swanson et al., 1992). However, in porcine uterine muscle, the 
fundus-corpus area has more abundant TP receptors with lower binding affinity than 
cervical end tissues (Cao et al., 2004). Since two TP isoforms exist (Hirata et al., 
1991; Raychowdhury et al., 1994), their expression ratio may account for regional 
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contractile effects. As a result, the roles of thromboxane in myometrial contraction, 
vascular tone and vascular haemostasis are likely to be intricately regulated. This 
could be important for reducing menstrual blood loss during menses (Dawood & 
Khan-Dawood, 2007). Nevertheless, FP and TP-deficient mice were fertile (Sugimoto 
et al., 1997; Kobayashi & Narumiya, 2002), indicating supportive rather than essential 
roles in non-pregnant reproductive processes. 
In summary, this study confirms the heterogeneous array of functional EP, FP and TP 
receptors in the non-gravid human myometrium. Despite the gradient of spontaneous 
myometrial activity, responses to PGE2 were consistent throughout the menstrual 
cycle and along the length of the uterus. This indicates that the complement of 
inhibitory to excitatory EP subtypes does not alter topographically. In accord with 
crucial effects on fertility (Tilley et al., 1999), PGE2-induced utero-relaxation was 
predominantly mediated by the EP2 receptor. Conversely, the spasmogens PGF2α and 
thromboxane stimulated contractions. Enhanced TP and FP responsiveness related to 
the greater phasic motility at the lower segment of the uterus during the follicular 
phase of the cycle. This may facilitate retrograde contractions for successful oocyte 
fertilisation and implantation of the blastocyst. A balance in these PG receptor 
populations is likely to contribute to the total function of the uterus. 
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Chapter 4: Term pregnancy 
 
Functional prostanoid receptors in isolated myometrium at term pregnancy 
 
 
4.1 Introduction 
Throughout the majority of pregnancy the uterus is maintained in a state of functional 
quiescence. As term approaches, integrated changes in hormonal, chemical and 
mechanical signals transform uterine contractures to contractions. This is mediated by 
the upregulated cascade of genes for CAPs, which include connexin-43, ion channel 
proteins and agonist-mediated receptors (Challis et al., 2000). As a result, the uterus is 
primed for parturition.  
Myometrial prostanoid receptor proteins mediate responses via G-proteins coupled to 
distinct and complex signal transduction pathways (Coleman et al., 1994; Narumiya et 
al., 1999). Despite their similarities in structure, DP, EP2, EP4 and IP receptors inhibit 
smooth muscle activity whilst EP1, EP3, FP and TP receptors mediate contraction. 
Functional studies on the isolated human myometrium have characterised 
heterogeneous DP, EP2, EP3, FP, IP and TP receptor subtypes at term pregnancy 
(Senior et al., 1993; Hutchinson, 2005). However, responses have been difficult to 
distinguish pharmacologically due to a paucity of highly potent and selective PG 
ligands (Wilson et al., 2004). With the development of novel agonists and antagonists 
and the donation of tissue at elective Caesarean section, the aim of the present study 
was to characterise further functional PG receptors in isolated late gestational 
myometrium, taken prior to labour-onset (38-41 weeks). 
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Chapter 4.2: Results 
 
 
 
4.3 Myometrial activity of isolated term gravid tissues 
After equilibration, spontaneous regular contractions developed in lower myometrial 
segments from non-labouring, term pregnant donors (39.3 ± 0.4 weeks gestation). 
This phasic activity was maintained by vehicle controls (Figures 2.4b & 2.15b) with 
contractile episodes of 2-3 minutes duration, followed by relatively longer periods of 
quiescence. The mean amplitude and frequency of contractions were relatively 
uniform regardless of patient clinical profiles. This included factors such as ethnicity, 
smoking, hypertension and diabetes (Table 4.1). Whilst increased parity tended to 
reduce the contractile frequency, a history of abortions or miscarriages was associated 
with transitory contractions at lower amplitude (F (5, 283) = 2.84; p<0.05) (Figure 
4.1). Nevertheless, variations in spontaneous activity were analogous between 
myometrial strips from the same and different biopsies with mean coefficents of 
variance at 17.1 and 16.8 percent respectively. Of the 757 myometrial strips 
investigated using the immersion technique, 5.4 percent were devoid of myogenic 
activity; these were excluded from the dataset. 
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Table 4.1: Contractility exhibited by immersed myometrial strips from term pregnant, non-laboring patients. Donor groups were distinguished by 
different ethnic, social and pathophysiological backgrounds with results measured over 30-minute periods of phasic activity after equilibration 
and expressed as arithmetic means ± S.E. Measurements of % hypotonic shock, amplitude and frequency of myogenic contractions were 
uniform, regardless of donor groups. 
 
Patient info: White Indian subcontinents Black Non-smokers smokers diabetics Hypertensives 
number: 10 7 4 10 10 3 3 
% hypotonic shock 48.0 ± 2.50 48.7 ± 2.97 54.5 ± 5.93 46.5 ± 2.29 47.3 ± 2.49 49.0 ± 0.67 46.5 ± 6.73 
Amplitude (g) 5.4 ± 0.43 5.3 ± 0.40 5.0 ± 0.76 5.5 ± 0.72 5.2 ± 0.32 5.4 ± 0.34 5.4 ± 0.90 
Frequency (/ 30 mins)   3.0 ± 0.19 3.4 ± 0.63 3.5 ± 0.58 3.3 ± 0.28 3.6 ± 0.40 3.3 ± 0.75 3.3 ± 0.54 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: The a) % hypotonic shock and b) amplitude and frequency of spontaneous contractions exhibited by myometrial strips from term 
pregnant donors who had previously experienced abortions/ miscarriages (Ab/Mis), none or up to six previous live births (n=42). After 
equilibration in the immersion apparatus, regular phasic activity was measured for 30 minutes (area under the curve) with data expressed as 
arithmetic means ± S.E. Univariate analysis showed significance; *p<0.05 compared to myometrium from nulli and primiparous women. 
a) b) 
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4.4 Myometrial EP receptors at term pregnancy 
In lower segment uteri obtained from term pregnant, non-labouring donors, PGE2  
(10-10M to 10-5M) evoked a predominant inhibitory effect on myogenicity via a 
reduction in the amplitude of myometrial contractions (F (1, 92) = 23.86; p<0.01; 
Figure 4.2). Myogenic activity was attenuated by 40 percent and some excitation was 
observed at 10-5M. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Concentration-effect curves and representative traces for a) vehicle and b) 
PGE2 in isolated uterine muscle obtained from non-labouring term pregnant donors 
(n=9). Vehicle and PGE2 (10-10M to 10-5M) were added to immersion baths in a 
cumulative manner at 30-minute intervals. Results are expressed as arithmetic means 
± S.E. and data were analysed using a two-way ANOVA mixed model with 
Bonferroni’s post-hoc test; **p<0.01 compared to the time-matched vehicle control. 
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4.5 Inhibitory effects of EP2 agonists on myogenic activity 
The EP2 receptor agonists butaprost, CP533,536, AH13205 and AGN211330 
attenuated myogenic activity in a monophasic concentration-dependent manner in 
immersed myometrial strips obtained at term pregnancy. Butaprost and CP533,536 
produced a gradual decline in contractility with the complete cessation of activity at 
10-5M in some tissue strips (F (2, 137) = 29.65; p<0.001; Figure 4.3a).  
Compared to the maintained activity of vehicle controls, AH13205 and AGN211330 
predominantly suppressed contractions between 10-6M and 10-5M (F (5, 60) = 9.64; 
p<0.001; Figure 4.3b). This corresponded to their weaker potency values in relation to 
butaprost and CP533,536 (Table 4.2). Even so, none of the EP2 mimetics evoked 
excitatory responses in isolated term gestational myometrium. 
 
 
4.6 EP4 agonist effects on myogenic activity 
The concentration-effect curves for the EP4 mimetics AGN201734 and L-902688 
exhibited different responses in myometrial strips obtained at term pregnancy.  
AGN201734 induced a biphasic response, progressively inhibiting spontaneous 
activity (F (1, 59) = 5.15; p<0.05; Figure 4.4) until contractions were stimulated at  
10-5M. However, L-902688 produced no significant effect compared to vehicle, 
despite the decrease in contractile activity at 10-5M from 45.8 ± 3.30 to 39.0 ± 3.57 
percent hypotonic shock (F (1, 41) = 0.43; ns; Figure 4.4). 
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Figure 4.3: Vehicle, concentration-effect curves and typical traces for EP2 agonists    
a) butaprost, b) C533,536, c) AGN211330 and d) AH13205 on immersed lower 
segment myometrium taken at term gestation (n=6-10). Responses were measured 
over a 30-minute period as area under the curve, expressed as percentage hypotonic 
shock and presented as arithmetic means ± S.E. Statistical significance was 
determined by two-way ANOVA with Bonferroni’s post-hoc test; **p<0.01 for 
AGN211330 and ***p<0.001 for butaprost, CP533,536 and AH13205 compared with 
time-matched vehicle controls.  
 
 
Table 4.2: Mean pIC50 values (M) and percentage reduction in myogenicity for EP2 
agonist concentration-effect curves in immersed myometrium from term pregnant, 
non-labouring donors (n=4-10). 
 
Agonists: butaprost CP533,536 AH-13205 AGN211330 
pIC50 6.78 ± 0.26 6.62 ± 0.44 5.84 ± 0.56 5.73 ± 0.54 
% decrease 54.9 72.7 59.4 39.5 
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Figure 4.4: Vehicle and the concentration-effects of EP4 agonists AGN201734 and   
L-902688 in isolated myometrium obtained at term pregnancy, not in labour (n=4-6). 
Agonists were added in a cumulative manner to immersion baths at 30-minute 
intervals with responses measured as area under the curve as a percentage of 
hypotonic shock. Data are expressed as arithmetic means ± S.E. and statistical 
analysis was performed using two-way ANOVA with Bonferroni’s post-hoc test; 
*p<0.05 for AGN201734 compared with responses to vehicle.  
 
 
 
The effects of PGE2, butaprost and AGN201734 were also demonstrated in 
myometrial strips obtained from non-labouring donors using the superfusion 
technique (Figure 4.5). Unlike the immersion baths, responses were immediate and 
myogenic activity was restored before the addition of successive agonist 
concentrations. Bolus doses of PGE2 and AGN201734 produced a biphasic effect, 
consisting of an initial contraction followed by a period of inhibition at all doses 
tested. Whilst AGN201734 delayed contractions for up to 37.4 ± 23.62 minutes (F (1, 
24) = 10.34; p<0.01), the period of inhibition was extended by a third with doses of 
PGE2 (F (1, 24) = 54.50; p<0.001). Butaprost did not evoke tissue excitation and, at 
the highest dose of 3x10-7mol, activity was suppressed for 75.5 ± 20.37 minutes (F 
(1,30) = 22.85; p<0.001). Maximal responses to EP agonists were not achieved due to 
the restricted volume of bolus doses that could be administered into the superfusate.  
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Figure 4.5: Vehicle and inhibitory dose-response curves with representative traces for 
a) PGE2, b) butaprost and c) AGN201734 in isolated myometrium from term 
pregnant, non-labouring donors (n=4). Tissue strips were suspended in superfusion 
baths with bolus doses of agonist and vehicle administered into the superfusate after a 
contraction of similar magnitude to the myogenic activity. Results are expressed as 
arithmetic means ± S.E. and two-way ANOVA with Bonferroni’s post-hoc test 
showed statistical significance; *p<0.05; **p<0.01; ***p<0.001 for EP agonists 
compared to vehicle. 
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4.7 Excitatory EP agonists on myogenic activity 
In immersion baths, whilst myogenicity was not affected by the EP1 agonist ONO-D1-
004 (F (5, 54) = 0.245; ns), the EP3/1 agonist sulprostone evoked a 27.8 percent 
increase in the frequency and amplitude of contractions (F (1, 72) = 8.90; p<0.01; 
Figure 4.6). This excitatory response reached 59.4 ± 2.59 percent hypotonic shock at 
10-6M.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Vehicle and concentration-effect curves (10-10M to 10-5M) for the EP1/EP3 
agonists sulprostone and ONO-D1-004 in isolated myometrium taken at Caesarean 
section from non-labouring donors (n=4-7). Treatments were added to individual 
organ baths and, every 30 minutes, agonist or vehicle applications were measured as 
area under the curve. Data are expressed as a percentage of the final contraction 
induced by hypotonic shock and analysed using two-way ANOVA with post-hoc 
Bonferroni’s adjustment; **p<0.01 for sulprostone compared to vehicle.  
 
Traces represent the typical myometrial responses to a) vehicle, b) sulprostone and    
c) ONO-D1-004 in tissue strips obtained at term pregnancy. 
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Using the superfusion technique, sulprostone displayed a monophasic contractile response (Figure 4.7). Following bolus doses of sulprostone, 
contractions increased by 54.0 percent to reach 61.2 ± 8.21 percent hypotonic shock at 10-7mol (p<0.01). Although resultant contractions were 
quantitatively of a similar magnitude to immersion, the overall increase was more pronounced in superfusion experiments.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Vehicle and dose-response curves to bolus doses of the EP3/1 agonist sulprostone in isolated myometrium obtained from term 
pregnant, non-labouring donors (n=4). Responses were measured over a 30-minute period (area under the curve) and expressed as a percentage 
of hypotonic shock. Data are arithmetic means ± S.E. and two-way ANOVA with Bonferroni’s post-hoc test indicated statistical significance; 
**p<0.01 compared to vehicle.  
 
Representative traces show vehicle and dose-related excitation evoked by sulprostone added at the time points indicated by the arrows.
30 minutes
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Table 4.3: Mean pIC50 values (M) and percentage decrease in myogenicity for 
concentration-effect curves to EP agonists (10-10M to 10-5M) using immersed 
myometrial strips in the presence (treated) and absence (control) of the EP4 antagonist 
GW627368x (10-6M). Isolated human myometrium was obtained from donors at term 
pregnancy (n=3-6). Results are expressed as arithmetic means ± S.E. and significance 
was determined using paired t-tests; **p<0.01 for treated compared to control pEC50 
values of AGN201734.  
 
Control Treated 
EP agonists 
pIC50 % decrease pIC50 % decrease 
PGE2 8.4 ± 0.37 33.6 8.4 ± 0.36 36.8 
Butaprost 7.1 ± 0.47 47.0 7.5 ± 0.51 46.5 
CP533,536 6.6 ± 0.44 73.1 7.4 ± 0.92 60.6 
AGN211330 7.2 ± 1.62 41.1 6.5 ± 0.20 34.0 
AH13205 6.2 ± 0.53 54.9 6.9 ± 1.10 44.2 
AGN201734 8.4 ± 0.50 29.7      6.2 ± 0.35** 15.9 
L-902688 7.3 ± 0.64 20.8 6.6 ± 0.56 24.8 
 
 
 
 
4.8 EP agonists in the presence and absence of GW627368x 
In order to more fully characterise the EP receptors, EP agonists were tested in the 
presence of the EP4 antagonist GW627368x. At 10-6M, GW627368x did not 
significantly alter the spontaneous activity of immersed human myometrial strips 
obtained at term pregnancy (Figure 4.8). Likewise, GW627368x did not modify the 
profile of PGE2-induced contractions nor the maximal inhibitory effects of the EP2 
agonists butaprost, CP533,536, AGN211330 and AH13205 (F (10, 43) = 1.70; ns; 
Table 4.3; Figure A5).  
With EP4 agonists, despite the lack of effect of L-902688, GW627368x produced a 
rightward displacement of the AGN201734 concentration-effect curve, sustaining 
activity between 10-8M to 10-6M. The pA2 value was estimated at 8.1 and the pIC50 
value for AGN201734 was significantly attenuated in the presence of the EP4 
antagonist (F (5, 5) = 2.51; p<0.01; Table 4.3). 
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Figure 4.8: Vehicle and responses to PGE2, AGN201734 and L-902688 in the 
presence and absence (control) of the selective EP4 antagonist GW627368x (10-6M) in 
isolated human myometrium taken at term pregnancy (n=3-6). Agonist concentration-
effect curves were performed in immersion baths at 30-minute intervals and expressed 
as percentage of the final contraction induced by hypotonic shock. Results are 
arithmetic means ± S.E. 
a) b) 
c) d) 
  Chapter Four: Term pregnancy 
  Page 96
  
4.9 EP agonists in the presence and absence of AH6809 
Due to its lack of specificity, the EP1, EP2, EP3 and DP antagonist AH6809 was used 
at a concentration of 10-5M. The presence of AH6809 alone did not affect tissue 
myogenicity (F (1, 83) = 0.10; ns; Figure 4.9). However, AH6809 significantly 
antagonised PGE2, producing a rightward displacement of the biphasic curve with an 
estimated pA2 value of 7.2 (Figure 4.9; Table 4.4). Unlike PGE2 alone, AH6809 fully 
inhibited the contractile response characteristically produced at 10-5M (F (1, 59) = 
5.01; p<0.001). 
Each EP2 agonist elicited concentration-dependent inhibitory effects in the rank order 
of potency: butaprost > CP533,536 > AH13205 > AGN211330 (Table 4.4). In the 
presence of AH6809, activities were shifted rightwards and similar monophasic 
inhibitory curves were produced for butaprost, CP533,536 and AH13205 (Figure 
4.10) with pA2 values of about 5.5. This displacement was significant for CP533,536 
at 10-6M (F (1, 60) = 13.16; p<0.05). Even so, the effect of AH6809 was more 
pronounced with AGN211330, preventing the typical decline in activity at 10-5M (F 
(1, 36) = 8.06; p<0.01; Figure 4.10). 
AH6809 did not antagonise either of the EP4 agonists AGN201734 or L-902688 and 
had no effect on the EP1 agonist ONO-D1-004. Although the excitation evoked by 
sulprostone was potentiated in the presence AH6809, this response was variable (F (1, 
60) = 1.99; ns; Figure A6; Table 4.4). 
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Table 4.4: Relative pEC50 values (M) and the percentage change in activity for EP 
agonists determined in isolated lower segment myometrium obtained at Caesarean 
section from non-labouring donors (n=4-8). Agonists were added to parallel 
myometrial strips in the absence (control) or presence (treated) of the EP1, EP2, EP3 
and DP receptor antagonist AH6809 (10-5M). Data are shown as arithmetic means ± 
S.E. and statistical analysis was performed using paired t-tests; *p<0.05 for % change 
in AGN211330; ***p<0.001 for PGE2 pEC50 values of control compared with treated 
groups. 
 
Control Treated 
EP agonists 
pEC50+ % change pEC50 % change 
PGE2 8.4 ± 0.37 33.6     6.0 ± 0.25*** 61.6 
butaprost 7.1 ± 0.47 47.0 6.2 ± 0.33 57.7 
CP533,536 6.6 ± 0.44 73.1 5.5 ± 0.21 66.4 
AGN211330 5.8 ± 0.56 41.1 5.1 ± 1.20 1.5* 
AH13205 6.4 ± 1.23 54.9 6.2 ± 0.71 52.8 
AGN201734 8.1 ± 0.34 29.7 7.7 ± 0.06 28.5 
L-902688 7.3 ± 0.64 20.8 7.7 ± 0.39 19.5 
Sulprostone 7.4 ± 0.64 20.6 8.2 ± 0.39 44.7 
ONO-D1-004 7.3 ± 0.35 5.6 7.8 ± 0.82 7.5 
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Figure 4.9: Vehicle and concentration-effect curves for PGE2 in the absence (control) 
and presence of the EP1, EP2, EP3 and DP receptor antagonist AH6809 (10-5M) in 
myometrial strips from term pregnant, non-labouring donors (n=6-8). Vehicle and 
PGE2 (10-10M to 10-5M) were added to immersion baths at 30-minute intervals with 
myometrial activity expressed as a percentage of the final contraction induced by 
hypotonic shock. Results are arithmetic means ± S.E. and statistical analysis was 
performed using two-way ANOVA with Bonferroni’s adjustment; ***p<0.001 for 
PGE2 compared to PGE2 incubated with AH6809.  
 
Representative traces showing the effects of vehicle and PGE2 in the absence (a, c) 
and presence (b, d) of AH6809 (10-5M) on isolated late gestational myometrium. 
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Figure 4.10: In vitro utero-relaxant effects of the EP2 agonists a) butaprost,                
b) CP533,536, c) AGN211330 and d) AH13205 in human lower segment 
myometrium obtained from term pregnant, non-labouring women (n=4-8). EP 
agonists (10-10M to 10-5M) were added in a cumulative manner at 30-minute intervals 
to isolated myometrial biopsies either alone (control) or in the presence of AH6809 
(10-5M). Results are expressed as arithmetic means ± S.E. and statistical analysis was 
performed using two-way ANOVA with Bonferroni’s post-hoc test; *p<0.05; 
**p<0.01 compared to control EP myogenic activity.  
a) b) 
c) d) 
  Chapter Four: Term pregnancy 
  Page 100
  
10 -11 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4
25
35
45
55
65
ONO-D1-004 AGN211329 + ONO-D1-004
Log concentration of ONO-D1-004 (M)
%
 h
yp
ot
on
ic
 sh
oc
k
10 -11 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4
15
25
35
45
55
PGE2 AGN211329 + PGE2
Log concentration of PGE2 (M)
%
 h
yp
ot
on
ic
 sh
oc
k
10 -11 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4
15
25
35
45
55
vehicle AGN211329 + vehicle
Time-matched vehicles
%
 h
yp
ot
on
ic
 sh
oc
k
10 -11 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4
25
35
45
55
65
sulprostone AGN211329 + sulprostone
Log concentration of sulprostone (M)
%
 h
yp
ot
on
ic
 sh
oc
k
4.10 Contractile EP agonists in the presence and absence of AGN211329 
At 10-6M, the EP3 antagonist AGN211329 maintained myogenic activity at 47.5  ± 
6.89 percent hypotonic shock in vehicle-treated myometrial strips from term pregnant, 
non-labouring donors (Figure 4.11). Although the inhibitory phase of PGE2-induced 
activity was extended by 13.4 percent in the presence of AGN211329, the excitation 
exhibited at 10-5M was equivalent (F (1, 47) = 0.94; ns). Likewise, responses to 
sulprostone and ONO-D1-04 were not altered by AGN211329. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: a) Vehicle and concentration-effect curves (10-10M to 10-5M) for b) PGE2 
and the EP1/3 agonists c) sulprostone and d) ONO-D1-004 in isolated late gestational 
myometrium from donors not in labour (n=3-6). Increasing concentrations of EP 
agonists were added to parallel immersed myometrial strips either alone or in the 
presence of the EP3 antagonist AGN211329 (10-6M). Activity was determined over 
30-minute periods (area under the curve) and expressed as percentage hypotonic 
shock. Data are shown as arithmetic means ± S.E. 
a) b) 
c) d) 
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4.11 Relative uterotonic effects of PGF2α and U46619 
The spasmogens PGF2α and U46619 increased both the amplitude and frequency of 
phasic contractions without elevating the muscle tonus in myometrium from term 
pregnant, non-labouring donors. Using immersed myometrial strips, PGF2α elicited an 
excitatory monophasic response (Figure 4.12). This reached 77.1 ± 6.3 percent 
hypotonic shock, which was significant compared to sustained myogenicity with time-
matched controls (F (1, 55) = 26.55; p<0.001). Using the superfusion technique, 
contractions were evoked immediately after bolus doses of PGF2α. In contrast to 
immersion, enhanced activity was sigmoidal in shape, reaching 64.4 ± 2.64 percent 
hypotonic shock at 10-7mol (F (1, 60) = 49.66; p<0.001).  
U46619 augmented myogenic activity to 137.6 ± 19.2 percent hypotonic shock, which 
was nearly 2-fold higher than the concentration-effect curves generated by PGF2α. 
When added to the same organ bath, U46619 and PGF2α did not produce synergistic 
effects (Figure 4.14). In addition to the increase in amplitude, U46619 enhanced the 
duration of contractions and between 10-6M and 10-5M responses were potentiated (F 
(1, 55) = 83.56; p<0.001).  
 
4.11.1 Antagonism of U46619 with SQ29,548 and GR32191B 
Whilst the TP antagonists SQ29,548 (10-6M) and GR32191B (10-6M) had no effect on 
myogenicity, each suppressed U46619 concentration-effect curves in immersed and 
superfused isolated term gestational myometrium (Figures 4.15 & 4.16) with 
estimated pA2 values of 6.5 and 7.0 respectively. The reduction in U46619-induced 
contractility was notable with the addition of TP antagonists between repeated doses 
of U46619. 
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Figure 4.12: Vehicle, concentration-effect curves and typical traces for PGF2α in 
myometrium from term pregnant, non-labouring donors set-up using a) immersion 
(n=7) and b) superfusion techniques (n=7). PGF2α was respectively added in a 
cumulative manner to immersion baths and administered as bolus doses to the 
superfusate. Results are expressed as arithmetic means ± S.E. and statistical 
significance was determined using two-way ANOVA with Bonferroni’s post-hoc test; 
*p<0.05; ***p<0.001 for PGF2α compared with vehicle. 
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Figure 4.13 Representative traces showing the excitatory effects evoked by PGF2α 
compared to the thromboxane mimetic U46619 in myometrium from term pregnant 
donors, before labour-onset. Agonists were added at 30-minute intervals to the 
immersion apparatus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14: Concentration-effect curves for the uterotonin U46619 a) alone or in the 
presence of either TP antagonist b) SQ29,548 (10-6M) or c) GR32191B (10-6M) in 
myometrium from term pregnant, non-labouring donors (n=6-7). U46619 (10-9M to 
10-5M) was added to immersion baths in a cumulative manner and maximal responses 
for excitation are expressed as percentage hypotonic shock. Data were analysed using 
two-way ANOVA mixed model with Bonferroni’s post-hoc adjustment and expressed 
as arithmetic means ± S.E.; *p<0.05; ***p<0.001 significant attenuation by 
aSQ29,548 and bGR32191B compared with U46619 alone. 
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Figure 4.15: Concentration-effect curves for U46619 in the absence (control) and presence of the TP receptor antagonists SQ29,548 (10-8mol) or 
GR32191B (10-8mol) in myometrial strips from term pregnant, non-labouring donors (n=4-8). Bolus doses of U46619 (10-11mol to 10-7mol) 
were added to the superfusate immediately after myogenic contractions with activity expressed as a percentage of the final contraction induced 
by hypotonic shock. Results are arithmetic means ± S.E. and statistical analysis was performed using two-way ANOVA with Bonferroni’s 
adjustment; *p<0.05; **p<0.01; ***p<0.001 for U46619 alone compared to tissues superfused with aSQ29,548 and bGR32191B.  
 
Representative traces show the excitatory responses evoked in isolated gestational myometrium by a) repeated doses of U46619 (10-8mol) and  
b) antagonised by the addition of GR32191B (10-6M) into the superfusate. 
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 Chapter 4.12: Discussion 
 
 
The results show that late gestational human myometrium exhibited spontaneous and 
agonist-induced contractions in functional in vitro studies. Compared to the non-
gravid state (Chapter 3), myometrial tissue had been subjected to hypertrophy, 
hyperplasia and stretching due to the 400-fold increase in uterine volume during the 
course of pregnancy (Shynlova et al., 2010). The consequential changes in cell 
signalling and mechanotransduction pathways were manifested as well-defined 
intrinsic contractions in immersion and superfusion systems. This may reflect the 
lower segment uterine function to prevent premature delivery of the foetus. Even so, 
due to a lack of definitive markers, the imminent timing of parturition and related 
preparatory stage of tissues were unknown in this study. 
In spite of differences in donor clinical profiles, variations in myogenic activity did 
not relate to groups at high risk of preterm labour, including heavy smoking status and 
those with pathophysiological conditions. This indicates that compensatory changes in 
uterine physiology are responsible for pregnancy maintenance. Compared to 
uncomplicated normal pregnancies, isolated myometrium from diabetics have 
previously been shown to achieve similar isometric forces (Kaya et al., 1999). 
Likewise, the increased vascular resistance in preeclamptic pregnant women was 
related to peripheral rather than myometrial blood vessels (Wimalsundera et al., 
2005). This suggests that the haemodynamic changes to the uterus during pregnancy 
may minimise inter-donor variations. 
Spontaneous contractions of myometrial strips were also not affected by donor parity. 
The distension of the parturient uterus at term to fill almost the entire abdominal 
cavity may have standardised differences between individuals. Similarly, no 
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correlation was found between patient parity and the peak frequency of in vivo uterine 
electromyograph recordings (Maner et al., 2003). Even so, the contractile amplitude 
of isolated myometrium was relatively attenuated in women with a history of previous 
abortions or miscarriages. The timing and manner of pregnancy termination was not 
disclosed on patient information forms but accounted for 26 percent of donors.  
Distinct contractile profiles between and within donor tissues reflected differences in 
myometrial tensile strength (Buhimschi et al., 2006). This included variations in 
muscle content, the distribution and number of PG receptors, gap junctions, ion 
channel proteins, pacemaker cells, signal transduction pathways and endogenous PG 
production. In particular, the upregulated decidual synthesis of PGE2 and PGF2α has 
been reported for miscarriage and for preterm labour (Calder, 1990). This suggests 
that an aberrant release of endogenous PGs may be responsible for changes in uterine 
motility leading to pregnancy-related disorders. 
Increasing intrauterine PGE2 synthesis during the third trimester of pregnancy 
implicates its pivotal role for regulating myometrial tonus (Soloff, 1989). This was 
demonstrated in the present study by use of PGE2 and selective analogues for EP1-4 
receptors. In immersed myometrium taken from term pregnant, non-labouring donors, 
PGE2 attenuated contractions in a concentration-dependent manner followed by 
relative tissue excitation. Bell-shaped responses to PGE2 were also observed using 
superfusion techniques and corroborated previous functional studies (Word et al., 
1992; Senior et al., 1993). 
In lower segment myometrium, PGE2 was the most potent agonist tested with 
predominant utero-relaxatory effects (pEC50: 8.4 ± 0.37M). To mediate inhibition, 
PGE2 has been shown to augment intracellular cAMP in human myometrial cells 
(Oger et al., 2002; Asboth et al., 1997), suggesting the involvement of Gαs coupled 
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EP2 and EP4 receptors. Due to their common pathways and co-localisation, the 
physiological significance of these receptors remains obscure. Nevertheless, higher 
proportions of serine and threonine residues in the carboxyl-terminal tail of EP4 
distinguish it from EP2 (Regan et al., 1994). Accordingly a variety of selective 
agonists have been developed, which were used to determine the relative effects of 
EP2 and EP4 in isolated myometrial tissue. 
For EP2, the selective agonists assayed included butaprost (Gardiner, 1986), 
CP533,536 (Li et al., 2003; Paralkar et al., 2003), AH13205 (Coleman et al., 1994) 
and AGN211330 (Belley et al., 2005). The EP2 analogue butaprost was synthesised 
by replacing the α-carboxylic moiety with a methyl ester. In contrast, CP533,536 was 
a non-prostanoid pyridyl sulfonamide, AH13205 a heptanoic acid and AGN211330 an 
ortho-substituted cinnamic acid. Using myometrial strips in this study, the rank order 
of potency for EP2-mediated inhibition was butaprost = CP533,536 > AH13205 > 
AGN211330. In accordance with superfusion, butaprost attenuated activity in a 
monophasic concentration-related manner (Senior et al., 1993; Duckworth et al., 
2002). Although these studies employed the commercially available methyl ester, 
cellular de-esterification of butaprost to its free acid form would have enabled 
butaprost to attain full agonist potency (Abramovitz et al., 2000; Wilson et al., 2004; 
Alexander et al., 2007). The EP2 agonist, AH13205 only possessed modest affinity at 
EP2 receptors, but was essentially inactive at human EP1 and EP3 receptors (Coleman 
et al., 1994). The decline in activity with AH13205 indicated functional EP2 receptors 
in the isolated myometrium. In addition, AGN211330 was identified as a full EP2 
agonist, with some TP receptor activity (Belley et al., 2005). However, the low 
potency in this study (pEC50: 5.73 ± 0.54M) corresponded to its recent classification 
as an EP2 agonist with only partial EP2 affinity (personal communication, Woodward, 
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2007). Myocyte stimulation with PGE2 and EP2 agonists were also shown to produce 
similar rises in cAMP (Asboth et al., 1997), which indicates further predominant EP2 
receptor binding.  
To determine EP4 receptor action, concentration-effect curves for AGN201734 
(Elworthy et al., 2004) and L-902688 (Billot et al., 2003) were performed on 
myometrial strips. Each ligand was composed of a lactam template and maintained 
natural stereochemistry at C-12 and C-15 for optimal EP4 activity. Even so, 
myometrial responses to AGN201734 mimicked the biphasic response of PGE2, 
whilst L-902688 only attenuated myogenic activity at 10-5M.  This was surprising as 
each agonist had respectively demonstrated a 1000-fold greater affinity to EP4 
compared with the other EP receptors (Elworthy et al., 2004) and PG receptors (Billot 
et al., 2003). Even so, as the heptanoic acid moiety of AGN201734 is similar in 
structure to PGE1 analogues, it is plausible that AGN201734 either activated EP4 or 
exhibited off-target agonist potency at IP receptors. A common structural motif of 
some IP and EP4 receptor agonists has been demonstrated in human (Abramovitz et 
al., 2000; Wilson et al., 2004), porcine (Jones & Chan, 2001), guinea pig and rabbit 
preparations (Jones & Chan, 2005). As a result, EP4 activation was further 
investigated by use of the selective EP4 antagonist, GW627368x (Jones & Chan, 
2005; Wilson & Giles, 2005). 
Despite its affinity for human TP receptors, GW627368x is a highly potent and 
competitive EP4 antagonist (Wilson et al., 2006; Alexander et al., 2007). The 
selectivity of GW627368x was 100-fold greater for EP4 receptors over the EP2 
subtype (Jones & Chan, 2005; Wilson & Giles, 2005; Wilson et al., 2006). This was 
demonstrated in the present study, since GW627368x produced no effects in vehicle 
and EP2-treated myometrial strips. However, with EP4 agonists, the addition of 
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GW627368x caused a rightward displacement of AGN201734 curves, without 
affecting responses to L-902688. These contradictory results increased the ambiguity 
of EP4-mediated events. However, as GW627368x failed to shift PGE2-induced 
responses, it seems most likely that EP2 is the dominant functional isoform in the 
lower uterus at term pregnancy.  
Both EP2 and EP4 transcripts are highly expressed in isolated human lower uterine 
segments at term gestation (Leonhardt et al., 2003; Astle et al., 2005; Sooranna et al., 
2005; Grigsby et al., 2006), which confounds further the diversity of their actions. 
However, with only 38 percent homology between transmembrane domains, it has 
been reported that EP2 and EP4 receptors differ in their sensitivity and additional 
signalling pathways. The agonist-induced desensitisation (Nishigaki et al., 1996) and 
PGE2-mediated internalisation (Desai et al., 2000) of EP4 receptors may attribute to 
the lower PGE2-stimulated cAMP formation in EP4 compared to EP2-transfected cells 
(Fujino et al., 2002; Fujino et al., 2005). In addition, although both stimulate adenylyl 
cyclase, the EP2 receptor is mediated through a cAMP/ PKA-dependent mechanism, 
whereas the EP4 receptor predominantly activates phosphatidylinositol 3-kinase 
(PI3K) and extracellular signal-regulated kinase (ERK)-dependent systems (Fujino et 
al., 2002) via a cAMP-inhibitory G-protein (Gαi; Fujino & Regan, 2006). Moreover, 
the induction of early growth response factor-1 (ERG-1) by PI3K and ERK regulates 
the growth and motility of cells (Sheng et al., 2001). This implicates the involvement 
of EP4 receptors in uterine remodelling during pregnancy. Gene transcription by 
ERG-1 further enhances PGE synthase, inflammatory responses and hyperalgesia 
(Naraba et al., 2002; Slater et al., 2006). As a result, myometrial EP4 receptors may 
primarily mediate PG synthesis, inflammation and nociception whilst EP2 receptors 
appear to be more functional in maintaining uterine quiescence.  
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To identify responses to EP1 and EP3 analogues in gravid human myometrium, 
concentration-effect curves for sulprostone (Schaaf et al., 1981) and ONO-D1-004 
(Oka et al., 2003) were constructed. As a stable acyl sulphonamide, sulprostone 
showed affinity for both EP3 and EP1 receptors (Coleman et al., 1994; Alexander et 
al., 2007) with Ki values of 0.60 and 14nM respectively (Kiriyama et al., 1997). The 
excitatory responses to sulprostone were monophasic using immersion and 
superfusion techniques, indicating the absence of EP2 (Coleman et al., 1994) and EP4 
receptor activation (Wilson et al., 2004). A decline in the majority of EP3 receptors, 
including EP3-II mRNA and increased EP3-VI transcripts by term gestation (Matsumoto 
et al., 1997; Wing et al., 2003; Astle et al., 2005) may have reflected the 10-fold 
reduction in the potency of sulprostone compared with the non-pregnant state (Senior 
et al., 1993). However, the signalling cascades and transcriptional mechanisms for 
each of the EP3 splice variants have yet to be elucidated. 
In contrast, the novel EP1 receptor agonist, ONO-D1-004, produced negligible 
myogenic effects on tissues relative to time-matched vehicle controls. Although 
highly selective for the mouse EP1 receptor, the binding affinity of ONO-D1-004 was 
relatively weak with a Ki value of 150nM (Kiriyama et al., 1997). Moreover, its 
potency was 8-fold lower than PGE2 (Oka et al., 2003). Therefore, rather than 
discounting the influence of EP1 receptors, the population of myometrial EP receptors 
was further examined by use of selective antagonists. 
AH6809 has been used as a putative EP1 antagonist for receptor classification 
purposes (Coleman et al., 1994). However, in human recombinant receptors, the 
affinity of AH6809 was equipotent for EP1 and EP2 receptors (Woodward et al., 1995) 
with further weak, but specific antagonism displayed at human EP3 and DP receptors 
(Keery & Lumley, 1988; Kiriyama et al., 1997; Abramovitz et al., 2000). As the pA2 
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for AH6809 has been reported to be between 5.3 and 7.0 (Keery & Lumley, 1988; 
Meja et al., 1997; Abramovitz et al., 2000), it was added at 10-5M to competitively 
block functional receptors. 
Accordingly, AH6809 had no effect on spontaneous myometrial activity or responses 
to the EP4 receptor agonists AGN201734 and L-902688 in this study. However, a 
notable change in the concentration-effect curves for PGE2 was elicited in the 
presence of AH6809 with an apparent pA2 value of 7.2. Between 10-10M and 10-7M, 
the relative enhancement of contractions indicated the antagonism of EP2 receptors. 
However, the subsequent 2.6 ± 0.21 fold attenuation in activity may have represented 
blocking of EP1 and EP3 receptors, enabling PGE2 to target relaxatory EP receptors. 
Despite the lower affinity of the EP2 mimetics (pA2 values: 5.3 to 5.7), the inhibitory 
effects of PGE2 with AH6809 were similar to butaprost, CP533,536 and AH13205. 
This implies that high concentrations of PGE2 couple to functional EP2 receptors due 
to their prevalence in lower myometrial tissue at term pregnancy. The full antagonism 
of AGN211330 also demonstrated its weak affinity for EP2 receptor sites. 
In accord with previous functional studies (Senior et al., 1993), AH6809 did not alter 
contractile responses to the EP3/1 agonist sulprostone. With AH6809 having 50-fold 
greater affinity for EP1 over EP3 receptors (Abramovitz et al., 2000), this suggests a 
paucity of functional EP1 receptors in isolated human myometrium. It would also 
substantiate the lack of excitation observed with the EP1 agonist ONO-D1-004. Even 
so, AH6809 decreased the height of the PGE2-induced Ca2+ peak in myometrial cells 
(Asboth et al., 1997), which was displayed as the loss of contractility by PGE2 at     
10-5M. This suggests that AH6809 can effectively block EP1/3 receptors when 
inhibitory receptors supersede contractile EP receptor function in late gestational 
lower myometrium. 
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Unfortunately, the EP3 receptor antagonist, AGN211329, did not modify excitatory 
responses to PGE2 and sulprostone in this study. This was in contrast to its reported 
high affinity for EP3 receptors in transfected human embryonic kidney cells (Belley et 
al., 2005) and guinea pig vas deferens and tracheal tissues (Clarke et al., 2004). The 
lack of inhibitory effect, however, was also determined using isolated mouse uterus 
(Griffiths et al., 2006) and additional antagonism for AGN211329 was shown at DP, 
EP4 and TP receptors using recombinant human receptors (personal communication, 
Woodward, 2007). Functional data on EP3 receptor activation has been particularly 
limited due to the multiple splice variants and the cross-reactivity of ligands. Whilst 
EP3 antagonists are just emerging, potent selective antagonists for EP2 receptors are 
yet to be developed (Woodward et al., 1995; Alexander et al., 2007). As a result, a 
more comprehensive pharmacological classification of EP receptor function still 
remains to be established. 
Unlike PGE2, PGF2α elicited monophasic excitation in isolated lower tissues taken at 
term pregnancy. Uterotonic responses were quantitatively similar to previous 
superfusion and immersion studies (Wikland et al., 1984; Word et al., 1992; Senior et 
al., 1993; Crankshaw & Dyal, 1994; Friel et al., 2005; Hutchinson, 2005), indicating 
the presence of myometrial FP receptors. This was verified by the 16-phenoxy FP 
analogues fluprostenol and 17-phenyl PGF2α, which produced equivalent in vitro 
myogenic contractions (Senior et al., 1993; Hutchinson, 2005). High affinity for FP 
receptors was calculated in the rank order of PGF2α = fluprostenol > PGD2 > PGE2 > 
U46619 > iloprost with Ki values of 2.1, 2.7, 5.4, 65, 112 and 920nM respectively 
(Abramovitz et al., 1994). Although PGF2α was reported to also bind to EP1 and EP3 
receptors with significant affinity (Kiriyama et al., 1997; Breyer et al., 2001), PGF2α-
induced contractility was 23 percent more pronounced in this study compared to 
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sulprostone. This indicates the predominant involvement of FP-mediated effects on 
uterine motility. 
Human FP receptors consist of 359 amino acid residues with a predicted molecular 
mass of 40,060Da (Abramovitz et al., 1994). Despite the clone of a second FP 
carboxyl-terminal splice variant from ovine (Pierce et al., 1997) and bovine corpus 
luteal cells (Ishii & Sakamoto, 2001), only one isoform has so far been identified in 
human tissues. To support pregnancy, uterine FP mRNA expression was shown to 
decline with gestational age in humans (Matsumoto et al., 1997; Brodt-Eppley & 
Myatt, 1999; Sooranna et al., 2005) and in rats (Brodt-Eppley & Myatt, 1998). At 
term pregnancy, the human gene for myometrial FP receptors was downregulated by 
45 percent compared with the non-pregnant state (Matsumoto et al., 1997). This 
correlated with a decrease in the potency of PGF2α-induced contractions (Senior et al., 
1992; Senior et al., 1993) also observed in the present study. 
Although FP receptors are coupled to Gαq, the postreceptor actions of PGF2α are still 
uncertain. Signalling pathways are mediated via IP3 to enhance intracellular Ca2+ 
entry (Carrasco et al., 1996). However, functional studies have also suggested 
involvement of the Ca2+-independent RhoA pathway (Woodcock et al., 2006) and 
required adenosine-5’-trisphosphate (ATP) treatment to potentiate activity (Ziganshin 
et al., 2005). Challenge using the stable thromboxane mimetic, U46619, in this study 
augmented myometrial contractility by 1.8-fold above PGF2α, without enhancing 
responsiveness to PGF2α. This indicates differences in FP and TP receptor densities 
and specific signalling cascades to generate uterine force.  
The best characterised of the synthetic thromboxane analogues is U46619 (Coleman 
et al., 1994). As a potent and full contractile agonist, U46619 produced dynamic 
contractions in isolated human myometrium taken at term pregnancy. Significant 
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antagonism of U46619 was shown with selective TP antagonists SQ29,548 (Ogletree 
et al., 1985) and GR32191B (Lumley et al., 1989). These compounds both have Ki 
values at 13nM (Tsuboi et al., 2002) and respective pA2 values of 6.5 and 7.0, which 
confirmed TP-mediated responses in this study. In addition, SQ29,548 did not alter 
PGF2α-induced activity in myometrium obtained near term (Hutchinson, 2005; 
Griffiths et al., 2006); this demonstrates the paucity of off-target PGF2α action at TP 
receptors. 
The expression of thromboxane A2 synthase and splice variants TPα and TPβ has 
been identified in human myocytes and vasculature at term pregnancy (Swanson et 
al., 1992; Hirata et al., 1996; Sooranna et al., 2005). Although both TP isoforms 
exhibit identical ligand binding, each oppositely regulates adenylyl cyclase activity 
(Hirata et al., 1996). TPα receptors increase cytoplasmic cAMP, whilst TPβ receptors 
inhibit cAMP and stimulate PLC-IP3 and RhoA-mediated pathways (Moore et al., 
2002). U46619 activates PLC at lower concentrations than adenylyl cyclase (Hirata et 
al., 1991; Moore et al., 2002), which may account for the contractile effect of U46619 
in intact myometrial strips. Even so, the relative distribution of each TP subtype has 
yet to be discriminated in late gestational myometrium. 
In uterine myocytes, U46619 produced a transient rise in IP3 and intracellular Ca2+, 
consistent with TPβ receptor activation (Moore et al., 2002). Chronic challenge with 
U46619 generated two target mediators in the TP signalling cascade, rho-associated 
coiled coil-forming protein kinase (ROCKI; p160 ROCKI) and its isoform ROCKII 
(Kureishi et al., 1997; Moore et al., 2002; Moran et al., 2002; Moore & Lopez Bernal, 
2003). These activate the small G-protein RhoA, which sensitises the uterus to Ca2+. 
For further Ca2+ sensitisation, U46619 induced the cleavage of the p160 ROCKI 
protein to yield p130 ROCKI by caspase-3 (Moore & Lopez Bernal, 2003), associated 
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with enhanced uterine contractility and apoptosis (Coleman et al., 2001). Although 
the caspase-3 inhibitor Z-DEVD-FMK blocked this pathway (Moore et al., 2002; 
Moore & Lopez Bernal, 2003), it caused no appreciable effect on U46619-induced 
activity in the present study. This suggests that the expression of each ROCK protein 
type has similar efficacy on myometrial contractions.  
Specific inhibitors of the RhoA cascade have been investigated as smooth muscle 
relaxant agents. SQ29,548 has been shown to promote increased proteolysis of pre-
existing p160 ROCKI to p130 ROCKI (Moore et al., 2002). Even so, in myometrial 
strips the caspase-3 inhibitor did not reverse SQ29,548 actions, indicating that 
attenuated U46619 responses were blocked at cognate TP receptor sites. Use of the 
specific ROCKI and ROCKII inhibitor, Y-267632, also reduced smooth muscle 
contractility (Moran et al., 2002). This demonstrates ROCK protein involvement in 
spontaneous myometrial activity. Upregulated expression of the ROCK isoforms was 
shown in rat and human myometrial tissues either during the third trimester of 
pregnancy (Niiro et al., 1997; Moore et al., 2000) or after labour-onset (Friel et al., 
2005). Therefore, ROCK has the potential to regulate uterine contractions in a Ca2+-
independent manner during late gestation. In addition, U46619 stimulates mitogenesis 
and hypertrophic growth of uterine smooth muscle cells via mitogen-activated protein 
kinase (MAPK) cascades (Miggin & Kinsella, 2001). Accordingly, thromboxane may 
also influence muscle tone and uterine remodelling during pregnancy. 
In summary, this study demonstrates the heterogeneous population of functional EP, 
FP and TP receptors in lower segment myometrium from term pregnant, non-
labouring donors. To maintain quiescence, EP agonists induced predominant utero-
relaxant effects; this was primarily mediated by EP2 rather than EP4 receptors. Despite 
the multitude of isoforms, some excitation was elicited via EP3 receptors, whilst 
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responsiveness to the EP1 agonist ONO-D1-004 was negligible. Even so, functional 
EP3 and EP1 receptors appeared to represent a minor component of the overall 
receptor complement in this tissue. In contrast, activated FP receptors augmented 
myometrial activity with contractions further potentiated by the TP mimetic U46619. 
As EP, FP and TP receptors also contribute to hyperplasia and hypertrophy, it is likely 
that these receptors facilitate uterine distension and maintain myometrial tone 
throughout the majority of pregnancy. 
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Chapter 5: Labour 
 
Functional prostanoid receptors in isolated myometrium during parturition 
 
 
5.1 Introduction 
Successful parturition requires powerful and coordinated uterine contractions, in 
conjunction with cervical ripening and dilation. This is synchronised by changes in 
local maternal, foetal and mechanical factors (Keelan et al., 2003; Hertelendy & 
Zakar, 2004). Even so, due to its complexity, the physiological and molecular 
mechanisms underlying the transition from uterine quiescence to activation are not 
fully understood.  
Compelling evidence has shown that PGs, particularly those produced within the 
intrauterine tissues, are central in the initiation and progression of labour. In late 
pregnancy, enhanced PGE2 and PGF2α biosynthesis by intrauterine tissues precedes 
labour-onset (Gibb, 1998), whilst clinical applications of PGE analogues are widely 
used for labour induction, cervical effacement and to maintain patency of the ductus 
arteriosus. Moreover, in terms of tocolysis, many PG synthesis inhibitors can prolong 
gestation via temporary suppression of myometrial contractility (Vermillion & 
Landen, 2001). Even so, the functional dynamics of myometrial PG receptors during 
parturition have yet to be elucidated. 
To better understand parturient uterine function, myometrial responsiveness to 
selective EP analogues, PGF2α and U46619 were investigated in this study in lower 
segment myometrium obtained from labouring donors. After the onset of regular, 
painful in vivo uterine contractions, labour was categorised at cervical dilations of     
0-2cm, 3-8.5cm and 9-10cm for early, mid and late stages respectively. Myometrial 
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responses to PGs were examined to improve the efficacy of available tocolytics for 
labour-associated disorders. 
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Chapter 5.2: Results 
 
 
 
5.3 Myogenic activity at term pregnancy and labour 
Spontaneous contractions varied markedly between donor tissues taken at different 
stages of pregnancy and labour (Figure 5.1). In immersed isolated myometrium, the 
greatest activity was exhibited by samples taken at term (39.3 ± 0.4 weeks gestation) 
from pregnant non-labouring donors. By the early stages of parturition, myogenicity 
was variable and decreased by 14.9 percent (F (1, 18) = 1.34; ns). This group included 
patients labouring for 1.5 to 8 hours, with cervical dilation at 0-2cm; two donors 
presented placental praevia. Myometrial contractions substantially declined by 2.6 and 
3.3-fold in tissues collected during the mid (F (1, 18) = 47.33; p<0.001) and late (F (1, 
18) = 96.41; p<0.001) stages of labour. These groups were determined by cervical 
dilation at 3-8.5cm and 9-10cm respectively, correlating with the reduction in both the 
frequency and amplitude of in vitro contractions. Of the myometrial strips, 59 percent 
were devoid of rhythmic undulating myogenic activity late after labour-onset. This 
may have related to the relatively prolonged duration of labour in fully dilated donors. 
Even so, labour-associated pharmacological compounds, such as entonox and 
syntocinon, did not influence in vitro spontaneous myometrial contractions (Table 
5.1). 
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Figure 5.1:  Spontaneous activity of lower segment myometrial strips obtained from 
term pregnant donors, not in labour (n=10) and in early (n=9), mid (n=9) and late 
(n=9) stages of labour. Labour was defined as regular uterine contractions with early, 
mid and late stages categorised at 0-2cm, 3-8.5cm and ≥9cm cervical dilation 
respectively. Myometrium was immersed, equilibrated for up to 2.5 hours and 
myogenic activity was measured as 30 minutes area under the curve and expressed as 
a percentage of 30 minutes hypotonic shock, regardless of the presence of phasic 
activity. Results were displayed as arithmetic means ± S.E. and significant differences 
were identified using univariate ANOVA with Bonferroni’s post-hoc adjustment: 
***p<0.001 reduction in spontaneous activity relative to tissues taken at term 
pregnancy and early labour. 
 
Representative traces show typical activity of isolated myometrium equilibrated in 
immersion baths from donors at term pregnancy a) not in labour and after labour-
onset at cervical dilations of b) 2cm, c) 5-6cm and d) 9cm. 
b) 
30 minutes 
 
5g 
7g 
2g 
a) 
c) 
d) 
9g 
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Table 5.1: Spontaneous contractions of donated lower segment myometrium obtained 
during labour. Early, mid and late stages of labour were defined as regular in vivo 
contractions at cervical dilations of 0-2cm, 3-8.5cm and 9-10cm respectively. In 
addition to epidural anaesthetics, labouring women had been given entonox or 
pethidine for analgesic relief, Phenergan or Maxolon to prevent nausea and vomiting 
and/ or syntocinon to induce or accelerate labour before donation of tissues. These 
pharmaceutical agents did not influence myogenic activity established using the 
immersion technique, measured for 30 minutes after the equilibration period as area 
under the contraction curve.  
 
 Entonox/ Pethidine n Phenergan/ Maxolon n Syntocinon n
Early labour 1143.4 ± 172.4 4 1170.1 ± 207.7+ 1 n/a 0 
Mid labour 569.4 ± 92.9 5 417.2 ± 80.3 6 614.5 ± 107.2 4 
Late labour 174.0 ± 20.7 5 157.7 ±17.3 2 128.5 ± 12.5+ 1 
 
+Mean activity of 6-8 myometrial strips from the same biopsy 
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Figure 5.2: Trace showing the concentration-effect of PGE2 relative to spontaneous 
activity of myometrium obtained at 32 weeks of gestation from a fully dilated donor.  
 
 
 
 
5.4 Myometrial EP receptors after labour-onset 
In lower segment myometrium taken at term early labour, PGE2 caused a biphasic 
response, similar to that observed before parturition. PGE2 (10-8M to 10-6M) initially 
attenuated the amplitude and frequency of myogenic contractions by 2.1-fold (F (1, 
60) = 15.98; p<0.001), with tissue excitation subsequently evoked at 10-5M (Figure 
5.3a). This corresponded to the profile of myometrial strips taken preterm, at 32 
weeks of gestation from a fully dilated donor (Figure 5.2). However, by mid and late 
stage term labour, PGE2 (10-8M to 10-5M) fully inhibited myogenic activity in a 
monophasic concentration-related manner (Figures 5.3b & 5.3c). This was achieved 
by PGE2 suppressing contractile amplitude until the threshold was no longer reached. 
Compared to spontaneous activity, the main effects of PGE2 were significant for both 
mid (F (1, 72) = 7.03; p<0.01) and late (F (1, 60) = 4.31; p<0.05) stages of term 
parturition. 
  4g 
10-8M 10-6M 10-5M 10-7M Hypotonic shock Spontaneous activity 
30 minutes 
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Figure 5.3: Vehicle and concentration-effect curves for PGE2 in lower myometrium obtained from term pregnant donors in a) early (n=6), b) mid 
(n=7) and c) late (n=6) stages of labour. Labour was defined as in vivo contractions accompanied by cervical dilation at 0-2cm, 3-8.5cm and 9-
10cm respectively. Vehicle and PGE2 were added to individual organ baths at 30-minute intervals and excitatory responses to PGE2 were only 
evoked at 10-5M during early labour. Results are expressed as arithmetic means ± S.E. and univariate analysis using Bonferroni’s post-hoc test 
showed significant differences ***p<0.001 for PGE2 compared to vehicle. 
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Figure 5.4: Vehicle, concentration-effect curves and representative traces for the EP2 
agonists a) butaprost, b) CP533,536, c) AGN211330 and d) AH13205 in immersed 
myometrial strips taken at term, early labour (n=4-6). Early labour was defined as 
painful contractions accompanied by cervical dilation between 0-2cm. Myometrial 
responses to EP2 agonists were measured over 30-minute intervals as area under the 
curve, expressed as percentage hypotonic shock and presented as arithmetic means ± 
S.E. Statistical significance was determined using multivariate ANOVA with 
Bonferroni’s post-hoc adjustment; *p<0.05 for butaprost and AH13205; **p<0.01 for 
CP533,536 and AGN211330 compared with vehicle treatments. 
 
Table 5.2: Mean pIC50 values (M) for EP2 agonist concentration-effect curves (10-10M 
to 10-5M) in immersed myometrium from term pregnant donors after labour-onset   
(0-2cm cervical dilation; n=4-6). Results are expressed as arithmetic means ± S.E. 
 
EP2 agonists butaprost CP533,536 AGN211330 AH13205 
pIC50 6.20 ± 0.30 6.02 ± 0.55 5.81 ± 0.29 6.03 ± 0.19 
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5.5 Inhibitory effects of EP2 agonists on myogenic activity 
The steady and active nature of phasic myometrial contractions in tissues obtained 
early after labour-onset enabled inhibitory agonists to be assayed at this stage of 
parturition. Using immersed myometrial strips butaprost, CP533,536, AH13205 and 
AGN211330 attenuated myogenic activity in a linear concentration-dependent manner 
(Figure 5.4). This was achieved primarily between 10-7M and 10-5M due a reduction 
in both the amplitude and frequency of contractions. The rank order of potency was 
similar between EP2 agonists with AGN211330 having least efficacy (Table 5.2). 
Inhibitory responses were due to the main effects of butaprost (F (1, 48) = 9.35; 
p<0.01), CP533,536 (F (1, 54) = 16.75; p<0.001), AH13205 (F (1, 36) = 6.23 p<0.05) 
and AGN211330 (F (1, 36) = 15.52; p<0.001). 
 
 
5.6 EP4 agonist effects on myogenic activity 
In isolated myometrium obtained during early labour, the steady decline in myogenic 
activity for the EP4 agonist AGN201734 (10-8M to 10-5M) did not reach statistical 
significance (F (1, 48) = 2.85; ns; Figure 5.5). In comparison, the effects of L-902688 
were more variable. Contractions were predominantly maintained until 10-5M, 
whereby L-902688 attenuated activity from 55.5 ± 4.0 to 34.6 ± 18.6 hypotonic shock 
(F (1, 36) = 0.37; ns); this corresponded to its low potency value (Table 5.3). Even so, 
neither of the EP4 agonists altered myometrial tonus or induced excitatory responses. 
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Figure 5.5: Vehicle and concentration-effect curves for EP4 agonists AGN201734 and 
L-902688 in isolated myometrium obtained from term pregnant, early labouring 
donors (n=4-5). The contractions associated with labour were accompanied by 
cervical dilation between 0-2cm. Vehicle and EP4 agonists (10-10M to 10-5M) were 
added to immersed myometrial strips in a cumulative manner at 30-minute intervals. 
Results are expressed as arithmetic means ± S.E. 
 
 
 
 
Table 5.3: Mean pIC50 values (M) determined for the EP4 agonists AGN201734 and 
L-902688 (10-10M to 10-5M) using myometrium obtained from donors during early 
labour at emergency Caesarean section (n=4-5). Concentration-effect curves were 
performed using the immersion technique and results are expressed as arithmetic 
means ± S.E. 
 
EP4 agonists AGN201734 L-902688 
pIC50 7.53 ± 1.04 5.69 ± 0.86 
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Figure 5.6: Vehicle and concentration-effect curves for the EP1/3 agonists ONO-D1-
004 and sulprostone in myometrium obtained from donors in a) mid and b) late stages 
of term parturition (n=4-7). In vivo contractions accompanied by cervical dilation at 
3-8.5cm and 9-10cm respectively were used to distinguish the stages of labour. 
Immersed myometrial responses to EP1/3 agonists were measured over 30-minute 
periods as area under the curve and expressed as a percentage hypotonic shock. 
Results are arithmetic means ± S.E. and statistical significance was determined using 
two-way ANOVA with Bonferroni’s post-hoc test; **p<0.01 for sulprostone 
compared with vehicle. 
 
Typical traces show myometrial tissue in organ baths, contracting in response to 
sulprostone (10-7M to 10-5M). Myometrium was obtained from donors after the onset 
of a) mid and b) late stages of labour. 
 
 
 4g  5g 
30 minutes 30 minutes 
a) b) 
a) b) 
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5.7 Excitatory EP agonists on myogenic activity 
To ensure that responses were apparent, contractile agonists were primarily added to 
tissues with low myogenic activity. Although the EP1 agonist ONO-D1-004 did not 
evoke excitation either at mid (F (1, 48) = 0.18; ns) or late (F (1, 42) = 2.15; ns) stages 
of term labour, the EP3/1 agonist sulprostone produced a monophasic increase in 
activity (Figure 5.6). Despite a lack of significance compared with vehicle controls (F 
(5, 66) = 0.70; ns), sulprostone exhibited a main treatment effect at mid labour (F (1, 
66) = 9.36; p<0.01). This was better displayed during late labour with a 2-fold 
increase in activity at 10-5M relative to intrinsic contractions (F (5, 66) = 8.70; 
p<0.01). Using superfused tissues, the excitatory responses to bolus doses of 
sulprostone were observed throughout parturition; this included tissues taken early 
after labour-onset (Figure 5.9.1).  
 
5.8 Contractile effects of PGF2α 
PGF2α produced concentration-dependent excitation in uterine muscle obtained during 
early, mid and late stages of parturition (Figures 5.7 & 5.9.2). In immersed 
myometrial strips, the increase in activity was nearly 60 percent higher in tissues 
taken during mid-term labour rather than late labour at 10-5M (p<0.001). Whilst 
during mid labour PGF2α augmented myometrial contractions in a monophasic 
manner, by late labour, responsiveness was attenuated and was sigmoidal shaped (F 
(1, 50) = 22.18; p<0.001). The excitation evoked by PGF2α was more pronounced in 
superfused tissues with the greatest phasic activity reaching 48.7 ± 4.4 percent 
hypotonic shock early after labour-onset. In a late labour preterm myometrial sample, 
the PGF2α-induced contractile response increased to a similar extent from 25.8 to 46.1 
percent hypotonic shock between 10-7M and 10-5M (Figure 5.8).  
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Figure 5.7: Concentration-effect curves and representative traces for PGF2α in 
myometrium obtained from term pregnant donors at a) mid and b) late stages of 
labour (n=6-7). Labour was defined as in vivo contractions with respective stages 
determined at 3-8.5cm and 9-10cm cervical dilation. PGF2α was added to organ baths 
in a cumulative manner at 30-minute intervals with responses were measured as area 
under the curve relative to the contraction achieved by hypotonic shock. Results are 
expressed as means ± S.E. and statistical analysis was performed using multivariate 
ANOVA with Bonferroni’s post-hoc test; p<0.001 contractions in response to PGF2α 
at 10-5M for mid compared to late labour.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8: Representative traces for PGF2α in myometrium obtained at 32 weeks 
gestation from a fully dilated donor. Responses to PGF2α were similar regardless of 
agonist addition to a) immersed and b) superfused myometrial strips.  
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Figure 5.9: Representative traces showing the contractile effect of increasing bolus doses of 1) sulprostone, 2) PGF2α and 3) U46619 superfused 
on lower segment myometrium obtained during parturition at emergency Caesarean section. Labour was defined as in utero contractions with a) 
early, b) mid and c) late stages determined by cervical dilations at 0-2cm, 3-8.5cm and 9-10cm respectively. 
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5.9 Maintained uterotonic effects of U46619 
The thromboxane mimetic U46619 reliably produced a contractile phenotype in 
myometrial strips obtained during parturition. U46619 induced substantial tissue 
excitation and particularly enhanced contractile frequency. In immersed tissue strips 
during mid stage labour, activity was increased from 14.7 ± 2.6 to 89.7 ± 13.0 percent 
hypotonic shock. These contractile responses were substantially higher than in tissues 
taken during late term labour (p<0.001), despite the 13.6 percent attenuation of 
activity at 10-5M (p<0.05; Figure 5.10). Concentration-effects of U46619 reached 42.7 
± 6.6 percent hypotonic shock in myometrium obtained during late labour. Even so, 
responses to U46619 were greatly augmented in relation to the low amplitude and 
frequency of spontaneous contractions (F (1, 55) = 23.36; p<0.001). U46619-induced 
excitation was also maintained throughout parturition in superfused tissues (Figure 
5.9.3) as well as in the late labour sample obtained at 32 weeks of pregnancy (Figure 
5.11). In addition, the caspase-3 inhibitor had no effect on the augmented contractile 
frequency and amplitude of U46619 concentration-effect curves at mid and late stages 
of term parturition (Figures 5.12 & A7). 
 
 
5.10 TP antagonism by SQ29,548 and GR32191B 
Neither TP antagonists SQ29,548 (10-6M) or GR32191B (10-6M) affected myogenic 
activity. However, both antagonists suppressed U46619-induced contractions in 
myometrium taken at mid and late stages of term labour (Table 5.4).  
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Figure 5.10: Concentration-effect curves and representative traces for U46619 in 
myometrial strips from donors at a) mid and b) late stages of labour (n=6-7). Mid and 
late labour was categorised at 3-8.5cm and 9-10cm cervical dilation respectively. In 
all immersed myometrial strips, addition of the stable thromboxane mimetic U46619 
provoked contractile responses relative to spontaneous activity. This was measured as 
area under the curve relative to the contraction induced by hypotonic shock. Results 
are expressed as means ± S.E. and statistics were performed using two-way ANOVA 
with Bonferroni’s adjustment; *p<0.05; ***p<0.001 for U46619-induced contractions 
in samples taken at mid compared with late labour. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: Representative traces showing the concentration-effect and dose-
response of U46619 in myometrial strips set-up using a) immersion and b) 
superfusion techniques. The muscle biopsy was obtained from a fully dilated donor at 
32 weeks of gestation.  
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Table 5.4: Mean pEC50 values (M) and maximal excitatory responses (Em) for 
U46619 (10-9M to 10-5M) in the absence and presence of either SQ29,548 (10-6M) or 
GR32191B (10-6M) in myometrium from term pregnant donors in mid (n=6-8) and 
late stages of labour (n=5-8). Maximal responses for excitation are expressed as 
percentage hypotonic shock. Data were analysed using univariate ANOVA mixed 
model with Bonferroni’s post-hoc test and results were expressed as arithmetic means 
± S.E. Excitatory responses to U46619 were significantly different in myometrium 
taken at mid labour compared with alate gestation (p<0.001). Responses to U46619 
were also attenuated by action of SQ29,548 in cmid labour (p<0.001) and dlate labour 
(p<0.001) with similar antagonism by GR32191B at emid and flate labour  
 
 U46619 alone + SQ29,548 + GR32191B 
 pEC50 Em pEC50 Em pEC50 Em 
Mid labour 7.1 ± 0.2 106.2 ± 9.6 6.2 ± 0.5 28.7 ± 9.9c 6.7 ± 0.3 39.3 ± 14.1e 
Late labour 6.8 ± 0.1 56.9 ± 9.7a 6.1 ± 0.3 21.0 ± 7.6d 6.2 ± 0.6 20.1 ± 0.7f 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: Mean U46619-induced excitation in the presence or absence of the 
caspase-3 inhibitor (10-6M) on myometrial strips obtained at a) mid (n=6-8) and b) 
late (n=5-8) stages of labour. The caspase-3 inhibitor had no effect on contractions 
potentiated by U46619. Mid and late labour were defined at 3-8.5cm and 9-10cm 
cervical dilation respectively. Results are expressed as means ± S.E. 
 
a) b) 
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 Chapter 5.11: Discussion 
 
 
During parturition, regular and forceful uterine muscle contractions develop in a 
caudal direction from the fundus towards the cervix. These were exhibited as well-
defined spontaneous contractions in immersed (Hutchinson, 2005) and superfused 
myometrial tissues obtained early after labour-onset. However, as labour progressed 
into mid and late stages, the frequency and amplitude of phasic contractions in lower 
segment myometrial strips declined by 2.6 and 3.3-fold respectively. This would 
likely correspond to extensive in utero collagen tissue remodelling, which facilitates 
cervical effacement and dilation for delivery of the foetus (Leppert, 1995). 
To soften and retract the cervix prior to labour-onset, metalloproteinase inhibitors 
decrease the stability of collagen, whilst the water, glycosaminoglycan and 
noncollagenic protein content of tissues increase (Osmers et al., 1993). Cervical 
dilation and myometrial remodelling are advanced by the concurrent apoptosis of 
smooth muscle cells (Leong et al., 2008). Since muscle bundles transmit action 
potentials within the uterus, the changes in cellular composition would attenuate 
myometrial excitability (Wray et al., 2001; Blanks et al., 2007). Moreover, the 
presenting foetus exerts a constant tension against the cervix and begins stretching 
and passively dilating the lumen. This may further contribute to the reduction in 
myogenic activity observed with labour progression in this study. 
The attenuated myogenic force in lower segment tissues during labour was consistent 
with the topographical changes in contractile-associated protein expression and Ca2+ 
transients (Astle et al., 2005; Riley et al., 2005). For the uterus to act in synchrony, 
specialised pacemaker cells transduce electrical signals via gap junctions between 
myocytes (Kilarski et al., 2000; Duquette et al., 2005). These gap junction transcripts 
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become more pronounced in upper rather than lower segment myometrium during 
labour (Sparey et al., 1999), facilitating the vigorous spontaneous contractions of 
isolated fundus myometrium towards the cervix (Griffiths et al., 2006). At parturition, 
less sensitive isoforms of Ca2+-activated potassium channels are expressed in isolated 
lower segment tissues (Curley et al., 2004) whilst Ca2+-ATPase activity is reduced 
with uterine dystocia (Zyrianov et al., 2003). As a result, contractile constituents may 
have been depleted in prolonged labours, contributing to the low intrinsic myometrial 
activity. 
In this study, emergency Caesarean sections were performed due to labour-associated 
disorders. Indications included foetal distress, breech presentation, previous 
Caesarean sections, labour dystocia, placental abruption, maternal pregnancy-induced 
hypertension, epilepsy and asthma. Due to the limited sample numbers, no exclusion 
criteria were applied. Pharmacological medications provided for analgesia, nausea-
relief and to augment labour did not influence in vitro myogenic activity. In addition, 
similar tensile strengths of uterine muscle were demonstrated with intact and 
previously scarred tissues (Buhimschi et al., 2006). Even so, it was recognised that the 
tissue properties in this study may not have resembled uterine muscle obtained from 
normal, uncomplicated labours. 
Despite a high incidence of premature deliveries (Lumley, 2003), only one late labour 
myometrial biopsy was donated at 32 weeks of gestation. The spontaneous 
contractions by immersed preterm myometrial strips were twice as active as biopsies 
harvested from fully dilated donors at term. This suggests differences in preterm and 
term parturition cascades.  
Although functional progesterone withdrawal is a prerequisite for labour, its 
mechanisms are unclear. As systemic progesterone does not decline before labour-
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onset in women (Boroditsky et al., 1978), events appear to be mediated by 
biochemical changes within the uterus. These include the upregulation of cognate 
progesterone receptor (PR)-A, which repress PR-B function (Pieber et al., 2001; 
Mesiano et al., 2002), association of PR with nuclear factor kappa B (NF-κB) and a 
reduction in steroid receptor co-activators (Allport et al., 2001). Moreover, the 
progesterone block is positively correlated to rising oestrogen receptor-α (ERα) 
mRNA (Winkler et al., 2002). In the presence of ERα, oestrogen treatments have 
been shown to increase connexin-43 transcripts (Garfield et al., 1980; Kilarski et al., 
2000; Di et al., 2001; Grummer et al., 2004), COX-2 and oxytocin receptors 
(Mesiano, 2001; Mesiano et al., 2002), which are required for transient myometrial 
contractions. Thereby, the close apposition of placental oestrogen to the uterine 
fundus may attribute to forceful contractions, which dissipate towards the cervix for 
parturition to succeed. In addition, the heightened spontaneous activity observed in 
this study implicates sustained oestrogenic effects during preterm relative to term 
deliveries. Nevertheless, rather than exogenous steroids, uterotonins are crucial 
mediators in orchestrating and driving labour contractions (Challis et al., 2000). 
Profound increases in PG synthesis and metabolism by foetal membranes and 
myometrium precede the initiation and progression of labour (Gibb, 1998; Durn et al., 
2010). The biosynthetic capacity for PGs, especially of amnion-derived PGE2, is 
elevated prior to term and preterm labour in women (Gibb, 1998; Olson et al., 2003). 
This corresponds to the increased activities of PLA2 type-IIA and COX-2 in amniotic 
and lower myometrial tissues that catalyse PG output (Slater et al., 1999; Slater et al., 
2004; Sooranna et al., 2006). Concurrently, the conversion of active PGs into inactive 
15-keto metabolites by chorionic prostaglandin dehydrogenase (PGDH) diminishes 
(Cheung et al., 1992). This would facilitate passage of PGE2 from the amnion to the 
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underlying maternal decidua and myometrium for activation of spontaneous term and 
preterm labour (Giannoulias et al., 2005).  Moreover, at labour-onset, microsomal 
synthase mPGES-1 expression is upregulated within lower rather than upper segment 
myometrium and vasculature (Sooranna et al., 2006). The PGE2-induced 
vasodilatation and tissue remodelling (Kimura et al., 1995) perhaps reflected the dark 
red pigmentation observed in tissues obtained during late labour. 
PGE2 is associated with both inhibitory and excitatory mechanisms (Senior et al., 
1993). This was demonstrated using immersion and superfusion techniques in this 
study. Using myometrial strips obtained from labouring donors, PGE2 attenuated 
contractions in a concentration and dose-dependent manner. Relative tissue excitation 
was displayed at 10-5M in early term and late preterm labour samples. Despite limited 
functional data, this biphasic response corresponded to heterogeneous EP1-4 receptor 
subtypes within plasma and nuclear membranes of myometrial cells (Coleman et al., 
1994; Bhattacharya et al., 1999; Leonhardt et al., 2003). However, in the latter stages 
of term parturition, full cessation of myogenic activity was exhibited. These results 
substantiate a previous in vitro study using myometrium obtained during active labour 
(Wikland et al., 1984). Excitatory responses to PGE2 were solely at the fundus whilst 
lower myometrial activity was suppressed; this indicates a regional change in the 
complement of functional EP receptor subtypes. 
Myometrial responses to specific EP agonists during human labour were not 
previously examined. In this study, inhibitory compounds were tested in tissues 
harvested early after labour-onset, corresponding to the stability of active myogenic 
contractions. To determine EP2 receptor function, concentration-effect curves for 
butaprost (Gardiner, 1986), CP533,536 (Li et al., 2003; Paralkar et al., 2003), 
AH13205 (Coleman et al., 1994) and AGN211330 (Belley et al., 2005) were 
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constructed. In accord with myometrial biopsies from non-labouring donors, each EP2 
agonist attenuated spontaneous activity in a monophasic concentration-dependent 
manner (10-7M to 10-5M). Despite marginal differences between EP2-mediated 
inhibitions, the rank order of potency was butaprost > CP533,536 = AH-13205 > 
AGN211330. 
EP2 receptors have particularly been implicated in labour-associated events due to 
altered temporal and regional myometrial expression. EP2 receptors decline towards 
term gestation (Brodt-Eppley & Myatt, 1999; Leonhardt et al., 2003), although remain 
unaltered (Brodt-Eppley & Myatt, 1999; Astle et al., 2005; Sooranna et al., 2005) or 
increase during parturition (Grigsby et al., 2006). With advancing gestation with or 
without labour, the expression of total EP2 mRNA and nuclear EP receptors were 
more intense in lower compared with upper myometrial segments (Astle et al., 2005; 
Grigsby et al., 2006). This corresponds to consistent EP2 responses in myometrial 
strips obtained before and after labour-onset.  
Although EP4 mRNA and protein expression are abundant in lower segment 
myometrial tissue (Leonhardt et al., 2003; Astle et al., 2005; Grigsby et al., 2006), 
EP4 agonist AGN201734 (Elworthy et al., 2004) and L-902688 (Billot et al., 2003) 
effects were moderate. Whilst AGN201734 produced a gradual decline in 
spontaneous activity (10-8M to 10-5M), L-902688 solely attenuated contractions at   
10-5M. As these ligands have high affinity for EP4 receptors (Elworthy et al., 2004; 
Billot et al., 2003), the low responses may relate to poor receptor-effector coupling in 
isolated human myometrium. Nevertheless, myometrial EP4 mRNA and protein 
expression did not change regardless of gestational age, labour and regional location 
(Leonhardt et al., 2003; Astle et al., 2005; Grigsby et al., 2006). This suggests that 
EP4 may mediate PGE2-induced inflammatory responses (Slater et al., 2006) or 
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cervical ripening (Schmitz et al., 2001) rather than the functional suppression of 
myometrial activity. 
Using myometrial strips from mid and late stages of labour, the novel EP1 agonist 
ONO-D1-004 (Oka et al., 2003) did not influence myogenicity compared with time-
matched controls. This was surprising as the expression of EP1 subtypes was detected 
in upper and lower segments at term pregnancy (Astle et al., 2005; Grigsby et al., 
2006) and increased further in lower (Astle et al., 2005) or both lower and upper 
myometrial segments during labour (Grigsby et al., 2006). However, as ONO-D1-004 
has poor binding affinity and low potency values (Kiriyama et al., 1997; Oka et al., 
2003), alternative agonists such as 17-phenyl PGE2 are required to elucidate EP1 
function.  
By contrast, the EP3/1 agonist sulprostone (Schaaf et al., 1981) evoked myogenic 
contractions in both immersed (10-6M to 10-5M) and superfused (10-8mol to 10-7mol) 
tissue strips. Contractile responses were displayed at each stage of parturition. This 
was associated with the maintained expression of EP3 mRNA before and after labour-
onset. For uterine emptying, EP3 receptors were predominantly expressed in the 
fundus compared with lower segment myometrial biopsies (Astle et al., 2005; Grigsby 
et al., 2006). However, as PGE2 did not produce a contractile phenotype during late 
labour, the predominant inhibitory EP2 receptors may supersede EP1/3 mediated 
effects. Thereby, a shift in EP receptor dynamics and secondary signal cascades are 
likely to regulate labour-onset and postpartum involution.  
PGF2α elicited monophasic excitatory responses in isolated lower myometrium taken 
after labour-onset. The spasmogenic activity was quantitatively similar to previous 
superfusion and immersion studies (Wikland et al., 1984; Hutchinson, 2005). This 
was related to a transient rise in intracellular Ca2+ release in both intact myometrium 
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and myocytes (Carrasco et al., 1996; Shlykov & Sanborn, 2004). During pregnancy, 
myometrial FP mRNA was shown to decrease relative to the non-pregnant state 
(Matsumoto et al., 1997; Sooranna et al., 2005); this corresponded to the decline in 
potent PGF2α-induced contractions (Senior et al., 1992; Senior et al., 1993). At term 
parturition, human FP receptor expression significantly increased indicating hormonal 
and physiological influences on PG receptors (Brodt-Eppley & Myatt, 1999). Even so, 
this study showed that tissue responsiveness to PGF2α was attenuated through early, 
mid and late stages of labour in lower segment myometrial strips. Weak responses 
were also observed in superfusion, with marked stimulation by PGF2α evoked only in 
paired fundus end specimens taken during active labour (Wikland et al., 1984). This 
topographical difference in FP receptor activity parallels the decline in smooth muscle 
content of cervical tissue compared to the fundus (Adelantado et al., 1988). Moreover, 
instead of modulating activity, it is plausible that FP receptor populations mediate 
PGF2α-stimulated glycosaminoglycan activity for uterine compliance in the lower 
segment during labour (Weiss, 2000). This may account for the high PGF2α synthesis 
in lower myometrial segments at this time (Durn et al., 2010). Combined doses of 
PGE2 and PGF2α suppressed contractile activity in lower isolated myometrium after 
labour-onset (Wikland et al., 1984). Whilst reflecting a high PGE2 binding affinity, 
this also indicates the predisposition of the lower uterus to relax in order to subserve 
the birth process.  
The thromboxane mimetic U46619 potentiated contractions in isolated human 
myometrium taken after labour-onset. Significant attenuation with TP antagonists 
SQ29,548 (Ogletree et al., 1985) and GR32191B (Lumley et al., 1989) confirmed 
constitutive TP-mediated responses in this study. As SQ29,548 failed to shift PGF2α 
concentration-effect curves in myometrium obtained during labour (Hutchinson, 
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2005; Griffiths et al., 2006), off-target PGF2α activation was not displayed. TPα and 
TPβ splice variants have been identified in human myocytes and vasculature from 
both non-pregnant and term pregnant donors (Moore et al., 2002; Moran et al., 2002). 
However, little is known about labour-associated changes in human TP receptor 
function and expression.  
Despite a 2-fold reduction in U46619-induced contractile activity between early and 
late stages of labour, tissue excitation was significantly augmented compared with 
initial low myogenic contractions. At late gestation, urinary thromboxane excretion 
has been shown to increase and heighten during labour (Noort & Keirse, 1990), 
alongside thromboxane synthase (Swanson et al., 1992), augmenting uterine activity. 
This implicates a maintained function for TP receptors during the parturition-process. 
Two target mediators in the TP signalling cascade, ROCKI and its isoform ROCKII 
sensitise the uterus to Ca2+ (Kureishi et al., 1997) and may account for the potentiated 
contractile responses in this study. Aberrant ROCKI expression has been associated 
with uterine contractile dysfunctions such as preterm and prolonged labour at term 
(Moore & Lopez Bernal, 2003). Moreover, an increase in RhoA mRNA at parturition 
implies thromboxane involvement in the preparatory and stimulatory phases of labour 
(Noort & Keirse, 1990). This corresponded to the enhanced U46619 response at 
preterm late labour in this study. As a result, cognate TP receptors may control uterine 
tone required for foetal descent during labour and possibly uterine involution 
postpartum.  
For further Ca2+ sensitisation, U46619 induced the cleavage of the p160 ROCKI 
protein to yield p130 ROCKI by caspase-3 (Moore & Lopez Bernal, 2003), associated 
with enhanced uterine contractility and apoptosis (Coleman et al., 2001; Leong et al., 
2008). Although the caspase-3 inhibitor Z-DEVD-FMK blocked this pathway (Moore 
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et al., 2002; Moore & Lopez Bernal, 2003), no significant effect on U46619-induced 
activity was observed in the present study. This may be attributed to already high 
caspase-3 in myometrial cells resulting from shrinkage, oedema and apoptosis with 
tissue remodelling (Leong et al., 2008). It also suggests that p160 and p130 ROCKI 
proteins have similar efficacy for enhanced Ca2+ sensitisation in the uterus.   
In conclusion, this study showed that myometrial EP, FP and TP receptors are 
dynamic in nature at term pregnancy and during parturition. It seems likely that a 
change in the balance of these receptors and signal transduction pathways would 
mediate the transition from uterine quiescence to activation. Despite ethical 
constraints limiting research to the lower uterus in the present study, TP receptor 
function seemed to predominate. Therefore, targeting TP receptors or their 
downstream regulatory pathways in the parturient uterus may help to improve 
tocolytic therapy for labour-associated disorders. 
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Chapter 6: Methods for myometrial cell assays 
 
Cell culture models to assess intracellular signalling pathways 
 
 
6.1 Introduction  
Cell culture methodology was developed to separate and purify smooth muscle cells 
and fibroblasts from uterine biopsies taken at term pregnancy. The primary cell 
culture model enabled aspects of the human myometrium to be studied without the 
influence of endogenous steroid hormones. Despite the reported change in myometrial 
cell morphology from the in vivo state (Hongpaisan, 2000), cell cultures retain many 
characteristics of the intact tissue (Pressman et al., 1988; Carrasco et al., 1996). This 
includes sensitivity to PG and oxytocin agonists, measured by intracellular Ca2+ 
mobilisation (Thornton et al., 1999) and signal transduction pathways (Phaneuf et al., 
1993).  
 
The aim of this study was to isolate pure cultures of smooth muscle cells and 
fibroblasts from term gravid human myometrium. Subsequent optimisation and 
development of FLIPR and RT-PCR techniques were performed. By characterising 
myometrial cell populations, the contribution of PG and oxytocin-mediated 
intracellular Ca2+ and cAMP release could be assessed relative to receptor mRNA 
expression (Chapter 7). Study of these intracellular and molecular events would 
facilitate the high throughput screening of drugs to improve tocolysis for preterm 
labour. 
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Chapter 6: Cell Materials & Methods 
 
 
6.2 Materials 
 
Table 6.1: Materials used in this study were purchased from the following sources: 
 
Company Town County/ State Country 
Alpha Innotech Corporation San Leandro California USA 
Ambion Austin Texas USA 
Amersham Biosciences Björkgatan Uppsala Sweden 
BDH Laboratory Supplies Poole Dorset UK 
Becton-Dickinson Franklin Lakes New Jersey USA 
Bio-Rad Laboratories Hercules California USA 
Calbiochem Nottingham Nottinghamshire UK 
Cayman Chemicals Ann Arbor Michigan USA 
Cellgro Inc. Pensacola Florida USA 
Costar Lowell Massachusetts USA 
Decon Laboratories Ltd. Hove East Sussex UK 
EMD Chemicals Inc. Gibbstown New Jersey USA 
Fisher Scientific Ltd. Loughborough Leicestershire UK 
Gibco BRL Inchinnan Renfrewshire UK 
Invitrogen Ltd. Paisley Greater Glasgow UK 
Invitrogen Ltd. Carlsbad California USA 
Molecular Devices Sunnyvale California USA 
Perkin Elmer Waltham Massachusetts USA 
PromoCell GmbH Sickingenstraße Heidelberg Germany 
Qiagen Valencia California USA 
Riedel-de-haen Seelze Hanover Germany 
Roche Ltd. Grenzacherstrasse Basel Switzerland 
Serologicals Corporation Norcross Georgia USA 
Sigma Chemicals Co. Poole Dorset UK 
Vector Laboratories Burlingame California USA 
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6.3 Compounds and solutions for cell culture 
 
Table 6.2.1: Enzyme solution A diluted in Hanks’ balanced salt solution (HBSS) for 
initial collagen dissociation of myometrial tissues. 
 
Enzyme Solution A Final Conc. Source Catalogue No 
HBSS w/o phenol red, CaCl2 or MgSO4 Promocell C-40390 
Dispase enzyme solution (grade 2) 10mg/ml Roche (BD) 354235 
Calcium chloride 2.5mM Riedel-de-haen 12074 
Magnesium chloride 0.9mM Sigma M8266 
 
 
Table 6.2.2: Enzyme solution B for cell isolation from myometrial biopsies; in the 
final working solution, elastase was omitted. 
 
Enzyme Solution B Final Conc. Source Catalogue No 
HBSS w/o phenol red, CaCl2 or MgSO4 Promocell C-40390 
Collagenase type II 300U/ml Sigma C6885 
DNAse I type IV 30U/ml Sigma D5025 
Elastase type I 2U/ml Sigma E1250 
Fatty acid-free bovine serum albumin  1mg/ml Sigma A8806 
 
 
Table 6.3.1: Fully defined Dulbecco’s modified eagles medium (DMEM) A for 
culture of myocytes and fibroblasts. 
 
Basic defined medium Concentration Source Catalogue No 
DMEM with high glucose & sodium bicarbonate Sigma D6171 
Foetal calf serum 10% Sigma F6178 
L-glutamine 2mM Promocell C-42210 
HEPES solution 25mM Sigma H0887 
Penicillin (10,000U/ml) Streptomycin (10mg/ml)  Sigma P0781 
Amphotericin B 2.5ng/ml Sigma A2942 
Basic defined medium was also used with Waymouth’s Medium MB 752/1, 
Invitrogen 31220-023 or PromoCell C-73440, instead of DMEM A. 
 
 
Table 6.3.2: Fully defined DMEM B with reduced oestrogen content for seeding cells. 
 
Basic defined medium Concentration Source Catalogue No 
DMEM with high glucose and without phenol red  Sigma D1145 
Charcoal stripped foetal calf serum 1% Sigma F6765 
L-glutamine 2mM Promocell C-42210 
HEPES solution 25mM Sigma H0887 
Penicillin (10,000U/ml) Streptomycin (10mg/ml)  Sigma P0781 
Amphotericin B 2.5ng/ml Sigma A2942 
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Table 6.3.3: Fully defined DMEM C to culture cells for FLIPR assays. 
 
Basic defined medium Concentration Source Catalogue No 
DMEM with high glucose, L-glutamine & pyruvate Invitrogen 11995-065 
Foetal calf serum 10% Invitrogen 14040-133 
Geneticin 200µg/ml Invitrogen 10131-027 
Hygromycin B 200µg/ml Invitrogen 10687-010 
 
 
Table 6.3.4: Fully defined DMEM D with reduced oestrogen content for seeding cells 
in FLIPR assays. 
 
Basic defined medium Concentration Source Catalogue No 
DMEM with high glucose and without phenol red Sigma D1145 
Charcoal stripped foetal calf serum 1% Sigma F6765 
L-glutamine 2mM Promocell C-42210 
Penicillin-Streptomycin (10,000U) Amphotericin B (25µg) Gibco 15240-062 
 
 
Table 6.4: Solutions for cell trypsinisation. 
 
Compounds for cell passage Concentration Source Catalogue No 
Trypsin-EDTA solution 0.25% Sigma T4049 
Foetal calf serum 20% Sigma F6178 
  
 
Table 6.5: Preparation of coverslips (22mm2) and slides for cell or tissue adhesion. 
 
Compounds for coverslips Concentration Source Catalogue No 
Urea 1mM Sigma U2709 
Decon 90 5% Decon Lab Ltd. 1310-58-3 
Bovine fibronectin 50µg/ml Sigma F1141 
Ethanol 70% Fisher Scientific E/0400/17 
Poly-L-lysine solution 0.01% w/v Sigma P8920 
 
 
6.4 Compounds and solutions for cell assays 
 
Table 6.6: Buffers and solutions for immunocytochemistry & immunohistochemistry. 
 
Buffers for immunofluorescence Concentration Source Catalogue No 
HBSS without phenol red  Promocell C-40390 
Phosphate buffered saline (PBS) 0.01M Sigma P3813 
Tween 20 1.1g/ml Sigma T2700 
Bovine serum albumen (BSA) 10% Sigma A3059 
Paraformaldehyde solution 4% Sigma P6148 
Sodium hydroxide (NaOH) 1N Sigma S8045 
Mounting medium with DAPI      1.5µg/ml Vector Laboratories    H1200 
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Table 6.7: Solutions to quantify intracellular cyclic AMP (cAMP). 
 
HitHunter cAMP XS+ assay (Cat No: 90-0075L) Volume Catalogue No 
cAMP XS+ Lysis Buffer 76ml 30-213 
cAMP XA+ EA Reagent 200ml 30-352 
cAMP XS+ ED Reagent 100ml 30-353 
cAMP XS+ Antibody Reagent 50ml 30-354 
cAMP XS+ Standard (250µM) 13ml 30-355 
Galacton-Star® 4.0ml 10-069 
Emerald-IITM 20ml 10-068 
 
 
Table 6.8: Agonists and antagonists used to identify functional receptors in human 
myocytes and fibroblasts.  
 
Compound Receptor target Stock vehicle Source Catalogue No 
AH13205 EP2 DMSO Sigma A9102 
AH6809 EP1, EP2, EP3, DP1 DMSO Sigma A1221 
Atosiban Oxytocin receptors  0.1% BSA in dH2O Sigma A3480 
β-oestradiol Oestrogen α & β ethanol Sigma E2257 
Butaprost EP2    ethanol Cayman Chemicals     13740 
Caspase-3 inhibitor II DMSO Calbiochem 264155 
EDTA Ca2+ chelator DMEM D Sigma E6758 
Indometacin COX inhibitor ethanol Sigma I7378 
LaCl3  Ca2+ channel blocker        ethanol Sigma L4131 
Nifedipine L-type Ca2+ channels    ethanol Sigma N7634 
Oxytocin  Oxytocin receptors DMEM D Sigma O3251 
Progesterone Progesterone A & B        ethanol Sigma P6149 
PGE2 EP1-4    ethanol Cayman Chemicals     14010 
PGF2α FP    ethanol Cayman Chemicals     16010 
Rho-kinase inhibitor    DMEM D Cayman Chemicals     555550 
SQ29,548 TP    ethanol Cayman Chemicals     19025 
Sulprostone EP1, EP3    ethanol Cayman Chemicals     14765 
Thapsigargin    Ca2+-ATPase inhibitor    ethanol Sigma T9033 
U46619 TP           ethanol Cayman Chemicals     16450 
 
 
Table 6.9. Solutions for SuperScript III one-step quantitative RT-PCR system. 
 
Solutions for SuperScript III one-step RT-PCR Source Catalogue No 
DNase/ RNase free water Gibco 10977-015 
PCR supermix Invitrogen 10572 
Platinum PCR supermix Invitrogen 11306-016 
Run mix 2X Invitrogen 52202 
SuperScript III RT/ Platinum Taq mix Invitrogen 52118 
SuperScript III Invitrogen 12574 
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6.5 Isolated myometrium for cellular and molecular studies 
Uterine tissue was obtained from term pregnant women (aged 22-38) undergoing 
elective Caesarean sections before the onset of labour (n=17). To standardise myocyte 
cultures, women associated with any major complication of pregnancy, such as 
hypertension, pre-eclampsia and diabetes were excluded from cellular and molecular 
studies. Other exclusion criteria included donors taking prescription medicines and 
those who smoked. All donors signed informed written consent forms prior to 
surgery; this was in accordance with ethical approval from the Bradford Hospital 
NHS Trust and the University of Bradford Ethics Committee (Figure A2).  
 
At Caesarean delivery, full-thickness uterine biopsies were taken from the upper 
margin of lower transverse incisions. These were transported to the laboratory in 
sterile Krebs’ solution and processed for cell dispersion within 2 hours of excision. 
Adherent decidua, serosa, fat and connective tissues were trimmed using a sterile 
scalpel and the remaining myometrium was washed several times in sterile Hanks’ 
balanced salt solution (HBSS) to clean and remove residual mesentery and blood. 
Isolated myometrium was further processed for primary cell culture using explant or 
enzymatic digestion techniques. 
 
6.6 Primary cell culture 
Myometrial biopsies (~0.5g) were minced using a McIlwain Tissue chopper (Mickle 
Laboratory Engineering, Guilford, UK) into pieces <1mm3 and washed in HBSS.  
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6.6.1 Myometrial explant cultures 
For crude explant cultures, 30-50mg of minced myometrial tissues were added to 
0.5ml basic defined Dulbecco’s modified eagles medium (DMEM A), containing 10% 
v/v foetal calf serum (FCS) and 1% v/v antibiotic and antimycotic solutions. The 
explant suspensions were aliquoted into 25cm2 culture flasks or onto sterile treated 
coverslips in 35mm culture dishes (Section 6.10). These containers were carefully 
inverted to improve explant adhesion and DMEM A was added beneath to create a 
humidified atmosphere (Figure 6.1). After incubating at 37°C (5% CO2) overnight, 
the culture flasks and dishes were returned to their upright position and explants were 
submerged with fresh basic defined medium. The medium was changed every other 
day thereafter with cells maintained under the same conditions until sub-confluence. 
 
 
 
 
a)   b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Myometrial explants adhering to treated coverslips in culture dishes         
a) inverted overnight and b) subsequently returned to an upright position. Addition of 
basic defined medium and incubation at 37°C facilitated myometrial cell growth. 
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6.6.2 Enzymatic dispersion of myometrium 
The technique for enzymatic myometrial cell isolation was based on a protocol 
previously described by Phaneuf et al. (1993) with some adaptations. Between 0.5-
1.0g of the minced tissue was placed in 10ml HBSS (solution A) containing calcium 
chloride (CaCl2; 2.5mM), magnesium chloride (MgCl2; 0.9mM) and dispase 
(10mg/ml), which was incubated at 37°C for 1-2 hour with continuous stirring. After 
washing in Ca2+- and magnesium- (Mg2+) free HBSS, the mesh of softened tissue was 
triturated. Cell dispersion was achieved in the same solution, supplemented with 
collagenase (300U/ml), elastase (2U/ml), DNAse I (30U/ml) and fatty acid free-
bovine serum albumen (BSA; 1mg/ml) (solution B) at 37°C with gentle shaking. 
After 2 hours, the cell suspension was transferred to a centrifuge tube and washed 
three times with HBSS by centrifugation at 450g (~1200rpm). Basic defined medium 
composed of DMEM A, 10% v/v FBS, 100IU/ml penicillin, 10mg/ml streptomycin 
and 2mmol/l L-glutamine was used to resuspend the final cell pellet. 
 
6.7 Cell number and viability 
Before plating, a trypan blue exclusion assay was performed to determine cell number 
and viability.  The cell suspension was diluted 1:1 with 0.4% v/v trypan blue solution 
and 10µl of this mixed solution was added to each chamber of a Neubauer 
haemocytometric slide with a coverslip in place. Using the 10x focus on the Olympus 
CK40 microscope, live (unstained) and dead (trypan blue positive) cells were counted 
in five 1mm2 grids per chamber and an average was calculated per grid from the two 
chambers. Since the depth was 0.1mm, each grid represented a total volume of 
0.1mm3 or 10-4cm3.  
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The total number of cells and cell viability was therefore determined using the 
following calculations: 
 
 Cells/ ml = average cell count per grid x 104 x dilution factor 
 Total cells = Cells/ ml x volume of original cell suspension (ml) 
 % cell viability = total viable cells (unstained)/ total cells x 100 
 
If cells were too concentrated to count, the cell suspension was diluted further and the 
dilution factor was adjusted accordingly. In all cases cell viability was greater than 82 
percent (Table 6.10). 
 
6.8 Optimising isolation parameters 
Although cell viability with the trypan blue exclusion assay was at 90 percent using 
the method outlined by Phaneuf et al., (1993) (Section 6.6.2; Table 6.10), enzyme 
combinations were altered to optimise tissue digestion. Dissociation with trypsin and 
collagenase for 1 hour (Karasinski et al., 2000) increased cell damage by 8.9 percent. 
However, by omitting elastase from the digestion step, the yield and viability of cells 
was improved. As a result, elastase was subsequently excluded from solution B in the 
digestion process. 
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Table 6.10: Enzymatic digestion of minced isolated myometrium following exposure 
to solution A. The composition of enzyme solutions was based upon protocols 
described by a) Phaneuf et al. (1993), b) Fomin et al., (1999) and c) Karasinski et al., 
(2000). Cell number and viability were quantified using a haemocytometer and trypan 
blue exclusion assays; approximately 100,000 to 1,000,000 cells were isolated per 
gram of myometrial tissue. 
 
 
Collagenase 
(U/ml) 
Elastase 
(U/ml) 
DNase I 
(U/ml) 
FAF BSA 
(mg/ml) 
Total cell number 
(range; n=6) 
Average cell 
viability (%) 
a 300 2 30 1 1.2x105 – 1.1x106 90 ± 10.8 
b 300 0 30 1 1.1x105 – 1.3x106 94 ± 6.5 
 Collagenase 
(U/ml) 
Trypsin 
(%) 
DNase I 
(U/ml) 
FAF BSA 
(mg/ml) 
Total cell number 
(n=1) 
Cell viability 
(%) 
c 300 0.1 0 1 5.2x105 82 
 
FAF BSA: Fatty acid-free bovine serum albumen. 
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6.9 Purification of myometrial cells 
Different techniques were applied to purify smooth muscle cells from fibroblasts. The 
cell suspension was initially separated using Percoll two-phase discontinuous density 
gradient (Amersham Biosciences, Uppsala, Sweden). This consisted of the following 
solutions: 
 
Table 6.11: 10X Ads buffer composition in 100ml milli-Q water. 
 
10X Ads buffer Volume added Source Catalogue No 
Sodium chloride (NaCl) 6.8g Sigma S5629 
HEPES 4.76g Sigma H3784 
Sodium dihydrogen phosphate (NaH2PO4) 0.12g Sigma S5011 
Glucose 1.0g Sigma G7021 
Potassium chloride (KCl) 0.4g Sigma P5405 
Magnesium sulphate (MgSO4) 0.1g Analar 203726 
 
 
These substances were dissolved in milli-Q water to a final volume of 100ml. After 
adjusting the pH to 7.35 with 1N NaOH, the 10X Ads buffer was filter sterilised 
(Nalgene, 0.20 µm) and stored at 2-8°C. 
 
For 1X Ads solution preparation, the 10X Ads buffer was diluted with sterile dH2O. 
Percoll (density = 1.130g/ml) was diluted 9:1 with 10X Ads buffer to formulate the 
Percoll stock (density: 1.110g/ml). Gradients of Percoll for the top (density: 
1.059g/ml) and lower (density: 1.082g/ml) layers were prepared by diluting Percoll 
stock with 1X Ads buffer at ratios of 9:11 and 13:7 respectively. 
To establish the Percoll interface, 5ml top layer Percoll was transferred into a 15ml 
centrifuge tube. For this layer to rise, 5ml lower layer Percoll was added a drop at a 
time to the bottom of the tube. This two-phase Percoll gradient was overlaid with the 
myocyte/ fibroblast cell suspension (1x10-6 cells). By centrifuging for 20 minutes at 
2500g (~3000rpm), room temperature in a Mistral 3000 centrifuge, myocytes 
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sedimented at the Percoll interface, whilst fibroblasts and non-myocyte cells 
aggregated on the upper surface.  
Individual bands of cells were carefully removed, resuspended in DMEM A and 
centrifuged at 450g for 5 minutes. Despite the observed cell pellets, once seeded in 
flasks, recovery of viable Percoll-enriched myocytes and fibroblasts was poor. 
Therefore, alternative methods to this gradient fractioning were explored. 
 
Following enzymatic dissociation, myometrial cells were plated into 25cm2 vent-cap 
culture flasks (Costar, Lowell, Massachusetts, USA) at a density of 0.5-2x104 cells/ 
ml and stored at 37°C in a water-saturated atmosphere containing 5% CO2. To purify 
cultures based on differential adhesion, after 18 hours the supernatant containing late 
adherent cells was centrifuged at 450g for 5 minutes, resuspended and transferred to a 
separate 25cm2 flask with fresh basic defined medium added to both cultures. This 
preplating technique has been shown to isolate rapidly adherent fibroblast cells from 
myocytes (Hongpaisan, 2000; Rouger et al., 2007). The media was changed every 48 
hours thereafter to enhance cell proliferation. Culture growth and cell morphology 
were repeatedly examined using a phase contrast microscope (Olympus CK40) with 
pictures imaged using a JVC digital colour video camera (Figure 6.4). Near 
confluence, the cells were harvested using trypsin (Section 6.11). 
 
6.10 Coating coverslips for cell adhesion 
To enable myometrial cells to anchor, move and proliferate, the sterile flasks, plates 
and dishes were composed of treated polystyrene plastic (Costar, Lowell, 
Massachusetts, USA). However, when plating cells on glass coverslips (Ultima, 
22mm2), fibronectin was added as an extracellular matrix coating to facilitate the 
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attachment of cell surface cytoplasmic proteins, such as integrins and α-actinin 
(Sinanan et al., 2008). 
The coverslips were cleaned using 5% v/v Decon 90 detergent followed by urea 
(1mM). After rinsing with sterile 1x phosphate buffered saline (PBS) and ethanol in a 
laminar flow hood, glass coverslips were incubated with 50µg/ml bovine fibronectin 
for 30-45 minutes at room temperature. The coverslips were then rinsed with PBS and 
secured in 6-well plates or 35mm Petri dishes with tissue explant or cell suspensions 
(5x104 cells/ ml) added immediately. Following a 30-minute incubation in a water-
saturated atmosphere at 37°C, Petri dishes were flooded with media and incubated 
overnight. 
 
A time-lapse video was performed using Adobe Premiere software with images taken 
at 0 and 18 hours showing cell adhesion to a fibronectin-coated glass coverslip 
(Figure 6.2). To maintain cell pH and temperature, HEPES buffer (25mM) was added 
to the culture medium and a heating stage (RS) set to 38°C was used. 
 
 
 
 
 
 
 
 
Figure 6.2: Isolated primary myometrial cells incubated on a fibronectin-coated slide 
at 37°C for a) 0 hours and b) 18 hours under a phase contrast microscope (x10) 
equipped with a JVC digital camera. The rapid adhesion properties have been 
associated with cultures enriched in fibroblast cells (Rouger et al., 2007). 
a) 0 hours b) 18 hours 
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6.11 Harvesting cells 
To passage cells for subculture, myocytes were harvested upon reaching a semi-
confluent state. This was achieved after removing the conditioned medium by adding 
0.25% trypsin containing 2mM ethylendiamine tetra-acetic acid (EDTA) to the cell 
flasks. As a Ca2+ chelator, EDTA worked synergistically with the protease enzyme 
trypsin to cleave cell-matrix adhesion proteins. Thereby, as monitored under the phase 
contrast microscope (Figure 6.3), after 5-15 minutes at 37°C, the cells were rounded 
and detached from the flask surface. Due to its inhibitor proteins and divalent cations, 
FCS was immediately added to neutralise trypsin action. The cells were then 
centrifuged at 450g for 5 minutes and the cell pellet was diluted with fresh medium 
for culture or for freezing.  
 
  
 Figure 6.3: Trypsin-EDTA incubated at 
37°C/ 5% CO2 for 3 minutes in a flask 
of cultured myocytes. The rounding of 
the cells visualised under a phase 
contrast microscope (x10) indicates 
near detachment from the flask surface. 
 
 
 
6.12 Preservation, storage and recovery of cultured cells 
For freezing and storage of cells near confluence, the cells were trypsinised, harvested 
and counted (Sections 6.7 & 6.11). Following centrifugation at 450g for 5 minutes, 
the supernatant was discarded and the remaining cell pellet was resuspended at a final 
density of 1x106 cells/ ml in freshly prepared DMEM A, containing 10% v/v dimethyl 
sulfoxide (DMSO) and 10% v/v FCS. This freezing medium both prevented 
crystallisation of water, which would lyse cells during cryopreservation, and also 
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provided nutrients during the thawing process. The cells were stored in a cryovial 
within a freezing container (Nalgene Ltd., Ridderstraat, Neerijse, Belgium) at -80°C, 
which was transferred to liquid nitrogen the following day.  
Frozen cells were recovered within a year of storage. The cells were quickly thawed 
in a 37°C water bath, diluted in pre-warmed basic defined medium and plated for 
culture.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: Images of primary human a) fibroblasts and b, c, d) smooth muscle cells 
dissociated from myometrial biopsies and visualised under magnifications of a-b) x25, 
c) x4 and d) x40. Cell populations were separated using differential adhesion and each 
culture formed a typical whorl pattern near confluence. As myocytes and fibroblasts 
were difficult to distinguish morphologically, both immunohistochemistry and 
immunocytochemistry staining techniques were employed. 
a) Fibroblasts x25 b) Myocytes x25 
c) Myocytes x4 d) Myocytes x40 
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6.13 Solutions for immunofluorescent staining 
The purity of cell cultures was assessed using immunohistochemistry and 
immunocytochemistry techniques. The protein markers assayed included α-actinin, 
actin, desmin, vimentin and anti-human fibroblast surface protein to distinguish 
between myocytes and fibroblasts. 
 
6.13.1 Phosphate buffered saline (PBS) 
PBS was prepared by dissolving a sachet of 10x PBS in 1 litre of autoclaved milli-Q 
water for a working solution of 1x PBS (0.01M, pH 7.4). 
 
6.13.2 Wash buffer (PBS-Tween 0.5%) 
The mild detergent Tween 20 was added to PBS (0.01M, pH 7.4) at 0.5% v/v and 
stored at 2-8°C.  
 
6.13.3 Blocking buffer 
After addition of 1g BSA (Fraction V) to 100ml PBS-Tween (0.05%), the blocking 
buffer was heat inactivated at 65°C for 15 minutes and cooled. This was diluted to 3% 
v/v and 1% v/v working solutions using PBS-Tween (0.5%). 
 
6.13.4 Paraformaldehyde fixing buffer 
To prepare 4% paraformaldehyde-fixing buffer, PBS (0.01M) was pre-heated to 65°C 
and 4g of paraformaldehyde powder was added in a fume hood. This was maintained 
at 65°C for 15 minutes and then stirred at a low heat until the paraformaldehyde 
solution became clear.  After cooling, the pH was adjusted to 7.35 ± 0.5 with 1N 
sodium hydroxide (NaOH) and this fixing solution was stored in the dark. 
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6.13.5 Permeabilising buffer 
The permeabilising buffer was composed of the following substances (Table 6.12) 
dissolved in milli-Q water to a final volume of 100ml. The pH was adjusted to 7.2 
using 1N NaOH and this buffer was then filter sterilised (Nalgene, 0.20 µm) and 
stored at 2-8°C. 
 
 
Table 6.12: Permeabilising buffer composition in 100ml milli-Q water. 
 
Permeabilising buffer Volume added Source Catalogue No 
Sucrose 10.3g EMD Chemicals 102745C 
Sodium chloride (NaCl) 0.292g Sigma S5629 
Magnesium chloride (MgCl2) 0.06g Sigma M8266 
HEPES 0.476g Sigma H3784 
Triton X-100 0.5ml Sigma 9284 
 
6.13.6 Primary & secondary antibodies 
 
Table 6.13: Characteristics of primary antibodies diluted in 1% blocking solution for 
immunofluorescence. 
 
Primary antibody Donor species Working dilution Source Cat No 
α-actinin Mouse 1:200 Sigma A5044 
Fibroblast surface protein     Mouse 1:100 Sigma F4771 
Vimentin Goat 1:100 Sigma V4630 
Desmin Rabbit 1:100 Sigma D8281 
 
 
Table 6.14: Secondary conjugated antibodies diluted in 1% blocking solution for 
immunofluorescence, stored in dark to prevent photobleaching. 
 
Secondary antibody   Conjugate 
Working 
Dilution 
Protein target Source Cat No 
Alexafluor 488, rabbit 
anti-mouse IgG 
FITC 
(green) 
1:200 
α-actinin, 
Fibroblast protein 
Invitrogen A11059 
Alexafluor 568, rabbit 
anti-goat IgG 
TRITC 
(red) 
1:200 Desmin Invitrogen A11079 
Goat anti-rabbit IgG 
FITC 
(green) 
1:50 Vimentin Sigma F0382 
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6.14 Immunohistochemistry of myometrial sections 
To identify cell subsets in isolated human myometrium, tissue biopsies obtained at 
term pregnancy were cut to approximately 1 cm3 using a surgical blade (size 23). The 
specimens were submerged in optimal cutting temperature (OCT; a cryoprotective 
compound) in cuvettes, which were frozen and stored at -20°C.  
 
6.14.1 Preparation of poly-L-lysine coated slides 
Glass slides (BDH Laboratory Supplies, Poole, Dorset, UK) used for immunostaining 
were cleaned thoroughly to eliminate contamination. The slides were individually 
spaced on a slide carrier, soaked in 5% Decon 90 detergent for 5 minutes and washed 
twice with distilled water. After transferring to 100% ethanol, the slides were placed 
in a heated drying cabinet until the ethanol had evaporated. To optimise tissue section 
adherence, the slides were soaked in 0.01% w/v poly-L-lysine solution for 5 minutes 
and left to dry overnight. 
 
6.14.2 Preparation of frozen sections using the cryostat 
Myometrial biopsies frozen in the cryo-embedding substance OCT were left to thaw 
at room temperature. The chamber of the cryostat (Leica CM 1800) was adjusted to    
-25°C and a small disc of OCT was frozen onto the metal chuck. Once thawed, the 
myometrial tissue was placed in fresh OCT using forceps, which was then mounted 
on the metal chuck to freeze. Further layers of OCT were added and frozen to fully 
embed the tissue. Tissue sections were cut at 10µm using the cryostat and placed onto 
poly-L-lysine coated slides for storage at -20°C. 
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6.15 Immunofluorescent staining of myometrial sections and cells 
Before immunostaining, frozen sections were immersed in cold PBS for 5 minutes 
within a Coplin Jar and a small region above and below each tissue section was 
blotted with Whatman paper. To retain solutions during incubation steps, a liquid-
repellent slide marker pen (PAP pen, Sigma Chemicals, Poole, Dorset, UK) was used 
to encircle the tissue sections. For myometrial cells, coverslips with subconfluent 
cultures (Section 6.10) were washed three times with HBSS to remove medium. All 
preparations were fixed in 4% paraformaldehyde for 5 minutes at 37°C.  
Staining for α-actinin, desmin and vimentin was performed by rinsing slides and 
coverslips with PBS-Tween (0.5%) before treating with a permeabilising buffer 
containing 0.5% solution of the detergent Triton X-100 (Table 6.12). After washing 
twice, the cells and myometrial sections were blocked with a 3% BSA solution to 
minimise non-specific background staining. Fibre-free Whatman filter paper was used 
to decant the buffer. The tissue sections and cells were then incubated with primary 
monoclonal antibodies at their optimal concentrations (Table 6.13). To visualise 
proteins after a further three washes, secondary antibodies conjugated to a 
fluorochrome were incubated for an hour at 37°C; this corresponded to the donor 
species of the primary antibody (Table 6.14). The slides and coverslips were 
subsequently kept in the dark to prevent photobleaching. After three washes with 
PBS, cells stained with the α-actinin antibody were incubated for a further hour at 
room temperature with phalloidin-tetramethylrhodamine B isothiocyanate (1µg/ml), a 
toxin that binds to polymeric filamentous actin.  Three final washes with PBS were 
performed and coverslips were mounted on glass slides (BDH Laboratory Supplies, 
76mm x 26mm) using 1.5µg/ml DAPI (Vector Laboratories, Burlingame, California, 
USA). This mounting medium was used to counterstain cell nuclei and the edges of each 
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coverslip were sealed using clear nail varnish. Negative controls were performed in 
parallel, except that tissues and cells were treated with a solution of 1% v/v BSA in 
PBS without primary antibody. The slides were stored in the dark at 4°C for up to two 
days before imaging.  
 
 
Table 6.15: Overview of the procedure used to fix, permeabilise and stain intracellular 
protein markers. 
 
Step Procedure Temperature Time 
1 Aspirated medium and washed 3 times with HBSS 37°C 5 minutes x 3 
2 Fixed with 4% paraformaldehyde solution 37°C 5 minutes 
3 Washed 3 times with PBS-Tween (0.5%) 37°C 5 minutes x 3 
4 Incubated with permeabilising solution 4°C 5 minutes 
5 Washed 2 times with PBS-Tween (0.5%) 37°C 5 minutes x 2 
6 Incubated with 3% blocking solution 37°C  1 hour 
7 Incubated with primary antibody solution 37°C  1 hour 
8 Washed 3 times with PBS-Tween (0.5%) 37°C 5 minutes x 3 
9 Incubated with secondary antibody in dark 37°C  1 hour 
10 Washed 3 times with PBS on shaker in dark RT 5 minutes x 3 
11 Rinsed with milli-Q purified water and DAPI used to mount the coverslips on to 
slides. Once dry, slides were stored in dark at 4°C until examined under microscope. 
RT: room temperature 
 
6.15.1 Immunostaining for fibroblast surface proteins 
Unlike the above protocol (Section 6.15; Table 6.15), to detect fibroblast surface 
proteins the permeabilising step and addition of Tween 20 to wash and blocking 
buffers were omitted. This ensured that the integrity of the cell membrane remained 
intact and also prevented the monoclonal antibody from binding to cytosolic proteins. 
 
6.15.2 Fluorescence microscopy 
After immunostaining, tissue sections and cell cultures were viewed and 
photographed under a Nikon 32 phase contrast microscope equipped with a camera. 
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ACT-2U software was used to capture both fluorescent and bright field pictures; these 
images were superimposed using Adobe Photoshop version 6. 
 
6.16 Intracellular Ca2+ recordings 
To determine receptor-mediated intracellular Ca2+ signalling, a fluorescence-based 
assay was adopted. This was performed using a fluorometric imaging plate reader 
(FLIPR-Tetra; Molecular Devices).  
To prepare plates for the FLIPR system, myometrial smooth muscle cells and 
fibroblasts (passages 1-5) were harvested at 80-90% confluence using trypsin (Section 
6.11). The cells were diluted 100-fold into 10ml saline and total cell number was 
determined using a Coulter Counter (Beckman-Coulter Z2 Cell Counter). Following 
centrifugation at 450g for 5 minutes, myocytes and fibroblasts were resuspended in 
fresh basic defined medium C (Table 6.3.3) and plated at optimal concentrations 
(Chapter 7). The cells were then dispensed at 100µl or 50µl/ well into poly-D-lysine-
coated, black-wall and clear-bottom 96-well or 384-well plates (Becton-Dickinson, 
New Jersey, USA), covered and incubated overnight at 37°C under 5% CO2. 
 
6.16.1 Preparation of buffers for FLIPR 
 
Table 6.16: HBSS-HEPES buffer 
 
Stock solutions Volume added Source Catalogue No 
10x HBSS 600ml Gibco 14065-056 
1M HEPES buffer 120ml Gibco 15630-080 
 
Distilled water was added to prepare 6 litres of HBSS-HEPES buffer. The pH was 
adjusted to pH 7.4 using 1N NaOH and the buffer was then filter sterilised and stored 
at ambient room temperature for up to 2 weeks.  
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Table 6.17: Dye-loading buffer (2µM fluo-4) 
 
Solutions Final Concentration Source Catalogue No 
Fluo-4 AM dye 2µM Invitrogen F-23917 
Pluronic acid 0.02% Invitrogen P-3000MP 
 
The stock fluo-4 dye (2mM) was diluted in DMSO and pluronic acid was added at 
20%. To prepare the dye loading buffer, the fluo-4 mixture was diluted 1000-fold with 
HBSS-HEPES buffer. This was stored in the dark at room temperature and used on 
the same day.  
 
6.16.2 Standard agonist plates 
Test drugs were prepared at 10-2M in the appropriate diluent and stored at -20ºC 
(Table 6.8). 
To prepare standard agonist plates, all wells in a 96-well V-bottom Greiner plate were 
pre-filled with HBSS-HEPES buffer. Stock agonists (10-2M) were diluted to 4x10-4M 
with buffer and further diluted 10-fold in Row H for a working concentration of  
4x10-5M. The agonists were serially diluted 1:10 up the plate, leaving Row A with 
buffer alone as a negative control. Similarly for 384-well V-bottom Greiner plates, 
two serial dilutions were prepared from Rows H and P, with Rows A and I saved as 
blanks. The plates were stored at 4ºC and used on the same day after equilibrating to 
room temperature. 
 
6.16.3 Standard antagonist plates 
Antagonists (10-2M) were diluted in HBSS-HEPES buffer to 4 times the required final 
concentration. For negative controls, buffer was pipetted into columns 1-3 of 96-well 
V-bottom Greiner plates. Antagonists were then added to each of 24 wells in the three 
adjacent columns. Blank wells (columns 1-3; 13-15) and antagonists were plated in an 
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equivalent manner for 384-well plates, with a total of 6 antagonists assayed. These 
plates were stored at room temperature in the dark before use on the same day.  
 
In incubation experiments, compounds prepared in DMEM B were added to adherent 
plated cells, substituting the original seeding medium. Plates were incubated for 24 
hours before agonist additions using the FLIPR. 
 
6.16.4 FLIPR assay 
To determine intracellular Ca2+ responses, the cells were washed twice with HBSS-
HEPES buffer using a Microplate Cell Washer (BioTek Instruments, Winooski, 
Vermont, USA) leaving a resting volume of 50µl and 25µl in 96- and 384-well plates 
respectively. The cells were then incubated with the cytoplasmic Ca2+ indicator fluo-4 
dye in the acetylmethyl form (fluo-4 AM, 2µM) at 37°C for 45 minutes in the dark. 
During this time, the FLIPR was started, equilibrated to 39°C and an optics signal test 
was performed at set excitation/ emission wavelengths of 470-495nm/ 515-575nm 
using ScreenWorks software. 
To remove extracellular fluo-4 AM dye, myocytes and fibroblasts were washed three 
times with HBSS-HEPES solution leaving 100µl or 50µl buffer in each well of 96- or 
384-well plates. The FLIPR system was then loaded with disposable black tips 
alongside agonist and antagonist plates. After equilibrating at 37°C for 3 minutes, cell 
plates were placed in the FLIPR instrument and treated with antagonists for 4 minutes 
before an additional 4 minutes of agonist stimulation. A fluorescent signal emitted 
from the binding of cytosolic free Ca2+ with fluo-4 AM dye was detected using the 
FLIPR camera at an exposure time of 0.4 seconds. Fluorescence was also captured at 
excitation and emission wavelengths of 400nm and 506nm for Ca2+-bound and free 
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dye respectively. Average changes in these fluorescent light units (FLU) were 
calculated for triplicate wells. 
 
Responses were normalised relative to the maximum signal from control agonist wells 
and a 4-parametric sigmoidal curve was used to fit each data set. The background 
signal (negative control) of buffer alone was also taken into account using the 
following equation:  
 
 % Change in FLU   =  (average FLU - background) x100 
                                                                                                                                                                                                                                                                                                                                                                                   
 (average FLU (control wells) - background) 
 
 
 
6.17 Metabolic response assay: MTT 
To identify changes in cell proliferation, cytotoxicity was quantified using the yellow 
tetrazolium dye, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 
(MTT). For this assay, stock MTT (5mg/ml) was diluted 1:10 in phenol red-free 
medium (DMEM B), which was added to adherent cells in 96-well plates at 37°C for 
4 hours. During this time, the mitochondrial succinate-tetrazolium reductase system 
and cytoplasmic pyridine nucleotide cofactors within viable cells reduced the MTT to 
a blue/ purple, water-insoluble formazan salt. Following exposure to MTT, the 
conditioned media was aspirated and the formazan formed was solubilised by addition 
of 100µl DMSO per well. Colour development was read in a Bio-Rad plate reader at 
630nm. 
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6.18 cAMP assay for smooth muscle cells  
The cAMP assay was performed according to the HitHunter cAMP XS+ kit protocol 
(GE Healthcare Ltd., Buckinghamshire, UK). This was used for the quantitative 
determination of cAMP from cells and is based upon the complementation of the large 
enzyme acceptor (EA) and small enzyme donor (ED) fragments of Escherichia coli β-
galactosidase (β-gal). For this assay, the cAMP from cell lysates and ED-labelled 
cAMP (ED-cAMP) compete for antibody binding sites. In the bound state, the 
activated β-gal enzyme produces a luminescent signal, which indicates the presence 
of intracellular cAMP.  
 
6.18.1 Reagent preparation 
Each reagent was equilibrated to ambient room temperature before use and protected 
from light during all incubations. 
Lysis buffer/ antibody (Ab) working solution was gently mixed at a ratio of 3:1. 
cAMP XS+ ED/ lysis/ chemiluminescent (CL) substrate working solution was 
pipetted as a mixture. Galacton-star, Emerald-II and the Lysis buffer were gently 
mixed by inversion at a ratio of 1: 5: 19 before mixing with equal parts of ED at a 
ration of 1:1. 
To activate adenylyl cyclase and increase intracellular cAMP, forskolin was added to 
cells. Stock forskolin (9mM) was diluted 10-fold in PBS to 900µM and ten 3-fold 
serial dilutions were prepared. These dilutions were 3-fold higher than the final plate 
concentration. 
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6.18.2 Standard curve 
A cAMP standard curve was run to test the performance of cAMP XS+ kit reagents. 
The stock cAMP standard (2.5x10-4M) was diluted 1:8 with PBS and nine 3-fold 
serial dilutions of cAMP were then prepared using PBS as the diluent for a final range 
of 2.35x10-10M to 4.63x10-6M. PBS alone was used for zero standards. Zero and 
cAMP standard dilutions were dispensed at 10µl/ well, followed by 5µl/ well PBS, 
5µl/ well antibody reagent and 20µl/ well of ED/ CL/ Lysis mix. These compounds 
were incubated for 60 minutes at room temperate. After the addition of 20µl/ well EA, 
the plate was incubated for a further 4 hours at room temperature before the 
luminescent signal was read at 1 second/ well using a Victor Light precisely 1420 
Counter (Perkin Elmer, Waltham, Massachusetts, USA).  
 
6.18.3 Cell-based assay 
Myocytes were harvested (Section 6.11), counted and resuspended in PBS to the 
appropriate cell density. Isobutylmethylxanthine (IBMX, 0.5mM), an inhibitor of 
phosphodiesterase, was also added to the cell suspension to prevent the degradation of 
cAMP. The assay was performed in triplicate per condition within a white OptiPlate-
384 (Perkin-Elmer, Waltham, Massachusetts, USA). Controls included cAMP 
measurements in untreated cells and substitution of PBS for ED reagent to obtain 
background enzyme fragment complementation (EFC) signal.  
 
6.18.4 Optimal cell conditions 
Myocytes were trypsinised, washed, resuspended and diluted in IBMX-PBS solution 
for seeding densities of 2.5k, 5k, 10k, 20k and 40k cells/ well. Cell suspensions were 
added at 10µl/ well into the white OptiPlate-384 and treated with 5µl forskolin or PBS 
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as a zero control. To determine optimal conditions for cAMP induction, 3-fold 
forskolin for working concentrations of 5.1x10-9M to 3x10-4M were incubated with 
cells for 30 minutes at 37°C. Antibody reagent and ED/ Lysis/ CL Working Solution 
were added at 5µl and 20µl/ well respectively for 60 minutes incubation at room 
temperature. All cells were then treated with 20µl/ well EA solution for 4 hours at 
room temperature and the luminescence signal was read on the Victor Light plate 
reader (Table 6.18). 
   
6.18.5 Agonist-induced cAMP production 
The titre of myocytes in the preliminary assay established optimal cell density at 20k 
cells/ well (Figure 6.5). Based on this cell number, the EC80 concentration of 
Forskolin was calculated to be 10µM. To account for the working 3-fold dilution-
factor, concentration-effect curves for PG and oxytocin agonists (3x10-11M to      
3x10-5M) were constructed using 30µM forskolin. The 10µl/ well seeded myocytes 
were then incubated with 5µl of each agonist at 37°C for 30 minutes. After addition of 
the antibody reagent and ED/ CL/ Lysis mix at 5µl and 20µl/ well respectively, the 
plate was incubated for 60 minutes at room temperature. EA solution was then 
dispensed at 20µl/ well before a 4-hour incubation step at room temperature and the 
chemiluminescent signal was read on the Victor Light plate reader.  
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Table 6.18: Overview of the 3-reagent addition protocol for the HitHunter cAMP XS+ 
assay to perform a standard curve and cell-based assay in a 384-well plate format. 
 
Steps Standard curve Steps Cell-based assay 
1 10µl diluted cAMP standard 1 10µl cells (20µl/ well) 
2 5µl PBS 2 5µl agonists in 30µM forskolin 
3 5µl antibody reagent 3 30 minutes incubation at 37°C 
4 20µl ED/Lysis/CL solution 4 5µl antibody reagent 
5 1 hour incubation at RT 5 20µl ED/Lysis/CL solution 
6 20µl EA reagent 6 1 hour incubation at RT 
7 4 hours incubation at RT 7 20µl EA reagent 
8 Read luminescence signal 8 4 hours incubation at RT 
  9 Read luminescence signal 
 
RT = room temperature 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5: Standard curve for cAMP and forskolin-induced cell response data after 
subtraction of background relative luminescence units (RLU). Myocytes were seeded 
at different densities with optimal responsiveness determined in this preliminary assay 
at 20,000 cells/ well. Results are arithmetic means ± S.E. and two-way ANOVA with 
Bonferroni’s post-hoc test showed statistical significance; **p<0.01; ***p<0.001 for 
RLU compared to 2,500 cells/ well. 
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6.19 Protocol for mRNA isolation 
The reverse transcription polymerase chain reaction (RT-PCR) technique was applied 
to myocytes to analyse changes in gene transcripts. To avoid degradation by 
exogenous ribonucleases (RNases) and obtain high-quality RNA, the work area was 
cleaned thoroughly with 70% ethanol and RNaseZap solution (Ambion, Austin, 
Texas, USA). Gloves were changed on a regular basis and all plastics were supplied 
as sterile, DNase and RNase-free. In addition, glassware was either sprayed with 
RNaseZap or rinsed with 0.1% (w/v) diethyl pyrocarbonate (DEPC)-treated water 
(Sigma Chemicals Co, Poole, Dorset, UK) followed by autoclaving. 
 
6.19.1 Effects of PGs and oxytocin on myocyte transcription 
Myocytes were grown in a monolayer in 7x15cm2 Petri dishes (passages 1-3; n=6). At 
about 80 percent confluence, myocytes were either exposed to vehicle (DMEM B), or 
to combinations of agonists and antagonists (Table 6.19). Although all cells were 
harvested at 24 hours incubation, oxytocin was added at 21 hours for a 3-hour 
exposure time. 
 
Table 6.19: Myocytes were incubated with vehicle (DMEM B), oxytocin, the 
oxytocin antagonist atosiban, U46619 or the TP antagonist SQ29,548 at the following 
concentrations and incubation times before harvesting for RNA isolation. 
 
Compounds Concentration(s) Incubation Time 
Atosiban 10-5M 24 hours 
Oxytocin 10-6M 3 hours 
Atosiban  + Oxytocin 10-5M         + 10-6M 24 hours   + 3 hours 
U46619 10-6M 24 hours 
SQ29,548 10-6M 24 hours 
SQ29,548 + U46619 10-6M         + 10-6M 24 hours   + 24 hours 
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6.20 Purification of mRNA 
mRNA was extracted using RNeasy Mini Kits (Qiagen, Valencia, California, USA) 
following the manufacturer’s instructions. Before the start of experiments, RNA gels 
were prepared alongside the buffers. 
 
6.20.1 RNA agarose gels 
Electrophoresis tanks were cleaned with detergent solution, thoroughly rinsed with 
RNase-free water and then sprayed with ethanol and allowed to dry before use. Each 
RNA gel was prepared by mixing 0.5g agarose with 45ml of distilled water in a glass 
bottle. This solution was microwaved for 1-2 minutes to dissolve and sterilise the 
agarose mix. After cooling to about 65°C, 10x denaturing gel buffer at 1:10 dilution 
and 3µl ethidium bromide were added to the agarose gel mixture in a fume cupboard. 
This solution was immediately poured into an electrophoresis Sub-Cell (Bio-Rad, 
Hercules, California, USA) with 8 or 15 prong combs in place according to sample 
numbers. The final 1% agarose gel was covered and left to set without the addition of 
buffer.  
 
6.20.2 Preparation of buffers 
The running buffer 10X MOPS (Serological Corporation, Norcross Georgia, USA) 
and 10X TAE buffer (Cellgro Inc., Pensacola, Florida, USA) were diluted 1:10 with 
distilled water and stored for up to 1 week at 4°C before use. Buffer RPE concentrate 
was diluted 4-fold in 100% ethanol to obtain a working solution and stored at room 
temperature for use in all subsequent experiments. Buffer RW1 was provided as a 
working solution and stored at room temperature. To inhibit RNase function,            
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β-mercaptoethanol (β-ME) was diluted in buffer RLT at 10µl/ml in a fume hood. This 
was stored at room temperature for up to 1 month before use.  
 
6.20.3 Cell lysis 
After 24 hours incubation with vehicle or compounds (Table 6.19), the conditioned 
medium was removed from Petri dishes and myocytes were washed with PBS. The 
cells were then harvested with trypsin-EDTA (Section 6.11), transferred to individual 
centrifuge tubes and total cell number was determined using a Coulter Counter 
(Beckman-Coulter Z2 Cell Counter). Trypsinised cell mixtures were subsequently 
centrifuged for 5 minutes at 300g (~12,000rpm) and the supernatant was completely 
aspirated. As total cell count was below 5x106 cells (range: 1.0x10-6 to 4.4x106 cells), 
the cell pellets were resuspended in 350µl buffer RLT containing β-ME. This lysed 
the cells before RNA isolation. The high guanine-thiocyanate content of this buffer 
also inactivated endogenous RNases to ensure purification of intact RNA. 
 
6.20.4 Lysate homogenisation 
The cell lysates were directly added into individual QIAshredder spin columns 
(Ambion, Austin, Texas, USA), placed in 2ml collection tubes and centrifuged for 2 
minutes at 8,000g (~15,000rpm), 25°C. By shearing the high molecular weight 
genomic DNA and cellular components, the QIAshredder reduced the viscosity of 
lysates and improved RNA yields. Cleared lysates were then mixed in collecting tubes 
with 350µl ethanol to create appropriate conditions for RNA binding to the RNeasy 
membrane. 
 
  Chapter Six: Cell culture methods 
  Page 174 
 
6.20.5 RNA elution 
Samples were transferred to individual RNeasy spin columns, placed in 2ml collection 
tubes and centrifuged for 15 seconds at 8,000g, 25°C. After discarding the flow-
through, 700µl buffer RW1 was added to the RNeasy spin columns and centrifuged 
for 15 seconds at 8,000g, 25°C to wash the spin column membrane. Two further 
washes were performed for each sample by the addition of 500µl buffer RPE to the 
RNeasy spin columns with centrifugation for 15 seconds and then for 2 minutes at 
8,000g. This was followed by a further 2-minute centrifuge without buffer to dry the 
spin column membranes and remove any residual ethanol. After placing in a new 
1.5ml collection tube, 50µl RNase-free water was directly added to each spin column 
membrane. To elute the RNA, tubes were centrifuged for 1 minute at 8,000g, 25°C. 
These samples were kept on ice or aliquoted and stored at -70°C to avoid RNA 
degradation. 
 
6.21 Quantification of mRNA 
After extracting RNA from smooth muscle cells, 1µl mRNA was diluted 100-fold 
with TE buffer (Qiagen, Valencia, California, USA) into a cuvette. Optical densities 
(OD) were read for each RNA sample on a Beckman DU640 spectrophotometer at 
260nm (A260) and 280nm (A280). The cuvette was washed with RNase-free water and 
TE buffer was used as a blank between absorbance readings. To calculate 1) RNA 
content and 2) estimate RNA purity, the following equations were used: 
 
1) RNA concentration (µg/ml) = [OD (A260) x40 (constant) x100 (dilution factor)] 
 
2) A260/ A280 ratio 
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A ratio value of 1.5 and above was indicative of low RNA contamination. Denaturing 
agarose gel electrophoresis was also used to confirm the purity of RNA samples. 
 
6.21.1 Examining RNA integrity  
To eliminate DNA for RNA purification, deoxyribonuclease I (DNase I) was added to 
10µg RNA samples on ice (Equation 1) together with DNase buffer and DEPC-treated 
water (Table 6.20). The tubes were incubated for 15 minutes at 25°C. The addition of 
10µl of EDTA solution (25mM) to the reaction mixture inactivated the DNase I. This 
was heated for 10 minutes at 65°C on a heat block and transferred back to the ice. 
After removing the volume required for gel electrophoresis, samples were aliquoted 
for storage at -70°C for use in reverse transcription, prior to amplification. 
 
 
Table 6.20: Solutions added in the following order to an RNase-free eppendorf on ice. 
 
DEPC-treated water (µl) 10x DNase I buffer (µl) 10µg RNA sample (µl) DNase I (µl) 
*  10 = 1µg/ RNA (µg/ml) x 10 10 
 
*DEPC-treated water (µl) = 100µl - 20µl - RNA sample (µl) 
 
 
To examine RNA integrity, 10µl of DNase-treated RNA (1µg) was added to 10µl 
isopropanol and 1µl glycoblue (Ambion, Austin, Texas, USA). Following 
centrifugation for 10 minutes, 8,000g at 4°C, the supernatant was aspirated and the 
sample was air dried for 5 minutes. Blue RNA precipitates were resuspended with 3µl 
DEPC-treated water and 15µl NorthernMax Formaldehyde Load dye (Ambion, 
Austin, Texas, USA) on ice. To denature the RNA, these samples were incubated at 
70°C, placed on ice for 2-3 minutes and briefly spun.  
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Gel electrophoresis was run in 1X MOPS buffer at 80V/ cm after loading the DNase-
treated samples into each well. RNA was visualised by ethidium bromide staining on 
a UV light box. The larger ribosomal RNA bands 28S and 18S at an intensity ratio of 
2:1 indicated that cellular mRNA was intact (Figure 6.6). The RNA was then reverse-
transcribed into complementary DNA (cDNA); this was used as a template for PCR.  
 
6.21.2 Reverse transcription and PCR 
To perform RT-PCR, sense and antisense primers were designed using the computer 
software D-LUX programme (Invitrogen, Carlsbad, California, USA). PCR primer 
pairs were 23-25 nucleotides in length with similar A/T and G/C content for optimal 
annealing conditions (Table 6.22).  
DNase-treated RNA was converted into cDNA using the Platinum Taq Maloney 
murine leukaemia virus (M-MLV) reverse transcription system (Invitrogen, Carlsbad, 
California, USA). Each reaction mix, prepared on ice in a 0.5ml eppendorf tube in a 
reaction volume of 30µl contained the following: SuperScript III reverse transcription 
buffer (deoxyribonucleotide trisphosphates (dNTP; 0.4mM), magnesium sulphate 
(MgSO4; 6mM)), RNase-free water, sense and antisense primer pairs (10µM each), 
total RNA (100ng), 2x reaction mix and 200IU M-MLV Superscript III RT Platinum 
Taq (Table 6.21). Control RNA samples with Supermix of Platinum Taq M-MLV 
without the reverse transcription enzyme were included to confirm that no genomic 
DNA contamination was present. 
The tubes were placed in a PCR Sprint thermal cycler (Thermo Scientific, New York, 
USA) and set to run the reverse transcription programme: incubation for 30 minutes at 
50°C to allow cDNA synthesis from mRNA by reverse transcription. This was 
followed by denaturing samples at 94°C for 2 minutes to inhibit reverse transcription 
  Chapter Six: Cell culture methods 
  Page 177 
 
activity. cDNA amplification was subsequently carried out by 35 cycles of denaturing 
at 94°C for 15 seconds, annealing at 57°C for 30 seconds and elongation at 68°C for 
30 seconds. PCR products were finally heated at 68°C for 7 minutes and either stored 
at 4°C or placed on ice for immediate analysis by agarose gel electrophoresis. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: Intact RNA (1µg) samples from treated myocytes were run on a 1% 
denaturing agarose gel. The 28S and 18S ribosomal RNA bands were visualised on a 
light box with an even background smear of cellular mRNA for each sample.  
 
 
 
 
 
Table 6.21: The following solutions were added to 0.2ml thin-wall PCR tube on ice: 
 
Sample Control (µl) β-actin (µl) PGs (µl) 
Super mix of Platinum Taq 25 0 0 
2x Reaction mix 0 15 15 
RNase-free water 3 10 10 
10µM Human β-actin (sense) 1 1 0 
10µM Human β-actin (antisense) 1 1 0 
10µM Human PG primers (sense) 0 0 1 
10µM Human PG primers (antisense) 0 0 1 
Human mRNA 100ng/µl  0 1 1 
SuperScript III RT Platinum Taq 0 2 2 
 
 
28S 
18S 
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Table 6.22: PCR primer sequences. The accession number of each sequence for the 
EMBL/ Genbank/ DDBJ data library is provided. 
 
PCR primers Sequence nt Size Accession No 
s 5’-GTA CCA CTG GCA TCG TGA TGG AC-3’ 513 β-actin 
as 5’-GAG TTG AAG GTA GTT TCG TGG ATG-3’ 915 
403 NM_001101 
s 5’-GGT ATC ATG GTG GTG TCG TGC ATC-3’ 875 
EP1 as 5’-CAG GAT GTG GTT CCA GGA GGC AAG-3’ 1112 
238 L22647 
s 5’-TGG CAT CTG ACT GTG TAG AAC AGG-3’ 876 
EP2 as 5’-CTC CGC TCC TGA TAA TGA TGT TGA-3’ 1211 
336 NM_000956 
s 5’-CTC CGC TCC TGA TAA TGA TGT TGA-3’ 998 
EP3 as 5’-CTT CTC CGT GTG TGT CTT GCA GTG-3’ 1194 
197 NM_198716 
s 5’-GAT GGT CAT CTT ACT CAT TGC CAC-3’ 1309 
EP4 as 5’-CTT GGC TGA TAT AAC TGG TTG ACG-3’ 1494 
186 NM_000958 
s 5’-GTG CTT TAT CCA GAT GGT CCA CG-3’ 595 
DP 
as 5’-CCA TGA GGC TGG AGT AGA GCA CAG-3’ 971 
377 U31332 
s 5’-CAA CAC CAG CAT CCG CTA CAT CGA-3’ 84 
CRTH2 as 5’-CAC GAA GAG GAT GAC TCC ATT CTC-3’ 280 
197 AB008535 
s 5’-CAG CAC AGA CAA GGC AGA TCT CAT C-3’ 772 
FP 
as 5’-GAT TCC ATG TTG CCA TTC GGA GAG-3’ 1155 
384 NM_000959 
s 5’-CCT CTG CTC CTG TGG GAA AGG AG-3’ 1063 
IP 
as 5’-GCT TCT GCT TTG GAC GAC GTT CC-3’ 1192 
130 L29016 
s 5’-GTG GAG ATG ATG GCT CAG CTC CTG-3’ 735 
TP 
as 5’-CAG CAC TGT CTG GGC GAT GAA GAC-3’ 1024 
290 NM_201636 
s 5’-TGG CCT CCT ACA CGT ACT TCT ACC-3’ 1891 Oxytocin 
receptor as 5’-TGG TCA CCA ATC CTA TAT TTA CCG-3’ 2125 
235 NM_000916 
 
 
     
s 5’-GGT TGG GAA TAA GAA GGA TCT TCG-3’ 233 
Rho A 
as 5’-GCC ATA TCT CTG CCT TCT TCA GGT-3’ 571 
339 L25080 
s 5’-TTA AGA ATC TAA CCC TGC AAC TGG A-3’ 2917 
ROCK I 
as 5’-CAA TTC ATT TTG TAA CAA CAG CCG-3’ 3288 
372 NM_005406 
s 5’-GTG TGT GGC AGT ATT TTA GTA CCG-3’ 5481 
ROCK II 
as 5’-TTT GAG GCC ACT TCT TCC CAG TTG-3’ 5860 
380 NM_004850 
s 5’-CTC TAT GAC GCC TTC GAG AGC AAG-3’ 1609 
MLCK 
as 5’-GTG GTA CTT CTC ATC TGT GAT CCG-3’ 1914 
306 NM_182493 
s 5’-TTT CGA GCT AGA TCC CAC CAC TCT-3’ 972 IP3 
receptor as 5’-ATT AGT ACA TAG GTG TCT GAG CCG-3’ 1376 
405 D26070 
s 5’-GAA CTT TAC AAG GGT GTG TTG GCG-3’ 772 
Telokin 
as 5’-TGG CCT CCT ACA CGT ACT TCT ACC-3’ 1091 
320 U40712 
 
s: sense; as: antisense; nt: nucleotides 
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6.22 DNA electrophoresis 
RT-PCR products were analysed using a 3% pre-cast ready agarose gel (Bio-Rad, 
Hercules, California, USA), which was placed in an electrophoresis tank containing 
1X TAE buffer. A total of 10µl of each PCR product was combined with 2µl of DNA 
loading dye (Ambion, Austin, Texas, USA) to aid loading and to monitor the 
progression of the product through the gel during electrophoresis. Once the PCR 
products and negative controls were carefully loaded into the wells, 10µl of standard 
DNA fragments (1Kb plus DNA ladder; Invitrogen, Carlsbad, California, USA) was 
loaded on the left side of the gel for sizing. The tank was set to run at a constant 
100V/ cm for approximately 25 minutes when the DNA fragments were sufficiently 
resolved. Images of PGs, oxytocin and protein DNA products were then captured 
using a UV transilluminator UVP at a wavelength of 312nm and analysed with Fluor 
Chem H2 software (Alpha Innotech, Leandro, California, USA). 
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6.23 Summary diagram of cell-based assays 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: An overview schematic principle of the assays performed to develop an in 
vitro cell culture model for myocytes and fibroblasts. To isolate and characterise cell 
populations, enzymatic digestion, differential adhesion and immunocytochemistry 
techniques were performed on myometrial tissue taken at term pregnancy. Changes in 
Ca2+, cAMP and gene transcripts were assessed using the FLIPR-Tetra, a competitive 
cAMP assay based upon the complementation (EFC) of enzyme fragments (EA and 
ED) and RT-PCR respectively. Measurements were used to screen the effects of 
uterotonic agents on normal and pathological downstream signalling cascades. 
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Chapter 7: Uterine myocytes & fibroblasts 
 
Signal transduction in myometrial cells at term pregnancy 
 
 
7.1 Introduction 
The uterus adapts to the physiological process of pregnancy by achieving enormous 
expansion whilst sustaining muscle tone (Yu & Lopez Bernal, 1998). Such dynamic 
tissue remodelling depends on cell hyperplasia and hypertrophy, alongside smooth 
muscle cell (myocyte) and fibroblast interactions (Varayoud et al., 2001; Ono et al., 
2007; MacCannell et al., 2007; Wu et al., 2008; Shynlova et al., 2010). In response to 
mechanical stretch and biochemical stimuli, myometrial smooth muscle exhibits 
considerable plasticity, mediated in part by actin polymerisation (Taggart & Morgan, 
2007) and the recruitment of additional signalling proteins (Berridge, 2008). 
Gestational-related changes in the temporal and tissue-specific expression of PG and 
oxytocin receptors then contribute to the transition from uterine quiescence to 
contractility (Charpigny et al., 2003; Grigsby et al., 2006). This activates secondary 
signalling cascades, principally targeting cAMP, IP3 and intracellular Ca2+ pathways. 
The cAMP system suppresses myometrial activity, whereas IP3 generation and Ca2+ 
release augment contractions. Although PGs and oxytocin participate in cellular 
events, the signal transduction systems that orchestrate these striking changes at term 
gestation are not fully understood. 
This chapter focuses on the structural, functional and molecular aspects of myometrial 
cells at term pregnancy. As well as characterising primary cell cultures, PG and 
oxytocin-induced activation of signalling pathways involving Ca2+ and cAMP were 
studied relative to receptor mRNA. By using this cell culture model, high throughput 
screening of potential tocolytics could be performed. In particular, the nature of EP2-
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based interactions that antagonise oxytocic contractile effects (Duckworth et al., 
2002) would be investigated to develop a PG based therapy for preterm labour. 
Alongside responses in functional studies, these results would help to elucidate the 
contribution of receptors or messenger targets in regulating myometrial contractility. 
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Chapter 7.2: Results 
 
 
 
7.3 Immunostaining of uterine smooth muscle cells and fibroblasts  
Morphologic features of uterine cell populations were assessed using immunoassay 
and bright field images. The ultrastructure was identified with markers for smooth 
muscle actin, α-actinin, vimentin and desmin, generally used to characterise 
myometrial cells (Hongpaisan, 2000; Lopez Bernal & TambyRaja, 2000; Montes et 
al., 2002). In myometrial sections, positive expression and uniform distribution of 
these cytoskeletal elements were demonstrated (Figure 7.1). However, as clarity was 
compromised by tissue thickness, the structural components of monolayer primary 
cultures of myometrial cells were visualised.  
 
Images of myocytes and fibroblasts cultured by differential adhesion techniques were 
captured under a phase contrast microscope (Figure 7.2). Smooth muscle cells and 
fibroblasts each displayed a central oval nucleus containing several nucleoli. In their 
cytoplasm, bright field pictures revealed prominent dense bodies located throughout 
the bundles of thin filaments. These were interspersed with less discernable large 
areas of ribosomes, rough endoplasmic reticulum, mitochondria and Golgi complexes. 
Despite their characteristic flat, elongated and spindle-shaped morphologies, 
myocytes tended to be about 5-10µm narrower than fibroblasts. Likewise, the 
protruding flat sheets of membrane-enclosed cytoplasm, lamellipodia, were observed 
at polar ends in myocytes but were more spread in fibroblasts. Due to these subtle 
differences, immunocytochemistry was performed to distinguish cell types. 
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Figure 7.1: Typical micrographs showing sections of human myometrium taken at 
term pregnancy. Using immunohistochemistry techniques, sections were stained with 
a) vimentin (red) and b) desmin (green) at x10 magnification. Actin (red) and α-
actinin (green) were also imaged at c) x10 and d) x40 magnifications. Staining by the 
fluorescent DNA-binding probe DAPI (blue) indicated the uniform positive staining 
of cell filaments and proteins throughout myometrial tissue sections.  
  
 
 
a) Vimentin (x10) b) Desmin (x10) 
d) Actin & α-actinin (x40) c) Actin & α-actinin (x10) 
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Figure 7.2: Phase contrast micrographs of primary a) smooth muscle and b) fibroblast 
cells cultured from human myometrium at term pregnancy (passages 1-2). Cells were 
separated by differential adhesion techniques and photographed at x100 
magnification. Bright field images of cells show nuclei (N), black arrows indicate 
bundles of contractile filaments, and blue arrows more prominent dense bodies 
dispersed throughout the cytoplasm. In control fluorescent images of the same cells  
(c & d), nuclei were labelled with the fluorescent DNA-binding probe DAPI (blue). 
The green background staining was barely visible due to the addition of secondary but 
not primary antibodies.  
 
 
 
N
N
a) 
b) 
c) 
d) 
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7.4 Positive staining for α-actinin and actin 
All nuclei were labelled with the fluorescent DNA-binding probe DAPI (blue). In the 
absence of primary antibodies, negative controls displayed very low background 
fluorescence (Figure 7.2). Even so, myocytes and fibroblasts showed positive double 
immunostaining for smooth muscle actin and α-actinin (Figure 7.3). The peripheral 
region largely consisted of a dense meshwork of thin actin filaments. These 
microfilaments were arranged into parallel bundles with fewer actin filaments in the 
central region close to the nucleus. As a cross-linking protein, α-actinin was highly 
dispersed throughout the cytoplasm and staining was punctate. Towards the nucleus, 
the co-localisation of α-actinin with actin was evident in merged images for myocytes 
and fibroblasts. For each cell phenotype, staining intensity and alignment of 
cytoskeletal structures were similar. Although colour intensity related to the plane of 
focus, mixed cell populations and myometrial tissue in explant cultures were also 
positive for α-actinin and actin (Figure 7.5). 
 
7.5 Positive staining for intermediate filaments 
Immunostaining of the two intermediate filaments vimentin and desmin were 
analogous in both primary myocyte and fibroblast cultures (Figures 7.4 & 7.5). The 
cells expressed abundant interconnected networks of vimentin with branches 
extending from the nuclear envelope to junctions in the lipid membrane. 
Distinguished in this longitudinal arrangement, all isolated myometrial cells and 
explant tissue stained positive for vimentin.  
Desmin was also detected in the cytoplasm of myometrial cells, even in their 
proliferating state. With attachment to the dense plaques, desmin filaments were 
closely packed in a more centrally located position when cells were elongated. Fewer 
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specks of desmin were also present at the cell periphery in both smooth muscle cells 
and fibroblasts. In myometrial explants, due to the difficulties in focusing on raised 
and flat surfaces together, the tissue was brighter than desmin-labelled cells. 
 
7.6 Positive staining for fibroblast surface proteins  
To better distinguish between smooth muscle cells and fibroblasts, immunostaining 
was performed using a fibroblast antigen. This monoclonal antibody was reported to 
recognise fibroblast surface proteins on human fibroblasts as well as macrophages and 
blood monocytes (Singer et al., 1989; Esterre et al., 1992; Ronnov-Jessen et al., 
1992). Even so, this study showed identical staining patterns in myocytes, fibroblasts 
and explant tissues (Figures 7.4 & 7.6). The punctate staining of scaffold proteins 
extended over the surface to the periphery of each cell. Searches through the literature 
indicated that specific conjugation of this fibroblast-associated marker and alternative 
smooth muscle specific antibodies, such as smoothelin, had not previously been tested 
to distinguish any cultures of both myocytes and fibroblasts in the uterus. As a result, 
differences in proliferation rate, morphology and intracellular events were used to 
characterise myometrial cell types. 
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Figure 7.3: Phase contrast micrographs showing the co-expression of longitudinal 
actin filaments and α-actinin in primary cultures of a) myocytes and b) fibroblasts. 
Cells were cultured from myometrium taken at term pregnancy and separated by 
differential adhesion techniques (passages 1-2). Actin filaments (red), α-actinin 
(green) and cell nuclei, labelled with the fluorescent DNA-binding probe DAPI, (blue) 
were individually photographed at x100 magnification before images were merged.  
a) Actin & α-actinin (x100) 
b) Actin & α-actinin (x100) 
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Figure 7.4: Phenotypic assessment of a) smooth muscle cells and b) fibroblasts 
cultured from myometrium taken at term pregnancy and separated by differential 
adhesion techniques (passages 1-2). Positive expression of 1) filamentous vimentin,  
2) desmin and 3) anti-human fibroblast surface protein (AFSP) were detected in both 
cell types using immunocytochemistry. All nuclei were labelled with the fluorescent 
DNA-binding probe DAPI (blue). Photographs of these cytoskeletal proteins and 
nuclei were taken at x100 magnification and superimposed. 
 
1a) Vimentin (x100) 1b) Vimentin (x100) 
2a) Desmin (x100) 2b) Desmin (x100) 
3a) AFSP (x100) 3b) AFSP (x100) 
  Chapter Seven: Myometrial cells 
  Page 190 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5: Phase contrast micrographs showing 1) bright field and 2) fluorescent 
images of primary cells cultured for 7-10 days from myometrial explant tissue taken 
at term pregnancy. Positive expression of a) actin (red) and α-actinin (green),            
b) vimentin and c) desmin filaments were detected in cells and explant tissues using 
immunocytochemistry. All nuclei were labelled with the fluorescent DNA-binding 
probe DAPI (blue). Photographs of these cytoskeletal proteins and nuclei were taken 
at x20 magnification and superimposed. 
1a)  2a) Actin & α-actinin (x20) 
1b)  2b) Vimentin (x20) 
1c)  2c) Desmin (x20) 
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Figure 7.6: Micrographs showing myometrial cells formed from explant tissue after 
14 days in primary culture. Uterine tissue was excised at term pregnancy. A consistent 
pattern of reactivity for anti-human fibroblast surface protein (AFSP) was expressed 
in all cells and explant tissue using immunocytochemistry. Nuclei were labelled with 
the fluorescent DNA-binding probe DAPI (blue) and photographs of the cells taken at 
a) x20 and b) x100 magnifications were superimposed.  
 
 
a) AFSP (x20) 
b) AFSP (x100) 
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Chapter 7.7: Results - FLIPR 
 
 
 
7.8 Optimising agonist-induced Ca2+ readings 
Receptor-mediated mobilisation of Ca2+ was assessed using the FLIPR-Tetra 
(Molecular Devices, Sunnyvale, California, USA). In preliminary studies to optimise 
cell parameters, myocytes were seeded in 96-well plates overnight at 15k, 30k and 
60k cells/ well (Figures 7.7 and 7.8). Stimulation with vehicle (DMEM D), PGE2 and 
U46619 for 4 minutes evoked little flux in intracellular-free Ca2+. Even so, PGF2α 
increased the Ca2+ signal by nearly 2-fold (p<0.05), whilst exposure to oxytocin 
significantly augmented Ca2+ transients at all seeding densities (P<0.001). Since 
maximum responses were observed with 30k cells/ well, this plating density was 
continued for all FLIPR assays performed in 96-well plates.  
 
7.9 Responsiveness to PGs and oxytocin 
When oxytocin was assayed separately, the concentration-dependent increases in Ca2+ 
flux to PGE2, PGF2α and U46619 were observed above 10-7M (Figure 7.9). Whilst 
vehicle evoked negligible Ca2+ release, exposure to PGF2α (10-5M) peaked at 316 ± 
26.75 FLU counts; this signal was attenuated by 17 and 93 percent in response to 
U46619 and PGE2 respectively. As oxytocin-induced Ca2+ transients were more 
robust and reached better limits of detection at 1435 ± 53.20 FLU counts, oxytocin 
was used as the predominant agonist to study intracellular Ca2+ oscillations. 
 
 
 
  Chapter Seven: Myometrial cells 
  Page 193 
 
    Vehicle PGE2        PGF2α      U46619    Oxytocin
0
10
20
15k cells/ well 30k cells/ well 60k cells/ well
20
70
120
***
*** ***
*ab
abab
a
*ab
Agonist (10-6M)
%
 F
LU
 C
ou
nt
s
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7: Primary myocytes cultured from isolated myometrium obtained at term 
pregnancy were seeded overnight at densities of 15k, 30k and 60k cells/ well in 96-
well plates (n=4). After loading with fluo-4 AM dye (2µM), cells were exposed to 
vehicle (DMEM B), PGE2, PGF2α, U46619 or oxytocin at 10-6M for 4 minutes. Ca2+ 
transients, indicated by emitted fluorescence, were recorded using the FLIPR. Data 
are arithmetic means ± S.E. and statistics were performed using univariate ANOVA 
with Bonferroni’s post-hoc adjustment; *p<0.05; ***p<0.001 elevation in Ca2+ flux 
compared with avehicle and b15k cells/ well for the same agonist.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.8: Typical Ca2+ mobilisation in primary human myocytes seeded at 15k, 30k 
and 60k cells/ well and incubated with the Ca2+ sensitive fluo-4 AM dye. The 
screenshot traces recorded on the FLIPR represent myocyte responses to PG and 
oxytocin agonists (10-6M) with oxytocin challenge inducing the largest Ca2+ release. 
 
 
 
15k cells/ well
30k cells/ well
60k cells/ well
Vehicle PGE2 U46619 PGF2α Oxytocin 
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Figure 7.9: Vehicle (DMEM D) and concentration-dependent changes in intracellular-
free Ca2+ for PGE2, PGF2α, U46619 and oxytocin using FLIPR. Primary myocytes 
from term pregnant donors were seeded at 30,000 cells/ well and Ca2+ was detected 
using the fluo-4 AM indicator dye. Signals peaked at 316 ± 26.75 and 1435 ± 53.20 
FLU counts for plates run in the absence and presence of oxytocin respectively.  
 
 
 
7.10 384-well plate validation 
In later experiments, the cell seeding density was also validated for 384-well plates. 
To determine cell titre, several dilutions of myocytes and fibroblast populations were 
serially prepared (Figures 7.10 & 7.11). Responses to oxytocin (10-6M) peaked at 5k 
cells/ well before the signal plateaued (p<0.001). Accordingly for optimal Ca2+ 
recordings, the cell seeding density in 384-well plates was adjusted to 5k cells/ well.  
 
7.11 Intracellular-free Ca2+ in myocytes and fibroblasts 
When directly compared between cell types, oxytocin-induced Ca2+ mobilisation was 
nearly 2-fold higher in myocytes than fibroblasts (p<0.001). Therefore, to better 
distinguish Ca2+ release in fibroblasts, subsequent assays for each cell population 
were performed separately. 
Vehicle PGF2α U46619 PGE2
10-8M 
10-7M 
10-6M 
10-5M 
4 mins
Oxytocin
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Figure 7.10: Intracellular Ca2+ flux induced by oxytocin (10-6M) in primary myocytes 
and fibroblasts cultured from myometrial biopsies (n=8). Cells were seeded overnight 
at titrations of 600 to 10k cells/ well in 384-well plates. After loading with fluo-4 AM 
dye, responses to oxytocin were read using the FLIPR and calculated as % change in 
fluorescence units over baseline (% FLU). Statistics were performed using univariate 
analysis with Bonferroni’s post-hoc test; **p<0.01; ***p<0.001 compared to cell 
seeding densities of a0.6k, b1.25k and c2.5k cells/ well and between dmyocyte and 
fibroblast responses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.11: Changes in intracellular free Ca2+ after addition of oxytocin at 10-6M in 
duplicate to fluo-4 AM loaded primary myocytes (n=4) and fibroblasts (n=4) from 
term pregnant donors recorded on the FLIPR. Typical Ca2+ profiles for smooth muscle 
cells were higher than fibroblasts over 4 minutes of oxytocin stimulation. 
 
 
1.3k cells/ well
2.5k cells/ well
5k cells/ well
10k cells/ well
Smooth muscle cells
1 2 3 4
Fibroblasts 
1 2 3 4 
0.6k cells/ well
0 cells/ well
4 mins
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7.12 Pre-incubation with FP and TP agonists 
Although PGF2α (10-6M; p<0.001) and U46619 (10-6M) challenge each mobilised 
Ca2+ (Figures 7.7, 7.8 & 7.9), pre-incubation with these uterotonic agents did not 
affect the concentration-dependent signals evoked by oxytocin in myocytes (pEC50: 
9.17 ± 0.02M) and fibroblasts (pEC50: 8.98 ± 0.03M; Figure 7.12). In smooth muscle 
cells, even the 8.6 percent attenuation in maximal oxytocin-induced Ca2+ signals after 
exposure to both PGF2α and U46619 was not significant (F (1, 48) = 2.87; ns).  
 
  
 
a) smooth muscle cells b) fibroblasts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.12: Concentration-effect curves for oxytocin (10-11M to 10-5M) in 
combination with vehicle, PGF2α (10-6M) and U46619 (10-6M) for a) myocytes and  
b) fibroblasts. Primary cells cultures from myometrial tissue taken at term pregnancy 
(n=4) were incubated with the Ca2+ indicator fluo-4 AM dye (2µM) and washed. 
Changes in fluorescence counts from baseline (% FLU counts) were detected using 
the FLIPR-Tetra. Pre-incubation with the FP and TP agonists did not evoke a 
synergistic effect on oxytocin-induced Ca2+ transients. 
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Figure 7.13: Changes in intracellular free Ca2+ by atosiban on oxytocin-induced Ca2+ 
curves in human myometrial 1) smooth muscle cells and 2) fibroblasts. Cells were 
loaded with the Ca2+ indicator fluo-4 AM dye (2µM), washed and exposed to vehicle 
(DMEM D) or atosiban at concentrations of a) 10-7M to 10-5M or b) 10-10M to 10-8M 
for 4 minutes before stimulation with oxytocin (10-11M to 10-5M) for 4 minutes. Data 
are expressed as arithmetic means ± S.E. and multivariate analysis showed statistical 
significance; *p<0.05; **p<0.01; ***p<0.001 rightward shift for atosiban at a10-5M, 
b10-6M, c10-7M and d10-8M compared to vehicle. 
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Table 7.1: Mean pEC50 values (M) for concentration-effect curves to oxytocin (10-11M 
to 10-5M) in myocytes and fibroblasts (n=8) pre-incubated with vehicle (DMEM D) or 
atosiban (10-9M to 10-5M) for 4 minutes. Primary cells were cultured from 
myometrium harvested at term pregnancy. Results are expressed as arithmetic means 
± S.E. and significance was determined using one-way ANOVA with Bonferroni’s 
post-hoc test; *p<0.05; ***p<0.001 for atosiban shifted curves compared to vehicle. 
 
 Vehicle 
Atosiban 
(10µM) 
Atosiban 
(1µM) 
Atosiban 
(0.1µM) 
Atosiban 
(10nM) 
Atosiban 
(1nM) 
Smooth muscle cell s     
pEC50 8.7 ± 0.1  6.5 ± 0.1*** 7.1 ± 0.1*** 8.2 ± 0.1* 8.5 ± 0.2 8.9 ± 0.03 
Fibroblasts     
pEC50 8.9 ± 0.1 6.9 ± 0.2*** 7.7 ± 0.1*** 8.3 ± 0.2* 8.7 ± 0.1 8.7 ± 0.04 
 
 
 
 
a) b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.14: Representative Schild plots for human myometrial a) myocytes and       
b) fibroblasts obtained at term pregnancy. Cells were pre-incubated with atosiban   
(10-7M to 10-5M) before concentration-effect curves for oxytocin (10-11M to 10-5M) 
were performed using the FLIPR-Tetra.  
 
 
 
 
7.13 Pre-incubation with atosiban 
In myocytes and fibroblasts, challenge with oxytocin induced a concentration-
dependent increase in intracellular-free Ca2+. The resultant sigmoidal curve plateaued 
at 98.8 ± 0.79 percent fluorescent counts with a pEC50 of 8.8 ± 0.1M (Figure 7.13; 
Table 7.1). Although no change was evoked in the upper asymptote, the oxytocin 
antagonist atosiban (10-7M to 10-5M) produced parallel rightward shifts of the 
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oxytocin curve. Using Schild plot analysis, pA2 values of 7.55 and 7.56 were 
calculated for myocytes and fibroblasts (Figure 7.14). Atosiban at 10-7M displaced 
oxytocin-induced Ca2+ transients by a pEC50 value of 0.57 ± 0.15M (F (1, 32) = 2.85; 
p<0.05). Higher concentrations of atosiban further shifted the oxytocin-effect curve to 
the right (F (2, 64) = 263; p<0.001). The observed change in peak Ca2+ signals was 
displayed in screenshots from the FLIPR (Figure 7.15). Whilst responses to oxytocin 
were attenuated by atosiban at 10-8M in myocytes (F (1, 64) = 5.64; p<0.01), lower 
concentrations of atosiban did not competitively antagonise or modify the profile of 
oxytocin in either cell type. 
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1a) Vehicle + oxytocin (10-6M) 1b) Atosiban (10-5M) + oxytocin (10-6M) 
 
 
 
 
 
 
 
 
 
 
 
2a) Vehicle + oxytocin (10-7M) 2b) Atosiban (10-5M) + oxytocin (10-7M) 
 
 
 
 
 
 
 
 
 
 
 
3a) Vehicle + oxytocin (10-8M) 3b) Atosiban (10-5M) + oxytocin (10-8M) 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.15: Screenshot images of Ca2+ transients in primary myocytes in response to 
oxytocin at 1) 10-6M, 2) 10-7M and 3) 10-8M pre-incubated with either a) vehicle 
(DMEM D) or b) atosiban for 4 minutes. Fluorescent change counts were detected 
using the FLIPR camera from the binding of intracellular-free Ca2+ with fluo-4 AM 
dye at excitation and emission wavelengths of 400nm and 506nm respectively. 
Oxytocin-induced Ca2+ release was attenuated in the presence of atosiban at 10-5M. 
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Table 7.2: Mean maximum percentage fluorescent count (Em) and effective half 
maximal concentrations (pEC50) (M) for smooth muscle cells (n=4) pre-exposed to 
vehicle (DMEM D), EP receptor agonists (10-6M) or an EP3 antagonist (10-5M) for 4 
minutes before stimulation with oxytocin (10-11M to 10-5M). Data are expressed as 
arithmetic means ± S.E. EP receptor compounds evoked no effect on oxytocin-
induced Ca2+ release curves. 
 
 Smooth muscle cells 
 Vehicle PGE2 Butaprost CP533,536 AGN211330 AGN211329 
Receptor target EP1-4 EP2 EP2 EP2 EP3 antag 
Em 100.5 100.5 104.0 104.3 98.2 99.0 
S.E. 0.3 2.9 2.7 1.0 4.8 1.3 
pEC50 8.91 8.78 9.04 8.98 8.69 8.97 
S.E. 0.05 0.2 0.04 0.04 0.1 0.03 
 
 
Table 7.3: Mean maximum percentage fluorescent count (Em) and effective half 
maximal concentrations (pEC50) (M) for fibroblasts (n=4) pre-exposed to vehicle 
(DMEM D), PGE2 (10-6M), butaprost (10-6M) or the EP3 receptor antagonist 
AGN211329 (10-5M) for 4 minutes before stimulation with oxytocin (10-11M to       
10-5M). Data are expressed as arithmetic means ± S.E. EP receptor compounds 
evoked no effect on oxytocin-induced Ca2+ release curves. 
 
 Fibroblasts 
 Vehicle PGE2 Butaprost AGN211329 
Receptor target - EP1-4 EP2 EP3 antag 
Em 100.2 102.5 100.4 97.5 
S.E. 1.12 2.1 2.2 1.8 
pEC50 8.82 8.88 8.80 8.87 
S.E. 0.1 0.2 0.1 0.1 
 
 
 
7.14 Pre-incubation with EP receptor compounds 
Treatments with oxytocin (10-11M to 10-5M) depolarised the membrane of smooth 
muscle cells. This was characterised by Ca2+ influx, which plateaued at 100.5 ± 0.3 
percent fluorescence counts (pEC50: 8.91 ± 0.05M; Table 7.2). Pre-incubation with 
PGE2 or the EP2 receptor agonists butaprost, CP533,536 and AGN211330 did not 
alter the sigmoidal oxytocin-effect curve (F (4, 120) = 1.44; ns). Likewise, PGE2 and 
butaprost had no affect on oxytocin-induced Ca2+ release in fibroblasts (F (2, 72) = 
1.53; ns). Although the EP3 receptor agonist AGN211329 induced a transient rise of 
41.2 ± 5.15 percent fluorescent counts, the effect of oxytocin on cytosolic-free Ca2+ 
remained unaltered in both cell populations. 
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a) smooth muscle cells b) fibroblasts  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.16: Concentration-effect curves for oxytocin alone (10-11M to 10-5M) and in 
combination with a caspase-3 inhibitor (2x10-5M) and rho-kinase inhibitor (3x10-5M) 
for a) myocytes and b) fibroblasts. Primary cells cultures from myometrial tissue 
taken at term pregnancy (n=4) were incubated with the Ca2+ indicator fluo-4 AM dye 
(2µM) and washed. Cells were exposed to vehicle (DMEM D) or inhibitors and 
oxytocin each for 4 minutes with changes in fluorescence detected using the FLIPR-
Tetra. Data are expressed as arithmetic means ± S.E. and statistical significance was 
determined using two-way ANOVA with Bonferroni’s post-hoc test; **p<0.01 for 
caspase-3 inhibitor compared to vehicle. 
 
 
 
7.15 Effects of rho-kinase compounds on oxytocin signalling 
In primary myometrial cells, oxytocin mobilised intracellular-free Ca2+ in a 
concentration-dependent manner reaching 99.6 ± 2.25 percent fluorescence counts 
between 10-7M and 10-5M (Figure 7.16). To elucidate their contribution on oxytocin-
induced transduction pathways, rho kinase compounds were investigated as described 
by Moore & Lopez Bernal (2003). Challenge with the caspase-3 inhibitor potentiated 
the oxytocin-effect curve by 10.2 and 8.1 percent fluorescence counts in myocytes (F 
(1, 48) = 8.77; p<0.01) and fibroblasts respectively (F (1, 48) = 1.45; ns). Short 
exposure to caspase-3 and rho-kinase inhibitors alone did not influence oxytocin-
induced Ca2+ transients. Despite the 5.7 percent reduction in fluorescence counts in 
myocytes, pre-incubation with both inhibitors for 4 minutes had no large effect on 
oxytocin signalling in either cell type. 
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Figure 7.17: Concentration-effect curves for oxytocin (10-11M to 10-5M) pre-incubated 
with vehicle (DMEM D), indometacin (10-6M) or EDTA (2x10-3M) for 4 minutes. 
Primary cells were cultured from myometrial tissue taken at term pregnancy (n=4). 
After loading with fluo-4 AM dye (2µM), Ca2+ flux was read using the FLIPR and 
calculated as percentage change in fluorescence units over baseline (% FLU). 
Exposure to indometacin and EDTA did not alter oxytocin signalling. 
 
 
 
a) b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.18: a) Concentration-effect curves for oxytocin (10-11M to 10-5M) pre-
incubated with oxytocin (10-6M) for 0, 3, 16 and 24 hours. Primary smooth muscle 
cells were cultured from myometrial tissue excised at term pregnancy (n=4). After 
loading with fluo-4 AM dye (2µM), responses to oxytocin were measured as 
percentage change in fluorescence units over baseline (% FLU) using the FLIPR. 
Results are expressed as arithmetic means ± S.E. and statistical significance was 
determined using multivariate ANOVA with Bonferroni’s post-hoc test; ***p<0.001 
for oxytocin incubated over 3, 16 and 24 hours compared to 0 hours.  
 
b) FLIPR traces showing the decline in Ca2+ transients by oxytocin (10-11M to 10-5M) 
when myocytes were pre-incubated with oxytocin (10-6M) for 3, 16 and 24 hours.  
10-8M
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10-6M
10-5M
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10-11M
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7.16 Pre-incubation with indometacin and EDTA 
Pre-incubation with indometacin, a non-selective COX inhibitor (10-6M) and 
ethylenediaminetetraacetic acid (EDTA), a Ca2+ chelating agent (2x10-3M), for 4 
minutes had no effect on Ca2+ influx within smooth muscle cells (Figure 7.17). 
Challenge with indometacin (pEC50: 8.81 ± 0.25M) and EDTA (pEC50: 9.12 ± 0.15M) 
similarly had no effect on oxytocin, which mobilised Ca2+ in a concentration-
dependent manner (pEC50: 9.07 ± 0.04M; F (2, 72) = 0.49; ns). 
 
7.17 Pre-incubation with oxytocin. 
Oxytocin at 0 hours (vehicle) liberated intracellular-free Ca2+ in a concentration-
dependent manner, reaching 99.3 ± 0.82 percent fluorescence counts above 10-7M 
(pEC50 of 8.83 ± 0.19M; Figure 7.18a). When smooth muscle cells were pre-
incubated with oxytocin (10-6M), oxytocic responses were attenuated in a time-related 
manner (p<0.001). Exposure to oxytocin for 3 hours produced an oxytocin-induced 
sigmoidal curve, which was 23 percent lower and 0.8 log M right shifted compared to 
oxytocin at 0 hours. Whilst challenge with oxytocin for 16 hours diminished oxytocin-
induced Ca2+ transients by nearly 90 percent (pEC50: 6.81 ± 0.37M; F (1, 48) = 1163; 
p<0.001), pre-incubation with oxytocin for 24 hours suppressed Ca2+ influx by a 
further 2.5 fold (pEC50: 3.37 ± 2.81M; F (1, 48) = 1276; p<0.001). This marked 
decline in Ca2+ mobilisation was manifest in the 4-minute traces recorded on the 
FLIPR (Figure 7.18b). 
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Figure 7.19: Concentration-effect curves for oxytocin alone (10-11M to 10-5M) and in 
combination with 17-β oestradiol (E2; 10-6M to 10-8M) and progesterone (P4; 10-6M to 
10-8M) in primary myometrial smooth muscle cells obtained at term pregnancy (n=4). 
Once exposed to vehicle (DMEM D) or steroid hormones for 24 hours, the cells were 
loaded with fluo-4 AM dye (2µM) before intracellular Ca2+ responses to oxytocin 
were measured using the FLIPR. Data are expressed as arithmetic means ± S.E. and 
statistical significance was determined using two-way ANOVA with Bonferroni’s 
post-hoc adjustment; *p<0.05; **p<0.01 respectively for E2 (10-6M & 10-7M) and P4 
(10-6M) compared to vehicle. 
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Figure 7.20: Cell viability for vehicle (DMEM B) and treatments with 17-β oestradiol 
(E2; 10-6M) and progesterone (P4; 10-6M) for 24 hours. Myocytes were cultured from 
myometrial tissue taken at term pregnancy (n=4) and seeded at a density of 30k cells/ 
well. Cytotoxicity was quantified using MTT dye (0.5mg/ml), which was reduced to a 
purple formazan salt by viable cells; this was visualised at a) x4 and b) x25 under a 
phase contrast microscope. Compared to vehicle controls, incubation with the steroids 
did not significantly alter cell proliferation or apoptosis.  
 
 
 
7.18 Steroidogenic effects on oxytocin signalling 
To elucidate the effect of steroid hormones on oxytocin-mediated Ca2+ signalling 
pathways, myocytes were exposed to vehicle or combinations of progesterone and 
17β-oestradiol for 24 hours as described by Backlin et al. (2003). In vehicle-treated 
cells, oxytocin evoked a concentration-dependent Ca2+ flux, which plateaued at 100.7 
± 1.33 percent fluorescence counts with a pEC50 value of 8.61 ± 0.23M (Figure 7.19). 
17-β oestradiol at 10-6M and 10-7M augmented oxytocin-induced Ca2+ transients by 
24 percent (p<0.05), without shifting the curve (pEC50: 8.28 ± 0.29M and pEC50: 8.36 
± 0.24M respectively). Exposure to progesterone (10-6M) attenuated oxytocic 
responses by 28 percent fluorescence counts (p<0.01), but also had no effect on the 
position of the curve (pEC50: 8.86 ± 0.07M). The performed MTT assay indicated that 
this was not associated with cell proliferation, which was uniform irrespective of 
b) x25 
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steroid treatment (Figure 7.20).  The effects of oxytocin on Ca2+ oscillations were 
restored in myocytes pre-incubated with a combination of oestrogen and progesterone. 
 
7.19 The effects of Ca2+-channel blockers on oxytocin 
The mechanisms of oxytocin-induced Ca2+ release were initially assessed using the L-
type Ca2+ channel blocker, nifedipine. To inhibit these cell membrane channels, 
myocytes were pre-treated with vehicle and nifedipine (10-5M to 10-7M) for 4 minutes 
before stimulation with oxytocin (10-11M to 10-5M; Table 7.4). For each 
concentration-effect curve, oxytocin mobilised Ca2+ until a plateau phase was 
sustained between 10-7M and 10-5M. Nifedipine at 10-5M increased oxytocic effects 
from 104.3 ± 2.01 to 122.0 ± 9.02 percent fluorescent counts (p<0.01), without 
shifting the curve. Although exposure to nifedipine at 10-6M and 10-7M also enhanced 
Ca2+ influx, the <9 percent change was not significant compared to vehicle (F (2, 72) 
= 2.60; ns).  
 
The combined effects of thapsigargin, lanthanum chloride (LaCl3) and nifedipine on 
oxytocin-induced responses in myometrial cells were subsequently investigated to 
elucidate localised Ca2+ dynamics. LaCl3 (25µM) and thapsigargin (2µM) were 
chosen due to their respective inhibition of store-operated Ca2+ channels (Fu et al., 
2000) and endoplasmic reticulum Ca2+ pumps (Fomin et al., 1999; Kupittayanant et 
al., 2002; Wray & Shmygol, 2007). As before, uterine myocytes responded to 
oxytocin with a concentration-dependent increase in Ca2+ transients, followed by a 
plateau at 100.5 ± 1.54 percent fluorescent counts (pEC50: 8.66 ± 0.23M; Figures 7.22 
and 7.23). Potent responses to oxytocin were maintained in the presence of LaCl3 
alone and together with nifedipine (pEC50: 8.53 ± 0.28M and 8.81 ± 0.20M 
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respectively). Whilst exposure to nifedipine alone augmented oxytocin-induced Ca2+ 
signalling by 16.5 percent (F (1, 48) = 9.36; p<0.01), thapsigargin attenuated Ca2+ 
transduction mechanisms. The 20 percent decrease in oxytocic effects (F (1, 48) = 
10.39; p<0.01) may relate to the direct mobilisation of intracellular-free Ca2+ by 
thapsigargin (Figure 7.21). Even so, this reduction was potentiated in the presence of 
both nifedipine and LaCl3 (p<0.001). 
 
 
 
Table 7.4 Maximal responses (Em) and effective half maximal concentrations (pEC50) 
(M) for myocytes challenged with nifedipine at 10-5M, 10-6M or 10-7M for 4 minutes 
before stimulation with oxytocin (10-11M to 10-5M) (n=4). Data are expressed as 
arithmetic means ± S.E. and analysed using multivariate ANOVA with Bonferroni’s 
post-hoc test; **p<0.01 for nifedipine (10-5M) compared to vehicle. 
 
 Vehicle Nifedipine (10µM) Nifedipine (1µM) Nifedipine (0.1µM) 
Em 104.3 ± 2.01 122.0  ± 9.02** 113.3 ± 5.11 107.3 ± 5.48 
pEC50 9.3 ± 0.11 9.1 ± 0.14 9.4 ± 0.07 9.3 ± 0.17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.21: Concentration-dependent changes in intracellular-free Ca2+ for myocytes 
challenged with oxytocin (10-11M to 10-5M) for 4 minutes after pre-incubation with 
vehicle (DMEM D), thapsigargin (2x10-6M), lanthanum chloride (LaCl3; 25µM) or 
nifedipine (10µM) for 4 minutes. To detect Ca2+, primary smooth muscle cells from 
term pregnant donors were loaded with the Ca2+ indicator fluo-4 AM dye (2µM) for 
60 minutes and washed. Traces were recorded using the FLIPR-Tetra.  
 
LaCl3 Thapsigargin Vehicle Nifedipine 
 
4 mins 
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Similar trends were observed in fibroblasts (Figures 7.24 and 7.25). The characteristic 
concentration-effect curve evoked by oxytocin reached a plateau at 101.6 ± 0.86 
percent fluorescence counts (pEC50: 8.93 ± 0.12M). Again LaCl3 alone and with 
nifedipine did not alter temporal changes in Ca2+, whilst challenge with nifedipine 
(10-5M) increased oxytocic effects by 18 percent (F (1, 48) = 10.81; p<0.01). 
Responses to thapsigargin and oxytocin were marginally more pronounced in 
fibroblasts compared to myocytes. Thapsigargin alone and in the presence of 
nifedipine decreased oxytocic effects by 13 percent (F (2, 72) = 6.02; p<0.05). 
Conversely, thapsigargin with oxytocin at 10-11M stimulated relatively high Ca2+ 
release, reaching 27.0 ± 6.20 percent fluorescence counts; this created a more linear 
sigmoidal curve. Thapsigargin combined with LaCl3 further suppressed oxytocin-
mediated Ca2+ influx to 70.9 ± 7.72 percent fluorescence counts (p<0.001). In both 
myocytes and fibroblasts, pEC50 values were consistent throughout. 
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Figure 7.22: Concentration-effect curves (left) for oxytocin (10-11M to 10-5M) pre-
incubated with combinations of vehicle (DMEM D), nifedipine (nifed; 10-6M), 
lanthanum chloride (LaCl3; 2.5x10-5M) and thapsigargin (thaps; 2x10-6M). To detect 
Ca2+ flux, primary smooth muscle cells obtained at term pregnancy were loaded with 
Ca2+ fluo-4 AM indicator dye (2µM; n=4). Ca2+ channel blockers and oxytocin were 
each added to cell plates for 4 minutes using the FLIPR-Tetra. Data are expressed as 
arithmetic means ± S.E. and analysed using two-way ANOVA with Bonferroni’s post-
hoc test; *p<0.05; **p<0.01; ***p<0.001 for nifedipine (red), thapsigargin (blue), 
nifed + thaps (green) and LaCl3 + thaps (purple) compared to vehicle. 
 
Figure 7.23: Bar chart (above) showing the effects of nifedipine (nifed; 10-6M), 
lanthanum chloride (LaCl3; 2.5x10-5M) and thapsigargin (thaps; 2x10-6M) on oxytocin 
at 10-6M in human myocytes (n=4). Responses to oxytocin were read using the FLIPR 
and calculated as % change in fluorescence units over baseline (% FLU). Univariate 
ANOVA showed statistical differences; ***p<0.001 compared to oxytocin (black), 
nifed (red), LaCl3 (green) and thaps (blue) alone.   
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Figure 7.24: Concentration-effect curves (left) for oxytocin (10-11M to 10-5M) pre-
incubated with combinations of vehicle (DMEM D), nifedipine (nifed; 10-6M), 
lanthanum chloride (LaCl3; 2.5x10-5M) and thapsigargin (thaps; 2x10-6M). To detect 
Ca2+ flux, primary myometrial fibroblasts obtained at term pregnancy were loaded 
with Ca2+ fluo-4 AM indicator dye (2µM; n=4). Ca2+ channel blockers and oxytocin 
were each added to cell plates for 4 minutes using the FLIPR-Tetra. Data are expressed 
as arithmetic means ± S.E. and analysed using two-way ANOVA with Bonferroni’s 
post-hoc test; *p<0.05; **p<0.01 for nifedipine (red), thapsigargin (blue), nifed + 
thaps (green) and LaCl3 + thaps (purple) compared to vehicle. 
 
Figure 7.25: Bar chart showing the effects of nifedipine (nifed; 10-6M), lanthanum 
chloride (LaCl3; 2.5x10-5M) and thapsigargin (thaps; 2x10-6M) on oxytocin at 10-6M in 
human fibroblasts (n=4). Responses to oxytocin were read using the FLIPR and 
calculated as % change in fluorescence units over baseline (% FLU). Univariate 
ANOVA showed statistical differences; ***p<0.001 compared to oxytocin (black), 
nifed (red) and LaCl3 (green) alone. 
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Figure 7.26: Concentration-effect curves for oxytocin (10-11M to 10-5M) pre-incubated 
with a) vehicle (DMEM D), indometacin (10-6M), EDTA (2x10-3M) and atosiban   
(10-7M); b) vehicle, PGE2 (10-6M), butaprost (10-6M) and PGF2α (10-6M); c) vehicle, 
caspase-3 inhibitor (2x10-5M), rho-kinase inhibitor (3x10-5M) and SQ29,548 (10-6M); 
d) vehicle, nifedipine (10-5M), lanthanum chloride (2.5x10-5M) and thapsigargin 
(2x10-6M) for 24 hours. Primary smooth muscle cells were cultured from myometrial 
tissue excised at term pregnancy (n=4). After loading with fluo-4 AM dye (2µM), 
responses to oxytocin were measured as percentage change in fluorescence units over 
baseline (% FLU) using the FLIPR-Tetra. Results are expressed as arithmetic means ± 
S.E. and statistical significance was determined using multivariate ANOVA with 
Bonferroni’s post-hoc test; ***p<0.001 compared to vehicle. 
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Figure 7.27: Concentration-effect curves for oxytocin (10-11M to 10-5M) pre-incubated 
with a) vehicle (DMEM D), indometacin (10-6M), EDTA (2x10-3M) and atosiban   
(10-7M); b) vehicle, PGE2 (10-6M), butaprost (10-6M) and PGF2α (10-6M); c) vehicle, 
caspase-3 inhibitor (2x10-5M), rho-kinase inhibitor (3x10-5M) and SQ29,548 (10-6M); 
d) vehicle, nifedipine (10-5M), lanthanum chloride (2.5x10-5M) and thapsigargin 
(2x10-6M) for 24 hours. Uterine fibroblasts were cultured from myometrial tissue 
excised at term pregnancy (n=4). After loading with fluo-4 AM dye (2µM), responses 
to oxytocin were measured as percentage change in fluorescence units over baseline 
(% FLU) using the FLIPR-Tetra. Results are expressed as arithmetic means ± S.E. 
and statistical significance was determined using multivariate ANOVA with 
Bonferroni’s post-hoc test; *p<0.05; ***p<0.001 compared to vehicle. 
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7.20 The effects of overnight incubations on oxytocin 
To identify their prolonged effects on the oxytocin cascade PGs, rho-kinase 
compounds and Ca2+ channel blockers were exposed to myometrial cells for 24 hours 
before oxytocin challenge (10-11M to 10-5M). In myocytes, pre-incubation with 
vehicle (DMEM D) did not influence typical oxytocin-stimulated Ca2+ entry, which 
plateaued at 100.6 ± 1.13 above 10-7M (pEC50: 9.0 ± 0.12M; Figure 7.26). The 
transient rise in Ca2+ was consistent in the presence of the COX inhibitor indometacin 
(F (1, 48) = 1.27; ns), the TP antagonist SQ29,548 (F (1, 48) = 0.19; ns) and PG 
agonists PGE2, butaprost and PGF2α (F (3, 96) = 0.51; ns).  
Overnight pre-incubation with the oxytocin antagonist atosiban (10-5M) also did not 
alter Ca2+ signals (F (1, 48) = 3.88; ns); this was in contrast to the results for short-
term atosiban treatments (Figures 7.13 & 7.15; Table 7.1). In the presence of the Ca2+ 
chelator EDTA (2x10-3M), the concentration-response curve for oxytocin was 
displaced 1.33 log M rightward, accompanied by a 57 percent reduction in peak Ca2+ 
release (F (1, 48) = 758.7; p<0.001). Likewise, 24-hour incubation with rho-kinase 
but not caspase-3 inhibitors attenuated oxytocin-induced Ca2+ transients. Although 
Ca2+ mobilisation plateaued at 69.2 ± 2.94 fluorescence counts (F (1, 48) = 169.6; 
p<0.001), the oxytocin-effect curve was not shifted to the right (pEC50: 8.98 ± 
0.15M). Myocytes challenged overnight with nifedipine (10-5M; L-type) and 
lanthanum chloride (2.5 x 10-5M; store-operated) Ca2+ channel blockers did not 
modify the profile of oxytocin. Even so, 24-hour exposure to thapsigargin (2x10-6M), 
an inhibitor of endoplasmic reticulum Ca2+-ATPase, completely prevented oxytocin-
induced cytosolic Ca2+ influx (p<0.001).  
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In fibroblasts, oxytocin similarly mobilised intracellular-free Ca2+ in a concentration-
dependent manner, reaching a sustained plateau at 101.4 ± 0.32 fluorescence counts 
(pEC50: 8.9 ± 0.08M; Figure 7.27). No changes in integrated Ca2+ elevation were 
evoked by 24-hour pre-incubation with indometacin (F (1, 48) = 3.31; ns), SQ29,548 
(F (1, 48) = 3.89; ns), PGE2, butaprost or PGF2α (F (3, 96) = 1.78; ns). The sigmoidal 
uterotonic action of oxytocin was also unchanged after overnight exposure to atosiban 
(10-5M; F (1, 48) = 1.69; ns), the caspase-3 inhibitor (F (1, 48) = 0.047; ns) and Ca2+ 
channel blockers nifedipine and lanthanum chloride (F (2, 72) = 0.69; ns). Unlike in 
myocytes, external Ca2+ sequestered by EDTA (2x10-3M) suppressed oxytocin-
induced Ca2+ transients by 28 percent (F (1, 48) = 80.27; p<0.001), without shifting 
the curve (pEC50: 8.92 ± 0.17). Even so, pre-treatment with the rho-kinase inhibitor 
had a more pronounced effect, decreasing peak fluorescence counts to 59.1 ± 3.14 
percent (F (1, 48) = 404.0; p<0.001). Again challenge with thapsigargin for 24 hours 
totally blocked the stimulatory effect of oxytocin on Ca2+ channel activity. 
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Chapter 7.21: Results - cyclic AMP 
 
 
 
7.22 Agonist-induced cAMP formation in myocytes  
Agonist activation of cAMP was quantified to elucidate alternative intracellular 
signalling pathways (Figure 7.28). In smooth muscle cells, 30-minute oxytocin 
treatments produced a moderate monophasic increase in relative luminescence units 
from 3099 ± 858 to 6877 ± 909, which was not significant compared to vehicle (F (1, 
48) = 3.26; ns). Butaprost conversely augmented cAMP formation by 18-fold in a 
concentration-dependent manner (F (1, 48) = 451; p<0.001). When pre-incubated at 
10-6M, butaprost also enhanced oxytocin-mediated cAMP mobilisation by nearly 100 
percent (F (1, 48) = 23.11; p<0.001; pEC50: 6.66 ± 0.11M). This concentration-related 
increase in liberated cAMP was analogous to the curve evoked by U46619 (F (1, 48) 
= 25.46; p<0.001; pEC50: 6.54 ± 0.26M). Even so, in myocytes treated with PGE2, 
cAMP signalling substantially increased 22-fold (F (1, 48) = 1148; p<0.001) and 20-
fold (F (1, 48) = 692.3; p<0.001) above basal cAMP respectively. 
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Figure 7.28: Myocyte cAMP flux for vehicle (DMEM D) and concentration-effect 
curves (10-11M to 10-5M) for a) butaprost, oxytocin and oxytocin together with 
butaprost (buta; 10-6M) and b) PGE2 and U46619. Primary smooth muscle cells were 
cultured from myometrium harvested at term pregnancy (n=4) and agonist treatments 
were pre-incubated for 30 minutes. Free cAMP was measured using a competitive-
based immunoassay with cell-response signals, relative luminescence units (RLU), 
directly proportional to the presence of intracellular cAMP. Results are expressed as 
arithmetic means ± S.E. and analysed using two-way ANOVA with Bonferroni’s 
post-hoc test; *p<0.05; **p<0.01, ***p<0.001 for a butaprost, b buta + oxytocin,          
c PGE2 and e U46619 compared to vehicle.  
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Chapter 7.23: Results - RT-PCR 
 
 
 
7.24 PG, oxytocin and rho-related mRNA expression in uterine myocytes 
Qualitative mRNA expression for PGs, oxytocin receptors and target proteins in Ca2+ 
sensitisation was determined using RT-PCR in uterine myocytes harvested at term 
pregnancy. As well as their relative contribution in signal transduction pathways, the 
effects of vehicle (DMEM D), PG and oxytocin treatments were assessed. Only high 
quality, intact RNA was assayed, as shown by the clear 28S and 18S ribosomal RNA 
bands imaged before RT-PCR (Figure 6.6). In each PCR reaction, the absence of 
product in control RNA samples confirmed that no genomic DNA contamination had 
occurred (Figures 7.30 & 7.32). 
 
Myocyte mRNA was normalised as a percentage of the housekeeping gene β-actin, 
which was highly expressed at 377bp. All primer sets yielded RT-PCR products of the 
expected sizes (Table 6.21; Figures 7.30 & 7.32). DP and MLCK were the only 
amplified transcripts showing marked multiple bands; this indicated poor primer 
design. Of the EP isoforms, EP2 receptor expression was most abundant at 40 ± 2.12 
percent of β-actin (p<0.001; Figure 7.29). Although the density of EP1 mRNA was 
2.4-fold lower (p<0.001), only negligible compliments of EP3 and EP4 receptors could 
be detected. At 107.9 ± 2.58 percent β-actin, the expression of FP mRNA was 
considerably higher than the EP subset and other PGs (p<0.001). Despite greater 
effects on Ca2+ transients, oxytocin receptors were half as abundant as FP receptor 
transcripts. Even lower was the expression of DP and TP mRNA, followed by IP 
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receptors at 15.6 ± 1.31 percent of β-actin (p<0.001). The chemoattractant receptor 
homologous molecule (CRTH2) was used as a negative control due to its expression 
only on T helper cells (Hirai et al., 2001). Therefore, CRTH2 was absent from the 
purified PCR products. 
 
To address rho-related pathways that regulate uterine sensitisation, the relative 
expression of smooth muscle specific proteins were also investigated (Figures 7.31 & 
7.32). Although the structure of telokin is identical to the C-terminus of MLCK, its 
expression was most abundant at 92.2 ± 1.42 percent β-actin. The density of RhoA 
and ROCKI bands were only 6.8 percent (p<0.05) and 11.5 percent (p<0.001) lower 
respectively. Inositol trisphosphate receptors (IP3R), which mediate Ca2+ release into 
the cytosol, were still abundant at 66.7 ± 1.69 percent β-actin and ROCKII isoforms 
were two-thirds lower at 22.6 ± 1.85 percent β-actin (p<0.001). Surprisingly, the 
detection of MLCK mRNA was only very faint. 
 
7.25 Effects of PG and oxytocin compounds on mRNA transcription 
As well as the above vehicle (DMEM D) treatments, myocytes were exposed to 
U46619 (10-6M), SQ29,548 (10-6M) and the oxytocin antagonist atosiban (10-6M) for 
24 hours. Due to the rapid desensitisation of receptors (Phaneuf et al., 1998; Plested & 
Lopez Bernal, 2001), oxytocin (10-6M) was only incubated with cells for 3 hours. The 
expression of PG, oxytocin and rho-related mRNA was consistent regardless of 
uterotonin or antagonist challenge (Tables 7.5 & 7.6). As a result, post-receptor 
transcriptional events appeared to be unchanged. 
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Figure 7.29: Relative expression of β-actin, EP1-4, CRTH2, DP, FP, IP, TP and oxytocin 
receptor (OTR) mRNA detected in human myocytes taken at term pregnancy (n=5). The 
density of each mRNA band was quantified using Fluor-Chem IS-8000 programme and 
normalised as a percentage of β-actin. Results are expressed as arithmetic means ± S.E. 
and analysed using univariate ANOVA with Bonferroni’s post-hoc test: ***p<0.001 for 
a EP1 and b EP2 compared to the other EP receptors and for PG mRNA compared to c the 
other PG receptors and to d DP alone.  
 
 
Figure 7.30: Representative agarose gel stained with ethidium bromide and 
photographed showing relative β-actin, PGs and oxytocin receptor (OTR) mRNA 
expression in human uterine myocytes taken at term pregnancy. PCR products were 
absent from the reverse transcriptase negative control lane and β-actin was used as a 
loading control. A 1Kb plus DNA ladder was run alongside for molecular weight sizing. 
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Figure 7.31: Relative expression of β-actin, RhoA protein, ROCKI, ROCKII, MLCK, 
IP3 receptors and telokin mRNA detected in human myocytes taken at term pregnancy 
(n=5). The density of each mRNA band was quantified using Fluor-Chem IS-8000 
programme and normalised as a percentage of β-actin. Results are expressed as 
arithmetic means ± S.E. and analysed using univariate ANOVA with Bonferroni’s 
post-hoc test: *p<0.05; ***p<0.001 compared to a RhoA and b all other mRNA 
transcripts, excluding β-actin.  
 
 
 
 
 
 
 
 
 
 
 
Figure 7.32: Representative agarose gel stained with ethidium bromide and 
photographed showing relative β-actin, RhoA, ROCKI, ROCKII, MLCK, IP3 
receptors and telokin mRNA expression in human uterine myocytes taken at term 
pregnancy. PCR products were absent from the reverse transcriptase negative control 
lane and β-actin was used as a loading control. A 1Kb plus DNA ladder was run 
alongside for molecular weight sizing. 
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Table 7.5: The effects of vehicle (DMEM D), oxytocin (10-6M), atosiban (10-6M), U46619 (10-6M) and SQ29,548 (10-6M) on PG and oxytocin 
mRNA receptor expression in smooth muscle cells cultured from myometrium at term pregnancy (n=5). Except for 3-hour oxytocin treatments, 
cells were incubated with agonists and antagonists for 24 hours. The density of mRNA transcripts were analysed with Fluor Chem IS-8000 and 
expressed as a percentage of β-actin ± S.E. Compared to vehicle, mRNA expression did not significantly change. 
 
mRNA Vehicle Oxytocin Atosiban Atosiban + OT U46619 SQ29,548 SQ + U19 
EP1 14.7 ± 2.84 14.2 ± 2.80 14.8 ± 3.02 13.2 ± 3.12 19.6 ± 4.12 18.0 ± 4.81 19.3 ± 2.58 
EP2 36.2 ± 6.88 42.3 ± 4.43 37.0 ± 5.30 41.5 ± 3.79 33.5 ±11.04 43.3 ± 5.41 44.0 ± 5.77 
EP3 4.0 ± 2.05 4.73 ± 2.42 4.7 ± 2.06 5.0 ± 2.41 5.3 ± 2.42 5.3 ± 2.03 5.4 ± 2.43 
EP4 1.6 ± 0.54 1.7 ± 0.74 2.1 ± 0.38 1.8 ±0.31 1.8 ± 0.81 1.5 ± 0.57 1.4 ± 0.67 
DP 31.7 ± 4.8 32.3 ± 4.11 32.4 ± 4.69 29.9 ± 6.80 32.2 ± 7.91 31.9 ± 3.47 38.1 ± 6.35 
FP 107.2 ± 9.26 106.0 ± 5.35 115.0 ± 11.87 104.6 ± 8.99 107.7 ± 7.17 106.6 ± 5.64 108.3 ± 6.43 
IP 11.5 ± 2.28 10.6 ± 1.84 13.8 ± 3.49 15.34 ± 3.59 15.9 ± 5.27 16.8 ± 3.09 18.9 ± 3.54 
TP 23.6 ± 8.24 25.6 ± 6.21 28.9 ± 6.10 31.2 ± 10.01 30.5 ± 10.20 35.2 ± 5.77 35.3 ± 7.17 
OT 53.2 ± 4.77 53.2 ± 5.56 49.7 ± 8.52 52.1 ± 4.66 50.5 ± 11.40 58.8 ± 2.96 60.1 ± 3.22 
 
 
Table 7.6: The effects of vehicle (DMEM D), oxytocin (10-6M), atosiban (10-6M), U46619 (10-6M) and SQ29,548 (10-6M) on rho-related mRNA 
expression in smooth muscle cells cultured from myometrium at term pregnancy (n=5). Except for 3-hour oxytocin treatments, cells were 
incubated with agonists and antagonists for 24 hours. The density of mRNA transcripts were analysed with Fluor Chem IS-8000 and expressed 
as a percentage of β-actin ± S.E. Compared to vehicle, mRNA expression did not significantly change. 
 
mRNA Vehicle Oxytocin Atosiban Atosiban + OT  U46619 SQ29,548 SQ + U19 
RhoA 85.2 ± 6.04 81.9 ± 7.18 85.9 ± 4.99 87.8 ± 3.44 83.9 ± 3.61 84.4 ± 4.52 89.9 ± 4.64 
ROCK I 78.5 ± 5.61 74.0 ± 4.53 81.6 ± 6.49 84.6 ± 1.97 79.8 ±3.71 78.0 ± 4.87 89.6 ± 2.98 
ROCK II 21.6 ± 3.19 27.4 ± 2.79 17.9 ± 4.17 18.1 ± 4.22 20.7 ± 4.82 19.6 ± 3.57 20.3 ± 5.60 
MLCK 2.1 ± 0.67 1.8 ± 0.43 2.0 ± 0.41 1.7 ± 0.19 2.11 ± 0.46 2.9 ± 0.56 2.9 ± 0.60 
IP3 61.2 ± 4.38 69.8 ± 3.66 62.3 ± 4.77 65.7 ± 2.84 65.4 ± 5.44 67.6 ± 5.12 72.75 ± 3.21 
Telokin 93.3 ± 3.90 90.3 ± 4.58 89.5 ± 4.99 92.0 ± 3.85 91.6 ± 2.97 89.8 ± 5.17 95.3 ± 2.69 
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 Chapter 7.26: Discussion 
 
 
In this study, smooth muscle cells and fibroblasts were isolated from human 
myometrial biopsies taken at term pregnancy. Although myocytes occupy most of the 
tissue volume, functional coupling with fibroblastic cells propagate electrotonic 
signals, contributing to the mechanical syncytium required for labour contractions 
(Lopez Bernal et al., 1993; Koumas et al., 2003; MacCannell et al., 2007). Myogenic 
activity is mediated through the ATP-dependent binding of myosin to actin, which is 
augmented by PG and oxytocin in the absence of autonomic innervation (Wray, 
1993). The associated liberation of intracellular-free Ca2+ was induced by uterotonins 
in this study; however, oxytocic effects were most pronounced. In spite of the noted 
similarities between myometrial cell populations, subtle distinctions in their 
morphologies and signalling mechanisms may be of physiological importance in 
preparing the uterus for pregnancy and labour. 
Myometrial cells are composed of intracellular filamentous systems that govern 
structural integrity and contraction. In the uterus, myometrial smooth muscle cells are 
arranged in bundles embedded in a matrix of connective tissue that enhance the 
transmission of contractile forces (Yu & Lopez Bernal, 1998) without directly altering 
Ca2+ flux (Shaw et al., 2006). In this study, uterine cryotome sections and cultured 
myometrial cells were similarly arranged in parallel arrays. This myofilament lattice, 
interspersed with focal adhesion dense plaques, was identified to envelop a centrally 
located nucleus by phase contrast microscopy. In isolated cells, immunocytochemistry 
was subsequently performed to characterise the distribution and intrinsic activity of 
myocyte and fibroblast populations in term gravid human myometrium. 
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Superficially, monolayer cultures of myometrial smooth muscle cells and fibroblasts 
exhibited similar morphologies. Although each cell type was fusiform in shape, 
myometrial fibroblasts were larger flattened cells with many processes that extended 
from the periphery. Due to their abundance in motile cells, these lamellipodia 
protrusions have been associated with cell survival, migration and aggregation to 
mediate tissue remodelling of the myometrium and pubic symphysis during 
pregnancy and delivery (Moraes et al., 2004). These ultrastructural features may also 
account for the faster attachment of fibroblast cells compared to myocytes, which 
constituted the basis of the adhesion separation technique. As the actin polymer 
constituents also have an integral role in traction and force generation, staining for 
smooth muscle specific α-actin was employed.  
Of the six different isoforms, α-actin and γ-actin are the major constituents of 
myometrial smooth muscle cells (Shynlova et al., 2005). In the uterus, these thin 
filaments have directly been shown to activate myosin-ATPase activity in a Ca2+- 
dependent manner for the development of tension (Borovikov et al., 1996). By 
binding with cross-linking proteins, such as α-actinin, filamentous actin forms 
complex architectures that enhance the mechanical response (Tseng et al., 2005). In 
both myometrial cell types, double immunofluorescent images showed strong co-
localisation of α-actin and α-actinin markers. Although expression of these proteins 
appeared consistent in this study, a greater abundance of actin filaments has 
previously been indicated in myocytes compared to myometrial fibroblasts taken from 
non-pregnant women (Casey et al., 1984). In contrast to the increase in γ-actin 
polymers, the expression of α-actin has been reported to decline (Skalli et al., 1987) 
or remain high (Shynlova et al., 2005) with the progression of pregnancy. Mechanical 
stretch is thought to contribute to this switch from α-actin to the γ isoform in smooth 
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muscle cells at late gestation due to enrichment in stress fibres and focal adhesion 
sites (Katoh et al., 2001; Wang et al., 2006). This may account for the similarities in 
myocyte and fibroblast structural phenotypes in the term gravid uterus. 
To identify further the cytoskeletal assembly, specific antibodies against desmin and 
vimentin were employed. These intermediate filaments displayed prominent 
networks, associated with providing mechanical integrity for myometrial cells (Leoni 
et al., 1990; Hongpaisan, 2000; Tang, 2008). In this study, filamentous vimentin was 
distributed throughout the cytoplasm, whereas desmin was located at the dense bodies 
of each cell. Spatial reorganisation and co-localisation of these filaments with the type 
IV protein synemin have been shown to regulate cell shape and alignment of 
myofibrils by linking intercellular apparatus (Gimona, 2008). This appears to 
facilitate mechanical transduction in smooth muscle tissues, contributing to mitosis 
and force development (Wang et al., 2006). In myometrial cells at term pregnancy, 
the upregulation of desmin content (Leoni et al., 1990) and genes encoding for 
intermediate filament-associated proteins have been related to the hypertrophic shape 
change and preparation of the cell architecture for labouring contractions (Salomonis 
et al., 2005; Shynlova et al., 2010). The positive immunostaining for both 
intermediate filaments in this study was therefore indicative of a smooth muscle 
contractile phenotype for both myocytes and fibroblasts.  
Distinguishing features of myometrial cell types were evaluated further using a 
monoclonal antibody against fibroblast surface protein. Immunocytochemistry 
showed dispersed fine staining of the cell surface, with slightly stronger granular 
staining over the perinuclear region. This was in accord with the ultrastructural pattern 
of antigen immunoreactivity detected on the cell surface of human fibroblasts 
(Ronnov-Jessen et al., 1992), tissue macrophages and peripheral monocytes (Singer et 
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al., 1989). Despite its reported lack of expression in vascular smooth muscle cells 
(Ronnov-Jessen et al., 1992), all myometrial cells stained positive for the fibroblast-
associated antigen in this study. With fibroblasts and endothelial cells comprising an 
estimated 5 to 10 percent of myometrial cell types in a digestion (Hongpaisan, 2000; 
Duquette et al., 2005), it is likely that the surface protein was present on smooth 
muscle cells as well as fibroblasts. This suggests that an alternative cytoskeletal 
marker would be required for the absolute identification of cell subsets. However, 
lineage-specific monoclonal antibodies were limited and even several smooth muscle-
associated antigens, including smoothelin, calponin, h-caldesmon and vinculin were 
positively expressed in some fibroblastic cells (Esterre et al., 1992; Lazard et al., 
1993; Hasegawa et al., 2003; D’Addario et al., 2002). Despite the concerted smooth 
muscle phenotype, cultured flasks appeared to contain enriched cell populations. This 
was based on differences in their morphology and the faster proliferation rate of 
fibroblasts compared with myocytes (Casey et al., 1984; Phaneuf et al., 1993; 
Hongpaisan, 2000; Rouger et al., 2007). To characterise separate contractile functions 
of these cells, PG and oxytocin-induced post-receptor signalling cascades were next 
assessed. 
PG and oxytocin agonists are known to modulate spontaneous uterine activity via 
functional excitation-contraction coupling between myometrial cells. The 
transmission of action potentials is reported to originate from myometrial Cajal-like 
interstitial cells, which are responsible for the endogenous pacemaker system (Ciontea 
et al., 2005; Young, 2007; Allix et al., 2008). Although undetected in primary cell 
cultures in this study, the Cajal-like interstitial cells are dependent on Ca2+ signalling 
cascades for generating the coordinated activity of ion channel pumps and exchanges 
throughout uterine muscle (Berridge, 2008). To induce phasic myometrial 
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contractions, Ca2+ in combination with calmodulin activates myosin light chain kinase 
(MLCK). This enzyme phosphorylates 20kDa myosin light chains (MLC20), 
enhancing both adenosine trisphosphatase (ATPase) activity and cross-bridge 
formation between the myosin head and actin filament (Word et al., 1994; Sanborn, 
2001). This activation only occurs when cytosolic Ca2+ reaches the threshold above 
resting potential for regenerative membrane depolarisation. Perturbations of this 
pathway are likely to cause untimely parturition (Word et al., 1994; Riley et al., 2005) 
and so the effects of PGs and oxytocin on Ca2+ release were tested using the FLIPR-
Tetra system. 
Cell loading with the Ca2+-sensitive fluo-4 AM dye indicated concentration-dependent 
stimulation of Ca2+ transients by PG and oxytocin agonists. Even so, low amplitude 
PG-induced responses were at the limits of detection, whilst oxytocic effects were 
marked in this study. Oxytocin, EP1, EP3, FP and TP receptors activate phospholipase 
C (PLC) β1, β2 or β3 through large heterotrimeric G-proteins (Phaneuf et al., 1996; 
Sanborn et al., 1998). Due to the induction of β1 and β2 isoforms during pregnancy, 
PLC efficiently hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP2) to release IP3 
and diacylglycerol (DAG) (Somlyo et al., 1999; Hurd et al., 2000). In myometrial 
tissue, IP3 binding to its cognate receptors on the endoplasmic reticulum liberates 
stored Ca2+ into the cytosol; this is vital for sustained uterotonic contractile activity at 
term (Yamada et al., 1994; Sanborn, 2001). By contrast, DAG activates protein kinase 
C (PKC) leading to the phosphorylation of cellular proteins. A direct correlation 
between intracellular Ca2+ transients, MLC20 phosphorylation and temporal force 
development has been shown in mouse (Matthew et al., 2004) and human myometrial 
tissues (MacKenzie et al., 1990; Word et al., 1990; Woodcock et al., 2004; Jie et al., 
2007). Therefore, based on the ability of PGs to modulate contractions (Chapter 4), 
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induce abortion during pregnancy as well as parturition and to treat postpartum 
haemorrhage, the minor Ca2+ flux detected using the FLIPR-Tetra was surprising.  
In primary cultures of human myometrial cells, PGE2 was shown to elevate cytosolic 
Ca2+ with peak depolarisation only 1.5-fold (Thornton et al., 1992) and 4-fold (Asboth 
et al., 1996) lower than oxytocin. The respective addition of PGE2 at 140µM and 
20µM relative to the 10µM stimulation of cells in this study may account for some of 
the discrepancies between results. In particular, chronic exposure to PGE2 is more 
likely to evoke biochemical changes rather than act through EP receptor sites. The 
effect of PGE2 may also be attributed to cross-reaction with the FP receptor (Kiriyama 
et al., 1997; Breyer et al., 2001), especially with PGF2α evoking large Ca2+ 
oscillations in primary human myocytes (Phaneuf et al., 1993; Fu et al., 2000). The 
expression of FP receptors was particularly abundant in myometrial cells compared to 
TP receptors in this study. Moreover, PGF2α was reported to be equipotent with 
oxytocin using a myometrial cell line (Molnar & Hertelendy, 1990), whilst U46619 
produced either a marginal Ca2+ release (Himpens & Somlyo, 1988) or analogous 
Ca2+ transients to PGE2 (Asboth et al., 1996; Moore et al., 2002). Whilst the trend in 
results was similar, it appeared that use of fura-2 tetraoxymethylester loaded cells 
with an epifluorescence microscope was more sensitive than the FLIPR-Tetra system 
for Ca2+ flux detection. However, due to its potent uterotonic effects, Ca2+ signalling 
pathways for oxytocin were further investigated.  
Despite the clinical significance of oxytocin as a pharmaceutical agent for augmenting 
uterine contractions during dysfunctional labour, its role in parturition is 
controversial. For myometrial depolarisation to occur, challenge with oxytocin has 
been shown to elevate inward Ca2+ and sodium (Na+) flux, in exchange for the 
outward flow of potassium (K+) and chloride (Cl-) ions (Thornton et al., 1992; 
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Rezapour et al., 1996; Shmigol et al., 2001). This change in ionic gradient produces 
an initial transient followed by slower repolarisation essential for effective excitation-
contraction coupling (Thornton et al., 1992). In human myometrium, whilst the 
resting membrane potential is generally between -45 and -50mV (Inoue et al., 1990), 
the threshold for activation becomes lower at term pregnancy (Sanborn, 2001). These 
action potentials are driven through large conductance Ca2+ channels and are 
potentiated by reduced sensitisation of prevalent voltage-dependent K+ channels (Szal 
et al., 1994; Korovkina et al., 2006).  
In this study, oxytocin mobilised intracellular Ca2+ in a concentration-dependent 
manner. This was almost 2-fold higher in uterine myocytes compared to fibroblasts, 
suggesting that cultures of enriched cell populations were isolated in this study. The 
results were substantiated by the higher incidence of typical oxytocin-generated Ca2+ 
transients (Hongpaisan, 2000) and electrotonic coupling (MacCannell et al., 2007) in 
myocyte cultures, compared to cultures contaminated with fibroblasts. As fibroblasts 
are the main effector cells in the cervix (Montes et al., 2002), such changes in action 
potential waveform could promote uterine contractions without modulating the cervix. 
The larger Ca2+ flux within smooth muscle cells may also relate to their extensively 
developed sarcoplasmic reticulum for enhanced Ca2+ storage (Sanborn, 2001) and 
high-density functional oxytocin receptors (Fuchs et al., 1984). 
For uterine contractions to proceed efficiently at term it is likely that Ca2+ signals are 
regulated by oxytocin in conjunction with other autacoids and hormones. Through 
DAG stimulation of PKC, oxytocin has been shown to activate the mitogen-activated 
protein kinase (MAPK) cascade promoting PG biosynthesis in human myometrial 
(Hoare et al., 1999; Molnar et al., 1999) and decidual cells (Fuchs et al., 1984; 
Asselin et al., 1997). The uterotonic action of these PGs may increase the 
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concentration of oxytocin receptors (Melin, 1993) and initiate crosstalk between 
pathways for positive or negative feedback loops, which could impact Ca2+ 
homeostasis (Sanborn, 2007). In particular, it is thought that heightened myometrial 
responsiveness to circulatory oxytocin and locally produced PGs may promote 
parturition (Molnar et al., 1999; Lopez Bernal & TambyRaja, 2000). As a result, 
possible cumulative effects of PGs on oxytocin-induced Ca2+ signalling were assessed 
in this study.  
Upon ligand binding, oxytocin interacts with two G-proteins of the Gαi and Gαq/11 
subfamily, determined according to pertussis toxin (PT) sensitivity (Phaneuf et al., 
1993; Phaneuf et al., 1996; Sanborn et al., 1998). Although PGF2α also operates 
through a PT-resistant pathway (Gαq), unlike oxytocin, a non-selective protein kinase 
inhibitor has been shown to partly inhibit PGF2α induced IP3 formation (Phaneuf et 
al., 1996). This suggests that PGF2α may also activate an alternative G-protein 
pathway via Gα13 (Cao et al., 2005), phospholipase A2 (Hertelendy & Molnar, 1995) 
or stimulate PLC-γ through the phosphorylation of tyrosine kinase receptors (Carrasco 
et al., 1996). Similarly, TPα and TPβ coupling proteins include Gαq/11, Gα12/13 and 
Gαi subunits and so signal via alternative transduction mechanisms (Vezza et al., 
1999; Moore et al., 2002). Despite these different routes of activating Ca2+ entry, 
short or 24-hour incubation of cells with combinations of PGF2α and U46619 did not 
amplify oxytocic Ca2+ signals. This lack of synergism may be attributed to the paucity 
of large PG-induced Ca2+ oscillations detected by the FLIPR-Tetra in this study.  
Likewise, oxytocin-evoked Ca2+ fluxes were not altered by the presence of PGE2 or 
the COX-inhibitor indometacin. In myometrial cell cultures, PGE2 was shown to 
elevate Ca2+ entry via voltage-sensitive membrane channels, without release from 
intracellular Ca2+ stores (Molnar & Hertelendy, 1990; Thornton et al., 1992). This 
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suggests that PGE2 binds to high affinity EP1 receptors coupled to Gαi without PLC 
activation (Thornton et al., 1992). Even so, the use of pharmacological analogues has 
since shown predominant Ca2+ signalling via the low affinity EP3 receptors coupled to 
Gαq and the PLC inositol messenger system (Asboth et al., 1996). Surprisingly in this 
study, addition of the EP3 antagonist AGN211329 immediately evoked Ca2+ transients 
in smooth muscle cells and fibroblasts. This indicates partial agonist activity, perhaps 
at FP receptor sites which stimulate the IP3-Ca2+ cascade. In contrast, PGE2 and EP2 
receptor agonists activate the cyclase adenylyl cascade, inhibiting Ca2+ transport 
through intracellular and extracellular membrane channels (Sanborn, 2001; Sanborn et 
al., 2005; Yuan & Lopez Bernal, 2007). Nevertheless, as the complex downstream 
events of cAMP also involve phosphorylation of MLCK (Word, 1995) and PLC target 
proteins (Sanborn et al., 2005), PGE2 and EP compounds did not appear to modulate 
oxytocic effects on Ca2+ influx in this study.  
Although the local paracrine effects of oxytocin are unclear, the uterus is sensitised to 
oxytocin mid-cycle (Janicek et al., 2007) and just before labour-onset (Keelan et al., 
1997). This correlates with the density of myometrial oxytocin receptors and their 
relative contractile effects (Richter et al., 2006; Janicek et al., 2007). In this study 
(Figures A8 & A9), responsiveness to oxytocin was potentiated in lower, but not 
fundal regions of non-gravid myometrium obtained during the follicular phase. This 
corresponds to the enhanced topographical distribution of oxytocin receptors towards 
the cervix around ovulation (Richter et al., 2004; Steinwall et al., 2004), perhaps 
facilitating retrograde sperm transport at this time of the menstrual cycle. Despite the 
reported low or negligible expression of myometrial oxytocin mRNA (Kimura et al., 
1996; Fuchs et al., 1998; Helmer et al., 1998; Steinwall et al., 2004; Wing et al., 
2006), uterotonic activation was notable in this study. Such responsiveness indicates 
 Chapter Seven: Myometrial cells 
  
  
  Page 232
the potential involvement of oxytocin in the pathogenesis of primary dysmenorrhoea 
(Liedman et al., 2008) or preterm labour (Phaneuf et al., 2000).  
Compared to the non-gravid condition, uterine sensitivity to oxytocin is enhanced at 
term pregnancy by an increase in oxytocin binding to its cognate cell surface 
membrane receptors (Fuchs et al., 1984). Similarly high expression of oxytocin 
receptor mRNA was detected in this study. The potent spasmogenic responses were 
observed in vitro as concentration-dependent phasic activity with superimposed tonic 
contractions. Whilst the mRNA expression is reported to be 10 to 100-fold higher at 
late gestation (Fuchs et al., 1984; Kimura et al., 1996; Riemer & Heymann, 1998; 
Terzidou et al., 2005), oxytocin receptors were 300-fold higher in the parturient uterus 
compared to myometrium in the non-gravid state (Kimura et al., 1996). Even so, other 
studies have shown a lack of change in mRNA expression with labour-onset 
(Charpigny et al., 2003; Havelock et al., 2005; Tattersall et al., 2008). This suggests 
that the increase in oxytocin receptor sensitivity may be of greater importance in 
activating parturition alongside its role in preventing postpartum haemorrhage and 
establishing lactation (Kimura et al., 1996; Zeeman et al., 1997; Tattersall et al., 
2008; Turton et al., 2009).  
To block specific receptor binding activity, the oxytocin antagonist atosiban was 
incubated with myocytes and fibroblasts. Atosiban is a synthetic derivative of 
oxytocin and possesses equal affinity for oxytocin and vasopressin V1a receptors 
(Nilsson et al., 2003). In contrast to oxytocin, circulatory arginine vasopressin and the 
expression of myometrial V1a receptors remain constant during late pregnancy and 
labour (Maggi et al., 1990; Helmer et al., 1998). Thereby, oxytocin rather than V1a 
receptors more likely represents a therapeutic target for parturition. 
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In smooth muscle cells and fibroblasts, atosiban caused parallel rightward shifts of the 
oxytocin effect curves in a competitive and concentration-dependent manner. This 
corresponds to reports that atosiban attenuates oxytocin-stimulated IP3 production and 
intracellular-free Ca2+ release with pEC50 values of 4.7 and 6.8 (Fuchs et al., 1984; 
Phaneuf et al., 1994). In this study, the pA2 for atosiban was 7.6 in both myocytes and 
fibroblasts. Likewise, atosiban reduces the amplitude and frequency of myometrial 
contractions in vitro with pA2 values of 7.6, 7.8 and 5.9 for immersed (Wilson et al., 
2001; Pierzynski et al., 2004) and superfused myometrial strips (Duckworth et al., 
2002). The enhanced inhibitory effect of atosiban may reflect its relative equilibration 
in the immersion rather than superfusion apparatus. Atosiban alone was also shown to 
reduce basal myogenic contractions, without partial agonism, indicating high 
functional activity of constitutive oxytocin receptors (Buscher et al., 2001; Wilson et 
al., 2001; Duckworth et al., 2002). Nevertheless, exposure to atosiban or vehicle for 
24 hours, followed by drug removal from the cell plates, did not influence cell 
responsiveness to oxytocin in this study. This confirmed a lack of intrinsic activity on 
Ca2+ channels and oxytocin transduction pathways as well as the competitive 
antagonistic properties of atosiban. 
With the promising reduction of uterine contractility in clinical trials (Akerlund et al., 
1987), atosiban was registered in 2002 on the indication of delaying imminent preterm 
birth. Even so, the efficacy and beneficial use of atosiban as a tocolytic agent is 
controversial. Early reports showed that intravenous infusions of atosiban were at 
least as effective as β-agonists in prolonging pregnancy with few maternal side effects 
(Goodwin et al., 1996; Coomarasamy et al., 2002). However, systematic literature 
reviews have since determined that atosiban and the more selective oxytocin 
antagonist barusiban were no better than placebo in delaying parturition or improving 
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neonatal outcome (Papatsonis et al., 2009; Thornton et al., 2009). This paucity of in 
vivo effect may be attributed to oxytocin receptor changes in the physiology or 
pathophysiology of the parturient uterus.  
It is acknowledged that myometrial oxytocin receptors lose hormonal responsiveness 
with repeated or prolonged oxytocin treatments (Phaneuf et al. 1994; Brenninkmeijer 
et al., 1999; Plested & Lopez Bernal, 2001). This homologous desensitisation was 
confirmed by a decline in oxytocin-induced Ca2+ transients in myocytes following 
continuous exposure to oxytocin. Although the mechanisms are unclear, the three 
intracellular loops and C-terminal tail of the oxytocin receptor are rich in putative 
phosphorylation sites for G-protein coupled receptor kinases or other kinases, such as 
PKA, PKC and calmodulin-dependent protein kinase II (Carrasco et al., 1996; Plested 
& Lopez Bernal, 2001; Willets et al., 2009). These kinases are thought to activate β-
arrestin for steric hindrance and uncoupling of G-proteins from receptors 
(Brenninkmeijer et al., 1999; Plested & Lopez Bernal, 2001). In primary myometrial 
cell cultures, the progressive decrease in oxytocin-stimulated PLC pathways 
correlates with a substantial loss of oxytocin binding sites (Phaneuf et al., 1994; 
Phaneuf et al., 1997). This process maintained the expression of total oxytocin 
receptor protein. To reverse the desensitisation of these oxytocin receptors, oxytocin 
was pre-incubated with atosiban (Phaneuf et al., 1994). However, on the basis of 
clinical practice outcomes, very early therapeutic intervention with atosiban would be 
necessary to successfully delay preterm labour. 
Desensitisation of oxytocin receptors is likely to occur in vivo during the course of 
spontaneous and induced labour at term (Bossmar et al., 1994; Phaneuf et al., 1998; 
Liedman et al., 2009). The decline in tissue responsiveness to oxytocin was observed 
in this study (Figure A10). Although the most potent contractions were evoked at term 
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and in tissues harvested shortly after labour-onset, oxytocin caused little effect in 
isolated myometrium from fully dilated donors. This may be attributed to the transient 
decrease in myometrial oxytocin binding sites (Fuchs et al., 1984; Bossmar et al., 
1994) and the steep decline in oxytocin mRNA with labour progression (Phaneuf et 
al., 1998; Liedman et al., 2009). During this time, plasma oxytocin concentrations 
remain stable (Dawood et al., 1978; Thornton et al., 1992), whilst the local production 
of oxytocin in intrauterine tissues and the frequency of pulsatile oxytocin release are 
elevated (Fuchs et al., 1991; Chibbar et al., 1993). Due to the slow process of 
oxytocin receptor desensitisation, the myometrium maintains its oxytocin-mediated 
effects for several hours during active labour. This may be an important feature of 
regulating early labour-contractions rather than the advanced stages of the birth 
process. 
Mechanical stretch and cervical effacement may also modulate myometrial sensitivity 
to oxytocin. The distension of the uterus in clinical conditions, such as multiple 
pregnancies and polyhydramnios, is associated with a marked increase in myometrial 
and decidual oxytocin mRNA and the increased risk of preterm labour (Fuchs et al., 
1991; Turton et al., 2009). Moreover, oxytocin receptor mRNA and oxytocin gene 
promoter activity are elevated in primary human myocytes exposed to acute stretch 
(Terzidou et al., 2005). In contrast, the lowest numbers of oxytocin receptor sites are 
located near the cervical end of the uterus at term pregnancy (Fuchs et al., 1984; 
Havelock et al., 2005). As the cervix effaces into lower segment tissue following long 
episodes of labour, this perhaps would also account for the observed attenuated 
responsiveness to oxytocin. 
In this study, 17β oestradiol enhanced oxytocin-induced Ca2+ transients, whilst 
exposure to progesterone attenuated responses. The changes in Ca2+ flux were not 
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associated with cell proliferation, which was uniform irrespective of steroid treatment, 
and were restored in myocytes pre-incubated with a combination of oestrogen and 
progesterone. These effects concur with changes in the ovarian hormonal milieu that 
influence further myometrial responsiveness to oxytocin (Word et al., 1992). 
Throughout most of pregnancy, progesterone promotes utero-quiescence by genomic 
and non-genomic mechanisms. Its predominant actions, mediated via the progesterone 
receptor (PR)-B isoform, are associated with the repression of many genes, including 
gap junctions (Garfield et al., 1980) and oxytocin receptor transcription (Soloff et al., 
1983). As a result, electrical coupling between cells, Ca2+ oscillations and in vitro 
oxytocin-induced myometrial contractions are attenuated (Thornton et al., 1999; 
Chanrachakul et al., 2005). Acute progesterone treatments have also been shown to 
inhibit transmembrane Ca2+ entry (Fomin et al., 1999) and deplete Ca2+ stores 
(Gehrig-Burger et al., 2010) by direct interaction with oxytocin receptors (Grazzini et 
al., 1998). Therefore, progesterone most likely reduced oxytocin receptor binding or 
intrinsic receptor activity in this study, decreasing cytosolic-free Ca2+.   
Although in most mammals parturition is associated with a marked decline in 
maternal progesterone, in humans, circulatory progesterone (Darne et al., 1987) and 
total PR in myometrium and decidua remain elevated (Haluska et al., 2002). Instead 
the myometrial PR-A: PR-B mRNA expression ratio increases from late pregnancy to 
spontaneous labour at term. This shift to the PR-A isoform represses PR-B mediated 
transactivation and may contribute to the reputed functional progesterone withdrawal 
at labour-onset (Pieber et al., 2001; Mesiano et al., 2002). Other proposed 
mechanisms include increased transcription nuclear factor kappa B (NF-κB) activity, 
inactivating PR-sensitive promoters (Allport et al., 2001), elevated progesterone 
metabolism (Astle et al., 2003) and a reduction in steroid receptor co-activators at 
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term (Condon et al., 2006). Oestrogen priming is also a necessary for PR function 
(Backlin et al. 2003; Thijssen, 2005). In accord, oestrogenic phenol red and serum-
containing growth medium appeared to maintain functional PR dynamics even after 
removal from seeded primary cells in this study. Also, unlike other studies (Sadovsky 
et al., 1992; Severino et al., 1996), the presence of functional oestrogen receptors in 
cultured uterine cells was confirmed. 
It is well accepted that oestrogens assist the development, growth and differentiation 
of the myometrium via oestrogen receptor (ER)-α as a transcription regulator. Despite 
the constant rise in systemic oestrogen before labour (Walsh et al., 1984; Darne et al., 
1987), oestrogens, particularly 17β-oestradiol, increase the formation of uterine gap 
junctions (Garfield et al., 1980; Dong & Yallampalli, 2000; Kilarski et al., 2000) and 
oxytocin receptors (Fuchs & Fuchs, 1984; Richter et al., 2004). Although analysis of 
the human oxytocin promoter does not reveal classical palindromic oestrogen 
response elements, eleven putative transcription motifs have been identified (Kimura 
et al., 1999; Terzidou et al., 2005). In addition, oestrogen-dependent transcription of 
Ca2+ channels in the parturient uterus has been proposed (Garfield et al., 1998; 
Dalrymple et al., 2004). These factors may account for the heightened oxytocin-
induced Ca2+ mobilisation in both myocytes and fibroblasts. Therefore, under 
oestrogenic conditions at term pregnancy, the enhanced sensitivity to oxytocin and 
resultant Ca2+ influx may facilitate uterine contractions; this could be an important 
prerequisite for the parturition process in women. 
Although oestrogen enhances myometrial excitation-contraction coupling, the relative 
contributions of localised Ca2+ dynamics have yet to be established. Extracellular Ca2+ 
entry through membrane voltage-gated Ca2+ channels principally mediates action 
potentials and sustained force development in the human gravid myometrium 
 Chapter Seven: Myometrial cells 
  
  
  Page 238
(Somlyo & Somlyo, 1994; Sanborn et al., 2005; Wray et al., 2005). These L-type 
dihydropyridine-sensitive channels are upregulated during the parturition process 
(Longo et al., 2003). Consequently, nifedipine, an L-type Ca2+ channel blocker, is 
used as a tocolytic agent to delay preterm labour (Papatsonis et al., 2009). In vitro 
studies show that nifedipine attenuates both myogenic and oxytocin-induced 
contractions (Phillippe & Basa, 1997; Parkington et al., 1999) and either reduces 
(Young et al., 1993; Fu et al., 2000) or does not affect Ca2+ oscillations (Burghardt et 
al., 1999). However, in both primary myocytes and fibroblasts, exposure to nifedipine 
alone augmented oxytocin-induced Ca2+ signalling. Although the mechanisms for this 
are unknown, nifedipine appears to prevent the release of cytosolic-free Ca2+ from the 
cells. 
As well as nifedipine, the inhibitor lanthanum chloride has been shown to block store-
operated Ca2+ channels (Fu et al., 2000; Young, 2002; Kim et al., 2005; Moynihan et 
al., 2008). Activation of these plasma membrane channels, termed either Ca2+ release 
activated currents or capacitative Ca2+ entry, is triggered via the emptying of Ca2+ 
from intracellular stores. In human myometrial cells, the Ca2+ release channels in the 
sarcoplasmic reticulum are gated by ryanodine and IP3 receptors. Whilst ryanodine 
receptors are expressed, functional units do not appear to be formed in human uterine 
smooth muscle cells (Kupittayanant et al., 2002). In contrast, mRNA encoding for the 
three IP3 isoforms are present in myometrial tissue (Shmygol & Wray, 2004) and the 
predominant type I isoform was displayed in myocytes. Oxytocin-generated IP3 
induces a global Ca2+ rise in myocytes contributing to potent oxytocic contractile 
effects (Luckas et al., 1999; Shmygol &Wray, 2004). In this study, responses to 
oxytocin were maintained in the presence of lanthanum chloride alone and together 
with nifedipine. Whilst lanthanum chloride was previously shown not to affect 
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Ca2+ waves (Young, 2002), it tempered additional Ca2+ entry. This may correspond 
with its role of mediating a low and sustained influx of Ca2+ to replenish the 
sarcoplasmic reticulum (Wray et al., 2005; Berridge, 2008). Therefore, this store-
operated system may facilitate Ca2+ homeostasis following cell depolarisation.  
Another mechanism for refilling intracellular Ca2+ stores is via the sarcoplasmic 
reticulum Ca2+-ATPase. The expression of this ATPase is upregulated from term 
pregnancy to labour, suggesting a functional role in potentiating myometrial 
contractions (Tribe et al., 2000). As a specific inhibitor of sarcoplasmic reticulum 
Ca2+ pumps, thapsigargin depletes intracellular Ca2+ stores without a concomitant rise 
in IP3 (Fomin et al., 1999). Accordingly, thapsigargin directly mobilised intracellular-
free Ca2+ in uterine myocytes and fibroblasts. Although oxytocin signalling was 
reduced, functional studies show that Ca2+-ATPase inhibitors decrease contractile 
frequency but enhance spontaneous uterine force (Kupittayanant et al., 2002). This 
suggests that Ca2+ sequestered into these stores regulates myometrial contractions.  
Combined incubations of thapsigargin with the L-type channel blocker nifedipine 
attenuated further oxytocin transduction pathways, associated with Ca2+ mobilised 
from both intracellular and extracellular pools. However, Ca2+ influx was even lower 
in the presence of lanthanum chloride, indicating the synergistic uptake of Ca2+ via 
ATPase and store-operated channels. To identify the contribution of each system, 24-
hour treatments with the strong Ca2+ chelating agent ethylenediaminetetraacetic acid 
(EDTA) and with thapsigargin were performed. Similar to previous studies (Thornton 
et al., 1992; Kupittayanant et al., 2002), the removal of extracellular Ca2+ using 
EDTA did not completely suppress Ca2+ signals. However, thapsigargin abolished 
Ca2+ release within myometrial cells. Taken together, these results suggest that in 
spite of the Ca2+ boost from the extracellular milieu, the sarcoplasmic reticulum is 
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particularly important for oxytocin-mediated uterine contractions. Even so, these 
effects would also depend on other membrane channels, secondary messenger 
cascades and the sensitivity of the uterus to Ca2+ (Taggart et al., 1999; Somlyo & 
Somlyo, 2000). 
As well as liberating cytosolic Ca2+, oxytocin stimulates the GTPase RhoA and 
ROCK cascade (Woodcock et al., 2004). This signalling process is Ca2+-independent 
and involves direct phosphorylation of MLC20 and inactivation of the myosin binding 
subunit of MLC20 phosphatase (Kimura et al., 1996; Amano et al., 2000). As this 
maintains MLC20 in a phosphorylated state, the uterus becomes sensitised to Ca2+. In 
vitro studies show that myometrial tissues are more responsive to Ca2+ and oxytocin 
in the term pregnant compared to the non-gravid state (Word et al., 1993; Riley et al., 
2005). This corresponds to the dramatic increase in RhoA mRNA, but not protein 
(Friel et al., 2005; Lartey et al., 2007), and elevated ROCKI and ROCKII mRNA and 
protein expression in rat (Niiro et al¸ 1997) and human myometrium at term 
pregnancy (Moore et al., 2000; Moran et al., 2002; Moore & Lopez Bernal, 2003). 
Although conflicting reports have been published (Friel et al., 2005; Lartey et al., 
2006), it is likely that the ROCK pathway is involved in augmenting uterine 
contractions during labour (Niiro et al., 1997; Moore et al., 2000; Moran et al., 2002; 
Lartey & Lopez Bernal, 2009).  
RT-PCR using total RNA revealed relatively high expression of RhoA and ROCKI in 
primary uterine myocytes compared to ROCKII at term pregnancy. The detection of 
ROCK proteins was also similar in human myometrial tissue (Moran et al., 2002; 
Friel et al., 2005). As the two ROCK isoforms have only 64 percent homology in 
sequence structure (Ishizaki et al., 1996) each isoform may have distinct functions. 
With abundant expression in the uterus, ROCKI may be the primary effector of RhoA 
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for actin myofilament assembly and indirect regulation of MLCK phosphorylation. 
However, despite the wide distribution of MLCK in smooth muscle tissues (Word et 
al., 1993; Moore & Lopez Bernal, 2001), MLCK transcripts showed faint and 
multiple banding after gel electrophoresis in this study. Therefore, it is likely that the 
complementary sequences of primers for MLCK were poorly designed and the 
experiments need repeating. In contrast the protein telokin, whose sequence is 
identical to the C-terminus of smooth muscle MLCK (Ito et al., 1989), was richly 
expressed in myocytes. In vitro, telokin blocks the unphosphorylated S2 region of the 
myosin head to competitively inhibit MLCK binding (Katayama et al., 1995). Smooth 
muscle telokin also acts a negative modulator of Ca2+ sensitisation by enhancing 
MLC20 phosphatase activity (Khromov et al., 2006). Such events resulting in utero-
relaxation and may be important before labour-onset. 
The contribution of rho on oxytocin-mediated Ca2+ transduction signals was 
investigated in this study. Agonist activation of RhoA has been shown to increase the 
stability of the p160 ROCKI isoform (Moore & Lopez Bernal, 2003) for enhanced 
tonic phase myogenic activity (Kupittayanant et al., 2001). As a result, several 
inhibitors of serine/ threonine protein kinase have been manufactured to block RhoA 
effects for smooth muscle relaxation (Uehata et al., 1997; Kupittayanant et al., 2001; 
Oh et al., 2003; Woodcock et al., 2004; Lartey & Lopez Bernal, 2009).  
Although the cyclohexane carboxamide Y-27632 is the most widely used ATP-
competitive inhibitor with equal potency against ROCKI and ROCKII (Fu et al., 
1998; Moran et al., 2002; Uehata et al., 1997; Ikenoya et al., 2002), the 
isoquinolinesulfonamide rho-kinase inhibitor was chosen for pre-incubation with 
myometrial cells. This was reported to be more potent, selective and membrane-
permeable than Y-26732 (Ikenoya et al., 2002; Sasaki et al., 2002). Unlike short 
 Chapter Seven: Myometrial cells 
  
  
  Page 242
exposure to the rho-kinase inhibitor, challenge for 24 hours attenuated oxytocin-
induced Ca2+ transients by up to 50 percent. This reduction was more pronounced in 
uterine fibroblasts than myocytes, indicating a larger involvement of rho transduction 
signals in these fibroblastic cells. Pharmacological inhibition of ROCK by Y-27632 
(Somlyo & Somlyo, 1998) or by ADP ribosylation (Otto et al., 1996) has also been 
shown to decrease oxytocin-induced Ca2+ sensitisation of uterine smooth muscle cell 
force. The mechanism of inhibiting this agonist-mediated Ca2+ pathway is not well 
understood. Even so, RhoA is known to promote cell migration and actin myofilament 
assembly, regulating the formation of stress fibres and lamellipodia protrusions 
(Matsumoto et al., 1997; Kawabata et al., 2004; Katoh et al., 2001; Lartey et al., 
2007). Therefore, it is likely that RhoA in fibroblasts improves the capacity and 
mechanotransduction properties of the gravid uterus by contributing to uterine 
hypertrophy and hyperplasia (Varayoud et al., 2001). In fibroblasts, the enhanced 
RhoA may also reflect their morphological features and faster proliferation rate 
compared to myocytes. Moreover, tissue remodelling is associated with the caspase-3 
effector, which is anti-contractile and activates cell hypertrophy at mid-gestation and 
apoptosis at term (Shynlova et al., 2010) by cleaving ROCKI (Sebbagh et al., 2005). 
It is possible that caspase-3 reduces the cell viability of fibroblasts over myocytes 
during postpartum involution, enabling the uterus to return to its non-gravid smooth 
muscle phenotype.  
To conversely assess the effects of enhanced ROCK activity, the caspase-3 inhibitor 
Z-DEVD-FMK was used in this study. Inhibition of caspase-3, a cysteine-dependent 
protease, prevents the cleavage of four putative functional domains within ROCKI 
(Ishizaki et al., 1996; Moore et al., 2002; Moore & Lopez Bernal, 2003), without 
affecting ROCKII (Sebbagh et al., 2005). This blocks the irreversible proteolysis of 
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pre-existing active p160 ROCKI to yield relatively inactive p130 ROCKI (Moore et 
al., 2002; Moore & Lopez Bernal, 2003). Despite the enhanced p160 stability, 
treatment with the caspase-3 inhibitor caused negligible effects on oxytocin-induced 
Ca2+ transients in both uterine myocytes and fibroblasts. This may reflect the 
mechanism of ROCK generating actomyosin cross-bridging and force generation at a 
constant concentration of intracellular-free Ca2+.  
The lack of effect on oxytocin-induced Ca2+ mobilisation was substantiated by the TP 
receptor antagonist SQ29,548. Unlike caspase-3 inhibition, chronic stimulation with 
SQ29,548 mediates cleavage of the C-terminal autoinhibitory domain of p160 ROCKI 
to produce p130 ROCKI (Moore & Lopez Bernal, 2003). In spite of promoting 
apoptosis, p130 ROCKI has been shown to irreversibly stimulate Ca2+ independent 
pathways (Moore & Lopez Bernal, 2003). Due to the contrast in results, this suggests 
that the rho-kinase inhibitor may have targeted an alternative pathway. As well as the 
six possible rho effectors identified in human myometrium (Lartey et al., 2007), the 
rho-kinase inhibitor has been reported to have weak affinity binding with other 
serine/threonine kinases, including protein kinase A (PKA) and PKC (Ikenoya et al., 
2002; Sasaki et al., 2002). Due to their reported interaction with Ca2+ transport 
systems (Sanborn et al., 1998), these kinases may have altered the Ca2+ dynamics 
observed in this study. In this regard, the secondary messenger cAMP cascade was 
also investigated. 
Activation of the effector enzyme adenylyl cyclase through Gαs is responsible for 
generating cAMP from ATP for muscle relaxation (Price & Lopez Bernal, 2001). 
Whilst the exact mechanisms remain obscure, cAMP-dependent PKA is reported to 
phosphorylate MLCK, inhibit PLC activation and block Ca2+ entry via K+ channels 
and Ca2+ pumps (Sanborn et al, 1998). As a result, cAMP attenuates the oxytocin-
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stimulated PLC pathway in rat myometrium (Anwer et al., 1990), but not in human 
myometrial cells (Phaneuf et al., 1993). In both species, the expression of Gαs 
increases throughout gestation and declines during labour (Europe-Finner et al., 1994; 
Sanborn et al., 1998) by a mechanism that is reported to involve alternative splice 
variants of Gαs (Europe-Finner et al., 1997). This may contribute to the loss of 
quiescence at labour-onset.  
As well as the diterpene forskolin, PGE2 and butaprost were shown to substantially 
increase cAMP in primary cultures of human myocytes. The formation of cAMP by 
the specific EP2 receptor agonist butaprost was nearly as potent as PGE2, which 
activates EP2, EP3-II, EP3-IV and EP4 receptors coupled to Gαs (Coleman et al., 1994; 
Regan et al., 1994; Kotani et al., 1995). Accordingly, previous studies have shown 
weaker Gαs binding by EP4 receptors than EP2 (Fujino et al., 2002) and a paucity of 
elevated cAMP in EP4-mediated PGE2 signalling (Pozzi et al., 2004). This indicates 
that EP4 receptors have a minor role in generating cAMP compared to the EP2 
subtype. As PGE2 also acts through EP1 and EP3 pathways coupled to Ca2+ influx and 
inhibition of adenylyl cyclase respectively (Regan et al., 1994; Asboth et al., 1997), 
the results also suggest that EP2-induced cAMP signalling predominates at term 
pregnancy.  
Of the EP receptor transcripts in cultured human myocytes, EP2 mRNA was more 
abundant than EP1, whilst the complement of EP3 and EP4 subtypes was low. A 
similar pattern of dominant EP2 expression over EP4 receptors was reported in late 
gestational myometrial cells (Erkinheimo et al., 2000) and lower segment biopsies 
(Brodt-Eppley & Myatt, 1999; Leonhardt et al., 2003; Astle et al., 2005; Grigsby et 
al., 2006). Given that EP2 receptors are more prevalent in the lower uterus, this further 
substantiates EP2-mediated PGE2 signalling for relaxation of the uterus. In both upper 
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and lower segments, EP1 transcripts are upregulated with labour (Astle et al., 2005), 
converse to the decreases in EP3 at late gestation (Matsumoto et al., 1997; Wing et al., 
2003; Astle et al., 2005). Unlike EP1 receptors, staining for EP3 proteins is weak and 
diffuse in myometrial smooth muscle cells (Astle et al., 2005) or only expressed by 
stromal and epithelial cells (Leonhardt et al., 2003). This was consistent with the low 
detection of EP3 in this study. Therefore, direct changes in the relative expression of 
EP2 and EP1 receptors are more likely to mediate functional myometrial effects. 
To elucidate the underlying mechanisms of EP2 on oxytocin receptors, uterine smooth 
muscle cells were pre-incubated with butaprost. As butaprost is shown to antagonise 
oxytocin-induced contractions, this EP2 receptor agonist has suggested tocolytic 
effects (Duckworth et al., 2002). In this study, the attenuated responses to oxytocin 
were inversely related to an increase in cAMP formation, without affecting Ca2+ 
release. As each receptor-binding site is distinct (Coleman et al., 1994; Kimura et al., 
1996), butaprost is likely to attenuate oxytocin-induced myometrial excitation through 
cAMP transduction mechanisms. In addition to implicating cAMP as a major 
component for maintaining utero-quiescence at term, the results suggest that a balance 
in these receptors and their downstream pathways influence the timing of labour-
onset.  
Gene transcripts for DP, EP1-4, IP, FP, TP, oxytocin receptors and contractile elements 
were detected in uterine myocytes in this study. Although the receptors are temporally 
and spatially regulated in the uterus, the underlying genomic changes are not well 
understood (Havelock et al., 2005). To regulate gene transcription, myometrial EP 
and FP receptors are reported to co-localise in the nuclear membrane (Bhattacharya et 
al., 1998; Leonhardt et al., 2003; Astle et al., 2005) together with COX enzymes for 
PG biosynthesis (Spencer et al., 1998). PGs have also been hypothesised to directly 
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interact and increase the expression of oxytocin receptors (Wing et al., 2006). Even 
so, pre-incubation of myocytes with combinations of U46619 and SQ29,548 or 
oxytocin and atosiban had no genomic effect on mRNA expression. It is possible that 
higher concentrations of these compounds, a longer duration of exposure or the 
measurement of translated proteins would have shown a more marked response in this 
study. Other endocrine factors, including oestrogen, progesterone or inflammatory 
cytokines may have also been required for transcription (Mohan et al., 2004). Even 
so, further studies would be needed to clarify their complex regulation. 
Taken together, these studies show that myometrial cells can be used as a model of 
the gravid uterus for high throughput screening of drugs. Whilst primary cell cultures 
showed similar ultrastructures, uterine fibroblasts had a lower capacity for Ca2+ 
release but higher sensitivity to the ROCK pathway than myocytes. This may have 
important implications in uterine tissue remodelling and postpartum involution. 
Compared with PGs, oxytocin-induced contractility and Ca2+ oscillations were of 
greater amplitude. However, complex Ca2+ and cAMP signalling pathways are part of 
a multiplicity of downstream events at term gestation. As it is probable that a loss of 
uterine quiescence is pivotal to successful parturition (Price & Lopez Bernal, 2001), 
maintaining EP2 receptors or intrinsic adenylyl cyclase activity may represent a novel 
tocolytic approach for hypercontractile uterine disorders, such as preterm labour. 
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Chapter 8: Final discussion 
 
 
The main aim of this thesis was to determine the functional expression of EP, FP, TP 
and oxytocin receptors in isolated human myometrial tissues. PGs and oxytocin have 
a critical role in orchestrating the changes between uterine quiescence and 
contractility. It is suggested that uterine receptor function is regulated by the hormonal 
milieu (Lopez Bernal, 2001), as well as the structural composition of the uterus 
(Luckas & Wray, 2000). This was demonstrated in the present study by changes in the 
in vitro responsiveness to PGs and oxytocin during the menstrual cycle, pregnancy 
and labour. 
Under physiological conditions, myometrial tissue strips exhibited sustained 
spontaneous contractions, which were most pronounced during the follicular phase of 
the cycle. The decline in fundus tissue activity through the luteal phase to sporadic 
contractions at menses corresponded to progesterone action at cognate PR-B receptors 
(Bulletti et al., 1998; Ijland et al., 1998) and the decrease in oestrogen and ERα 
expression at this time (Noe et al., 1999). Topographical differences were also shown 
mid-cycle with the most active contractile waves generated by lower segment non-
gravid myometrium. Although not anatomically defined (Wray et al., 2001), these in 
vitro intrinsic action potentials indicated the presence of pacemaker Cajal-like 
interstitial cells (Ciontea et al., 2005; Young, 2007). During the periovulatory period, 
this is reported to direct the retrograde transport of potential sperm (Kunz et al., 1996; 
Bulletti et al., 1998).   
With pregnancy, the uterus undergoes dramatic expansion whilst remaining relatively 
quiescent. The changes in tissue remodelling involve two growth phases of cell 
hyperplasia followed by cell hypertrophy, primarily within the distensible lower 
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segment tissue (Luckas & Wray, 2000; Shynlova et al., 2010). At Caesarean section, 
only lower segment gestational myometrium was available to study. This tissue was 
used in functional studies (Section I) and myometrial cell cultures (Section II) to 
elucidate better the underlying mechanisms of uterine contractility.  
At term, in vitro contractions were defined and up to 5-fold greater in amplitude, 
although less frequent, than tissues obtained from non-gravid donors. As well as 
mechanical stretch and foetal signalling, the elevated plasma oestrogen to 
progesterone ratio in late gestation may account for these changes in activity (Johnson 
et al., 1995). Progesterone represses the transcription of contractile-associated 
proteins (Garfield et al., 1980; Soloff et al., 1983) and also directly interacts with 
oxytocin receptors to maintain utero-quiescence (Grazzini et al., 1998). Conversely 
oestrogens activate the oestrogen response element on target genes for enhanced 
myogenic activity. In particular, 17β-oestradiol is shown to enhance the formation of 
gap junctions in the late gestational uterus for coordinated excitation-electrical 
coupling between cells (Garfield et al., 1990; Dong & Yallampalli, 2000; Kilarski et 
al., 2000). In this study, 17β-oestradiol also elevated oxytocin-induced Ca2+ release, 
whilst progesterone counteracted this effect. This confirms the importance of the sex 
steroids in sensitising the myometrium to stimulatory agonists. 
Mechanical responses to PGs and oxytocin reflected tissue spontaneous activity and 
appeared to be spatially and temporally regulated during the menstrual cycle. At the 
fundus, bell-shaped responses to PGE2 consisted of concentration-dependent utero-
relaxation, followed by partial restoration of activity. This demonstrated PGE2 
coupling at EP receptor subtypes (Coleman et al., 1994) in addition to the possible 
activation of FP receptors (Kiriyama et al., 1997). Corresponding to other studies 
(Senior et al., 1991; Popat & Crankshaw, 2001) use of sulprostone and ONO-D1-004 
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showed excitatory effects through the EP3 subtype and only a small compliment of 
EP1 receptors (Senior et al., 1991). In contrast, the selective agonists butaprost and 
AGN201734 attenuated myogenic activity via EP2 and EP4 subtypes respectively. 
Despite their presence, EP4 receptors are reported to be devoid of function (Hillock & 
Crankshaw, 1999), and did not contribute to PGE2-mediated utero-relaxation in this 
study. This suggests a prominent role for EP2 receptors in the non-gravid uterus. 
As little is known about the topography of functional PG receptors, responsiveness to 
PGs and oxytocin was investigated according to anatomical location in follicular 
phase myometrium. The inhibitory effects of PGE2, butaprost and AGN201734 were 
more pronounced towards the cervix, whereas active EP3/1 receptors were uniform. 
This may relate to the more abundant EP2 receptors in the lower segment tissues 
(Astle et al., 2005) or presence of EP4 receptors within uterine arteries that branch 
into the lower uterus before reaching the fundus and ovary (Baxter et al., 1995). The 
apparent functional regionalisation may also reflect total uterine physiology. 
Epithelial and vascular cells of the endometrium synthesise PGE2 and co-express EP2 
and EP4 receptors (Milne et al., 2001; Arosh et al., 2003). Through cellular 
proliferation and angiogenesis, the associated endometrial thickening at the fundus 
may reduce uterine activity for blastocyst attachment and implantation. On the 
contrary, PGE2 within the seminal plasma is likely to intensify intrinsic retrograde 
contractions for sperm delivery to the upper uterus (Templeton et al., 1978).  
Similar to PGE2, the uterotonic effects of PGF2α, U46619 and oxytocin were greater 
in lower segment myometrium compared to the fundus. This corresponds to the 
fundus to cervix gradient of oxytocin receptors around ovulation (Richter et al., 2004; 
Steinwall et al., 2004) but not the reported decrease in PGF-binding affinity 
(Hofmann et al., 1983; Adelantado et al., 1988) and homogeneous distribution of TP 
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receptors (Senchyna & Crankshaw, 1999). As a result, it is likely that the hormonal 
milieu and mechanical properties of the uterus account for these regional differences. 
This is further implied in mice knockout studies with only the EP2 subtype vital for 
successful establishment of pregnancy (Tilley et al., 1999). Even so, interactions 
between the receptor subtypes and their downstream effector signals are proposed to 
compensate for overall reproductive outcomes (Lopez Bernal et al., 2001; Duckworth 
et al., 2002). This was investigated further at term pregnancy. 
PGE2 is particularly important in the induction of labour by mediating both cervical 
compliance and myometrial activity (Gibb, 1998). Functional EP1-3 receptors have 
been characterised at term (Senior et al., 1993) with the temporal and tissue-specific 
expression of EP receptors shown over the course of pregnancy and labour (Astle et 
al., 2005; Grigsby et al., 2006; Sooranna et al., 2006). In this study, PGE2 and 
AGN201734 caused predominant utero-relaxatory effects with excitation re-
established at 10-5M. The EP2 agonists were consistent in mediating uterine 
quiescence, whilst the other EP4 mimetic L-902688 produced no response. The reason 
for this discrepancy in EP4 action was unclear. However, in cultured myocytes, 
similar EP2 and PGE2-induced elevations in cAMP were observed and the EP4 
antagonist GW627368x did not modify the profile of PGE2-induced contractions. 
These data suggest that PGE2 supports utero-quiescence via activation of the EP2 
subtype.  
PGE2 also serves as an uterotonin via the EP1 and EP3 receptor complement during 
pregnancy. To mediate excitation, EP1 receptors couple to Ca2+ influx whilst EP3 
inhibits adenylyl cyclase (Coleman et al., 1994; Narumiya et al., 1999). In functional 
studies, sulprostone evoked moderate stimulation at EP3/1 receptors, whilst ONO-D1-
004 and the EP3 antagonist AGN211329 produced negligible effects. Only minimal 
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Ca2+ mobilisation was induced by PGE2 in cultured human myocytes and fibroblasts; 
however, EP3/1 and EP2 receptor stimulation of myometrial strips were greater at term 
gestation than in follicular phase tissues (Table 8.1). This corresponds to previous 
functional studies (Senior et al., 1991; Senior et al., 1993) and the reported 
upregulated (Grigsby et al, 2006) or maintained expression of EP1 transcripts with 
advancing gestation and labour (Astle et al., 2005). Given the abundance of EP2 
mRNA over EP1, EP3 and EP4 receptors in primary uterine myocytes at term, the 
results further indicate predominant effects via EP2 receptors, whilst EP1/3 receptors 
regulate muscle tonus. This suggests that these receptors may be crucial tocolytic 
targets for maintaining utero-quiescence before parturition. Nevertheless, further 
studies using more selective compounds including ONO-AE-248 and ONO-AE1-329 
for EP3 and EP4 receptors respectively are still required to comprehensively elucidate 
EP1-4 receptor function. 
In late pregnancy, PGF2α-induced myogenic contractions were two-fold higher than in 
the non-gravid state (Table 8.2). This was inconsistent with the reported decrease in 
myometrial FP gene expression towards term (Matsumoto et al., 1997; Sooranna et 
al., 2005), perhaps reflecting differences in gestational age. In this study, however, 
U46619 was more potent than PGF2α and neither showed additive effects. This 
substantiates previous studies showing a lack of off-target PGF2α action at myometrial 
TP receptors (Hutchinson, 2005; Griffiths et al., 2006). Within uterine myocytes, 
exposure to PGF2α produced greater Ca2+ transients than U46619 via the abundant 
expression of FP mRNA over TP receptors. Even so, uterine sensitivity to TP 
activation indicates that alternative signalling cascades are involved.  
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Table 8.1: pEC50 values (M) and the percentage change in myogenicity for 
concentration-effect curves to EP agonists (10-10M to 10-5M) in immersed lower 
segment myometrial tissues obtained during the follicular phase (n=4), at term 
pregnancy (n=4-10) and during early labour (n=4-6). Early labour was defined as 
regular in vivo contractions at a cervical dilation of 0-2cm with % change calculated 
from baseline activity as a change in % hypotonic shock. Results are expressed as 
arithmetic means ± S.E. and univariate analysis was performed using Bonferroni’s 
post-hoc test; *p<0.05 for % difference in response to AGN201734 at early labour 
compared to the follicular phase of the menstrual cycle. ND = not determined. 
 
  Follicular phase Term pregnancy Early labour 
EP agonist Receptors pEC50 % change pEC50 % change pEC50 % change 
PGE2 EP1-4 7.6 ± 0.1 73.5 8.4 ± 0.4 33.6 8.1 ± 0.4 52.9 
Butaprost EP2 6.2 ± 0.4 83.1 7.1 ± 0.5 47.0 6.2 ± 0.3 45.2 
AGN201734 EP4 8.0 ± 0.1 68.2 8.1 ± 0.3 29.7 7.5 ± 1.0 31.5* 
Sulprostone EP3/1 7.0 ± 0.1 25.1 7.4 ± 0.6 20.6 ND ND 
 
 
 
 
Table 8.2: pEC50 values (M) and the percentage increase in myogenicity for 
concentration-effect curves to FP, TP and oxytocin agonists in immersed lower 
segment myometrial tissues obtained during the follicular phase (n=4), at term 
pregnancy (n=5-7) and during early labour (n=5-6). Late labour was defined as donors 
at full dilatation (9-10cm) with % change calculated from baseline activity as a 
change in % hypotonic shock. Results are expressed as arithmetic means ± S.E. and 
univariate analysis was performed using Bonferroni’s post-hoc test; *p<0.05 for % 
increase in response to U46619 for term pregnancy and late labour compared to the 
follicular phase of the menstrual cycle. N = no response. 
 
  Follicular phase Term pregnancy Late labour 
Agonists Receptors pEC50 % change pEC50 % change pEC50 % change 
PGF2α FP 7.0 ± 0.2 51.4 6.8 ± 1.8 100.3 6.1 ± 0.7 36.7 
U46619 TP 6.2 ± 0.2 81.6 7.3 ± 0.5 267.5* 6.8 ± 0.1 322.0* 
Oxytocin oxytocin 7.5 ± 0.7 132.1 7.4 ± 0.4 271.0 N N 
 
 
 
 
Signal transduction via RhoA and ROCK are important in sensitising the uterus to 
Ca2+. Challenge with U46619 is shown to generate p160 ROCKI and ROCKII, which 
maintains MLC20 phosphorylation (Moore et al., 20002; Moran et al., 2002; Moore & 
Lopez Bernal, 2003) and may account for the enhanced contractile responses at term 
in this study. Further Ca2+ sensitisation is mediated by irreversible caspase-3 cleavage 
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of p160 ROCKI to p130 ROCKI (Moore & Lopez Bernal, 2003). Despite the lack of 
change in caspase-3 inhibited tissues, the rho-kinase inhibitor attenuated Ca2+ 
signalling. This was more pronounced in fibroblasts over myocytes, suggesting a role 
for fibroblast-directed cell migration and apoptosis in tissue remodelling during 
pregnancy as well as postpartum involution. 
In functional studies, oxytocin-induced myogenic contractions were twice as high at 
term than in follicular stage tissues, relating to the upregulated expression of oxytocin 
receptors before labour-onset (Fuchs et al., 1984; Kimura et al., 1996; Terzidou et al., 
2005). Within primary uterine myocytes, Ca2+ influx by oxytocin was over 13-fold 
greater than that stimulated by PGF2α or U46619, perhaps due to principal Ca2+ 
release from the intracellular stores. Compared to oxytocin, PG responses were at the 
limits of detection. Whilst this implied the significance of oxytocin-induced Ca2+ 
signals, a more sensitive method such as the fura-2 loaded cell system (Asboth et al., 
1998) should replace use of the Flipr-tetra in further studies. 
Limitations of the Flipr-tetra may also account for the paucity of effect by butaprost 
on oxytocin-induced Ca2+ transients. However, the reported EP2-mediated attenuation 
of oxytocic effects in vitro (Duckworth et al., 2002) appeared to be mediated through 
cAMP rather than the Ca2+ signalling pathway in this study. This confirms cAMP as a 
major pro-relaxant mediator at term pregnancy and indicates that a decrease in uterine 
Gαs coupled receptors may lead to labour-onset.  
Successful parturition requires coordinated contractions of the uterus in a caudal 
direction for delivery of the foetus. This involves the differential expression of uterine 
PG, oxytocin receptors and gap junction proteins to transmit action potentials in 
syncytium (Sparey et al., 1999; Astle et al., 2005; Grigsby et al., 2006). Functional 
progesterone withdrawal is a considered a pivotal event for labour-onset, but its 
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mechanisms are unclear. In humans, plasma progesterone remains high until 
postpartum delivery of the placenta (Broditsky et al., 1978; Darne et al., 1987). 
Instead a rise in nuclear PR-A receptors, which act as a transrepressor of the PR-B 
isoform, may mediate the timing of labour (Pieber et al., 2001; Mesiano et al., 2002). 
Since PG receptors are also important mediators of parturition, novel functional 
effects were demonstrated in this study. 
Spontaneous contractions were attenuated in lower segment myometrial strips with 
advancing labour. During this time the extracellular collagen matrix in the cervix 
remodels and effaces upwards against the presenting foetus. The associated changes 
in tissue physiology include an increase in cervical fibroblasts within the lower uterus 
(Montes et al., 2002) as well as reduced ATPase activity (Zyrianov et al., 2003). 
Within cell culture systems, Ca2+ mobilisation was two-times lower in fibroblasts 
compared to myocytes. This may be a mechanism to moderate uterine resistance at 
the cervical end for controlled foetal passage. 
In parallel with PGE2 effects at term, predominant utero-relaxation was followed by 
relative contractility in tissues obtained early after labour-onset. In the latter stages of 
labour, however, the contractile component of the PGE2 curve was suppressed. In 
vitro studies also confirmed the loss of PGE2-mediated contractions in the lower, but 
not upper segment parturient uterus (Wikland et al., 1984); this corresponds to a 
regional change in the EP receptor complement.  
Due to its temporal and topographical distribution, EP2 receptors are particularly 
implicated in the parturition process. In the lower segment uterus, EP2 mRNA and 
protein expression decreases towards term (Brodt-Eppley & Myatt, 1999; Leonhardt 
et al., 2003), but either shows no change (Brodt-Eppley& Myatt, 1999; Astle et al., 
2005; Sooranna et al., 2006) or increases with advancing labour (Grigsby et al., 
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2006). The abundance of EP2 receptors in the lower compared with the upper uterus in 
pregnancy and labour relates to the continued relaxatory effects in myometrial strips 
at this time. For EP4 receptors, a reduction in mRNA expression from the non-gravid 
to term gravid state (Sooranna et al., 2006) also corresponds to the attenuated 
myometrial responses to AGN201734 in this study. However, no change in EP4 
receptors is reported by gestational age or anatomical location (Astle et al., 2005; 
Grigsby et al., 2006). As a result, the EP4 subtype may be responsible for cervical 
ripening (Schmitz et al., 2003) or vasodilatation (Baxter et al., 1995), rather than for 
modulating contractions during labour. 
In the lower uterus obtained during labour, ONO-D1-004 had no effect on myogenic 
activity. This was in contrast to the reported presence of myometrial EP1 receptors at 
this time (Astle et al., 2005; Grigsby et al., 2006). Although a more potent EP1 
agonist is required to clarify function (Kiriyama et al., 1997; Oka et al., 2003), it is 
suggested that EP1 receptors mediate intracellular signalling pathways rather than 
promote contractility pre and postpartum (Grigsby et al., 2006). Conversely with 
advancing labour, sulprostone and PGF2α stimulated weak in vitro myogenic 
contractions of low amplitude and frequency. This is consistent with the reported 
contractility induced by PGE2 and PGF2α only in paired fundus end specimens 
obtained during active labour (Wikland et al., 1984). The results also reflect the 
relative abundance of EP3 (Astle et al., 2005; Grigsby et al., 2006) and FP mRNA in 
upper rather than lower segment tissues (Grigsby et al., 2006). As well as to promote 
uterine emptying, this may contribute to the relaxant phenotype of the lower uterus 
during parturition (Figure 8.1). 
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Figure 8.1: A summary diagram showing a proposed model for labour-onset in the 
lower segment human uterus. For the majority of pregnancy, progesterone (P4) 
dominantly represses uterine activity. At term, increases in oestrogen (E2), myometrial 
progesterone receptor (PR)-A and oestrogen receptor (ER)-α correspond with a rise in 
contractile associated proteins (CAPs). Of the PG receptors, uterorelaxation is 
predominantly mediated via the EP2 receptor. This is coupled to the adenylyl cyclase 
pathway, which also attenuates oxytocic effects. Oxytocin stimulates potent 
intracellular-free Ca2+ flux to drive muscle contractions. The small GTPase RhoA and 
rho-kinase (ROCKI) pathway further sensitises the uterus to Ca2+ by phosphorylating 
(p) myosin light chain (MLC20) directly and indirectly through inactivation of myosin 
phosphatase (MPS). With the onset and progression of labour, the expression of 
functional PG and oxytocin receptors are decreased (red), maintained or upregulated 
(yellow). To facilitate the delivery of the foetus, the overall decline in myogenic 
activity relates to the relaxation and stretch of the lower segment uterus.  
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Responsiveness to U46619 was enhanced in lower segment myometrial strips taken 
after labour-onset relative to low spontaneous contractions. Increased thromboxane 
synthesis at parturition (Noort et al., 1990; Swanson et al., 1992) alongside ROCK 
protein expression (Noort & Keirse, 1990; Friel et al., 2005) likely potentiates its 
contractile effects during active labour. Accordingly, thromboxane may maintain 
muscle tonus in the lower uterine segment as well as contribute to postpartum 
involution of the uterus. However, functional oxytocin desensitisation was observed 
with advancing labour and chronic oxytocin pretreatments. As the untimely loss of 
oxytocin receptor function is associated with labour-associated disorders (Rezapour et 
al., 1996), accurate diagnostic indicators would be crucial to allow for early 
therapeutic intervention. This would particularly be useful for improving the efficacy 
of atosiban clinical treatments.  
Although myometrial responses to PG and oxytocin agonists were comparable, 
immersed tissue strips developed more stable phasic contractions of higher amplitude 
than tissues superfused with Krebs’ solution. This approach was particularly suitable 
for myometrium from labouring donors with intrinsically low myogenic activity. In 
spite of the larger volumes of antagonists required for superfusion, the findings 
complemented immersion studies and clarified direct agonist effects on receptor 
activation. Given the limited number of myometrial tissues taken in menstrual, luteal 
and preterm states, a wider range of these samples would assist future research. 
Subject to ethical approval, paired fundus and lower segment tissues would also 
enable functional regionalisation to be defined during pregnancy and labour. 
Based on the primary cell culture experiments in this study, cell isolation could be 
applied to tissues taken from differing hormonal and gestational states. This would aid 
direct comparisons of intracellular signalling events relating to the original tissue 
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dynamics. In screening for suitable tocolytics, receptor-binding studies would indicate 
the efficacy of receptor-effector coupling; this would be of particular interest for 
myometrial EP1 and EP4 receptors. By reconstituting cells into a collagen matrix 
(Dallot et al., 2003) or onto a polyglactin mesh (Young et al., 2002), the measurement 
of cellular contractile responses would also support immersion and superfusion 
studies. This use of cells in a regulated microenvironment may enhance understanding 
of the mechanisms that transform the uterus from a quiescent to an active state. 
It would also be beneficial to clarify uterine properties throughout pregnancy and 
during the involution process postpartum. Due to ethical constraints in women, the 
use of an animal model would be of great importance. Previous studies using mice 
indicate that the uterus expresses similar PG receptors to the human, but it more 
resembles expected fundus rather than lower segment characteristics (Griffiths, 2007). 
This is complicated further by the species-specific differences in the parturition 
process. As a result, the animal models alone would not be sufficient to translate into 
human uterine function.  
Taken together, the findings of this thesis have clarified further EP, FP, TP and 
oxytocin receptor functions in isolated myometrium taken during the menstrual cycle, 
pregnancy and at different stage of labour. Primary myocytes and fibroblasts models 
of the gravid uterus indicate that EP2 receptors are crucial in attenuating oxytocic 
effects via cAMP signal cascades. Oxytocin action corresponds to myogenic profiles 
and was desensitised in the lower uterus with advancing labour. However, TP-
mediated effects were maintained. These receptors and their secondary messenger 
systems therefore represent effective myometrial targets for uterine hypercontractile 
disorders. The identification of therapies with minimal side effects for the 
management of women’s reproductive health remains an important challenge.
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Figure A1: Copy of consent form used to obtain smooth muscle samples from non-
pregnant donors. 
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Figure A2: Copy of consent form used to obtain smooth muscle samples from 
pregnant donors. 
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Uterine Smooth Muscle Research 
 
 Postgraduate Studies 
 School of Pharmacy 
 Richmond Road 
 University of Bradford 
 BRADFORD 
 Telephone: (01274)234669 or 232323 ext. 4732/ 4675 
 
 
 Debbie Fischer, Anna Griffiths & Dr. K.M. Marshall 
 
Patient Number: 
 
 
Age:  
Blood pressure (mmHg): 
 
/ 
Last Menstrual Period: 
 
 
Reason for Hysterectomy: 
 
 
Ethnicity:  
Consultant:  
Any current medication: 
 
 
 
 
 
 
Figure A3: Patient information form for uterine muscle taken at hysterectomy from 
non-pregnant donors. 
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Uterine Smooth Muscle Research 
Miss Debbie Fischer, Miss Anna Griffiths, Dr. Kay Marshall 
 
Reproduction Research Group, School of Pharmacy, University of Bradford 
        Tel: 234669, 232323 ext. 4732 or 4675 
 
 Date: 
 Time of delivery: 
 
Patient Number 
 
 
Duration of Pregnancy  
Blood Pressure (mmHg)  
Number of previous pregnancies  
Number of previous labours 
 
 
Number of previous caesareans  
Age  
Ethnicity  
Consultant  
Does the mother smoke? 
If so, how many per day? 
 
Does the mother suffer from any 
of the following: 
- hypertension 
- pre-eclampsia/ PH 
- diabetes-IDDM 
                 NIDDM 
                 Gestational  
- Rh factor 
- Other (please state) 
 
Any current medication  
Anaesthetic: 
General/ Spinal 
 
If labouring: duration (hrs) 
stage of labour + dilation (cm) 
 
Drugs used in labour 
 
 
 
 
 
Figure A4: Patient information form for myometrial tissue taken at Caesarean section 
from pregnant donors. 
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Figure A5: In vitro uterorelaxant effects of the EP2 agonists butaprost, CP533,536, 
AGN211330 and AH13205 on myometrial strips from term pregnant donors (n=3-6). 
Agonists (10-10M to 10-5M) were added to organ baths in a cumulative manner at 30-
minute intervals in the presence and absence of the EP4 antagonist GW627368x     
(10-6M). Responses were measured over a 30-minute period as area under the curve, 
expressed as percentage hypotonic shock and presented as arithmetic means ± S.E. 
 
 
 
a) b) 
c) d) 
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Figure A6: The lack of effect of the EP1, EP2, EP3 and DP antagonist AH6809 on 
concentration-activity curves for a) AGN201734, b) L-902688, c) sulprostone and    
d) ONO-D1-004 in myometrial strips from term pregnant, non-labouring donors  
(n=4-6). Agonists were added to parallel organ baths at 30-minute intervals either 
alone or after preincubation of tissues with AH6809 (10-5M). Responses were 
measured over a 30-minute period as area under the curve, expressed as percentage 
hypotonic shock and presented as arithmetic means ± S.E. 
a) b) 
c) d) 
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Figure A7: Concentration-effect curves for U46619 alone or in the presence of either 
TP antagonist SQ29,548 (10-6M) or GR32191B (10-6M) in lower myometrium 
obtained from term pregnant donors in a) mid (n=6-8) and c) late (n=5-8) stages of 
labour. Labour was defined as in vivo contractions with respective stages determined 
at 3-8.5cm and 9-10cm cervical dilation. U46619 was added to organ baths in a 
cumulative manner at 30-minute intervals with responses measured as area under the 
curve relative to the contraction achieved by hypotonic shock. Results are expressed 
as means ± S.E. and statistical analysis was performed using multivariate ANOVA 
with Bonferroni’s post-hoc test; *p<0.05; ***p<0.001 for aGR32191B and bSQ29,548 
compared to U46619 alone. 
 
 
 
 
  Appendix 
  Page 299 
10 -13 10 -12 10 -11 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5
0
25
50
75
100
125
Lower segmentFundus
***
**
Log concentration of oxytocin (M)
%
 h
yp
ot
on
ic
 sh
oc
k
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A8: Concentration-effect curves for oxytocin in fundal (n=4) and lower (n=4) 
segment human myometrium taken at the follicular stage of the menstrual cycle. After 
equilibration in immersion baths, responses to oxytocin were measured as 30 minutes 
integrated area under the curve and expressed as a percentage of 30 minutes hypotonic 
shock. Results are arithmetic means ± S.E. with analysis performed using two-way 
ANOVA with Bonferroni’s post-hoc adjustment; **p<0.01; ***p<0.001 for 
responsiveness to oxytocin in fundus compared with lower segment tissue strips.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A9: Representative traces showing the excitatory effects evoked by oxytocin in 
a) fundal and b) lower segment myometrium harvested from non-pregnant donors 
during the follicular phase of the cycle. Agonists were added to the immersion 
apparatus at 30-minute intervals.  
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Figure A10: Vehicle, concentration-effect curves and representative traces for 
oxytocin in myometrial strips obtained from donors at a) term pregnancy, not in 
labour (n=5), b) mid (n=5) and c) late stages of labour (n=6). Mid and late labour was 
categorised at 3-8.5cm and 9-10cm cervical dilation respectively. In myometrial strips 
from fully dilated donors, the addition of the stable thromboxane mimetic U46619 
(10-6M) provoked contractile responses relative to spontaneous activity, indicating 
tissue viability. Responses were measured as area under the curve relative to the 
contraction induced by hypotonic shock. Results are expressed as means ± S.E. and 
statistics were performed using two-way ANOVA with Bonferroni’s adjustment; 
**p<0.01; ***p<0.001 for oxytocin-induced contractions compared to vehicle. 
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